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High throughput screening has resulted in a significant increase in the rate at which new chemical 
entities are discovered. However, major hurdles such as poor solubility, permeability and efflux limit 
their application. Not only is it difficult to get a drug into the body from the most convenient routes, once 
inside, challenges such as increasing resistance to drugs in cancer cells, fungi, bacteria and viruses 
present significant drug delivery challenges. To address these challenges, we have investigated the 
role and application of amino acids for solubility enhancement and in increasing drug uptake. 
Tetracycline (TC), ciprofloxacin (Cip) and digoxin were chosen as model drugs along with acidic and 
basic amino acids as counterions.  
 
Saturated solubility was studied in different concentrations of the acidic (L-aspartic acid and L-glutamic 
acid) and basic (L-arginine, L-lysine and L-histidine) amino acids. We have shown that solubility of both 
TC and digoxin can be enhanced using amino acids, with the extent depending on the ionisation ability 
of the solution. Whilst both acidic and basic amino acids led to increased TC solubility, acidic amino 
acids were considered suitable counterions due better stability of TC in solution. Likewise, basic amino 
acids were determined to be suitable for digoxin compared to acidic since the latter led to drug 
degradation. Permeability of digoxin was studied using caco-2 cell line. Basic amino acids L-arginine 
and L-lysine led to a decrease in efflux ratio of digoxin. In parallel, the same counterions enhanced the 
permeability of digoxin through caco-2 monolayers via mechanisms which are likely to involve tight 
junction modulation triggered para-cellular transport, transcellular transport through ion-pair formation 
or reduced efflux thorough P-glycoprotein inhibition. 
 
Use of amino acids as antimicrobial agents on their own as well as counterions to antibiotics, in a bid 
to investigate the potential optimisation of antibiotic activity, was investigated in planktonic cells as well 
as biofilms. For this, accumulation assays using ethidium bromide as an efflux competitor were done, 
showing that acidic L-amino acids were able to enhance both TC and Cip accumulation within 
Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa). This translated into 
specific combinations of the amino acids and the antibiotics exhibiting synergistic hindrance in the 
growth of both bacteria. Pyocyanin and pyoverdine pigment production was also inhibited in P. 
aeruginosa; both with amino acids alone and synergistically when the amino acids were combined with 
the antibiotics. Antimicrobial activity of acidic D-amino acids was also investigated on S. aureus biofilms, 
specifically on their effect on biofilm density (both D- and L-amino acids), colony forming units (CFU), 
rate of cell attachment to surface and biofilm architecture. A concentration dependent ability to inhibit 
S. aureus biofilm formation and disperse already formed ones was observed with these amino acids; 
effecting both biofilm density and CFU. Synergy with Cip in the anti-biofilm activity of acidic amino acids 
was witnessed at specific combinations. Most interestingly, confocal imaging with the nucleic acid dyes 
SYTO 9 and propidium iodide, revealed that the amino acids disrupt the honeycomb-like extracellular 
DNA (eDNA) meshwork whilst also preventing its formation; a finding which was not observed with the 
use of Cip on its own. It is likely that the acidic amino acids act through mechanisms which modulate 
the acid base interactions involved in anchoring eDNA to cells. Being very non-specific, mechanisms 
such as modulation of acid-base interactions or ionic interactions may hold a key in evading evolutionary 
challenges, since overcoming these would require, if at all possible, drastic changes within bacteria. 
Our work has concluded that the amino acids present a wide functionality, ranging from solubility and 
permeability enhancement to overcoming antimicrobial resistance. 
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High throughput screening (HTS) has resulted in a significant increase in the rate at which 
new chemical entities (NCEs) are discovered (1). However, in delivering these drugs to where 
they are required, major hurdles stand and continue to emerge. Not only is it difficult to get a 
drug into the body from the most convenient routes, once inside challenges such as increasing 
resistance to drugs in cancer cells, fungi, bacteria and viruses are ever emerging (2-5). This 
has compounded the challenge for targeted drug delivery. 
 
1.1 Drug delivery in humans via 
 
1.1.1 Oral drug absorption 
 
Once a drug enters via the oral route of administration, it is absorbed, distributed, metabolised 
and finally excreted. Since the therapeutic effect of the drug is highly influenced by its 
bioavailability, it is important that a sufficient level of the drug is reached and maintained at 
the target site. Bioavailability itself is effected by the amount and rate of drug absorption. So 
it is of vital importance that drug absorption is well understood to develop formulations with 
good efficacy and safety (6). 
 
Absorption can be described as the migration of the drug from the site of administration to the 
extracellular compartment of the body. Since oral route is the most commonly used route of 
drug administration, the gastrointestinal (GI) tract plays a key role in drug absorption. Drug 
absorption is influenced by three main factors; physiological, physiochemical and 
biopharmaceutical factors (6). Physiological factors relate to the GI tract and include GI pH, 
GI perfusion, surface area of absorption, gastric emptying, small intestinal transit time and 
absorption mechanisms (6, 7). Physiochemical factors on the other hand relate to factors 
about the drug including pKa, solubility, lipophilicity, particle size and polar-nonpolar surface 
area. Biopharmaceutical factors refers to the formulation characteristics of the dosage form, 
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An oral drug in the solid dosage form must first disintegrate into smaller particles. As the 
particles get smaller, it increases the surface area of the drug within the solid dosage from that 
is in contact with the gastrointestinal fluids (10). This ultimately leads to a higher rate of 
dissolution of the drug (10). Thus the rate of drug absorption is expected to be greater for a 
formulation with a faster disintegration time when compared to formulation with a lower 
disintegration time (6, 11). However, disintegration of a solid dosage form such as a tablet 
only increases the rate of dissolution of the drug rather than the solubility. In other words, with 
disintegration of the tablet, the maximum amount of drug which would dissolve in the medium 
would remain the same, only the rate at which it dissolves would increase. 
 
1.1.2.2 Dissolution and solubility 
 
As hinted above, though dissolution and solubility sound very similar, the words do not refer 
to the same phenomenon. When referring to the solubility of a substance, two main aspects 
can be described. First being the maximum amount of the substance which can dissolve in a 
given solvent, referred to as the solubility of the substance. Second being the time it takes for 
this to occur and this is referred to as the dissolution rate. Thus solubility is a capacity whilst 
dissolution is a kinetic process. 
 
Dissolution is the next step after disintegration of a solid dosage form, and refers to the process 
in which the drug becomes dissolved in a solvent. It is a vital requirement before a drug in the 
solid dosage form can be absorbed; if a drug is unable to dissolve in aqueous fluids of the GI 
tract, it will be unable to gain access to and interact with the epithelial cell surface where it 
needs to be for absorption. The extent of dissolution is dependent upon the solubility of the 
drug. The rate of drug absorption is thus influenced by the rate at which the drug dissolves; 
this is even more important for poorly soluble drugs (6, 11, 12). 
 
Amount of drug that gets absorbed is also affected by its solubility. Solubility is expressed as 
the mass of the solute (drug) that dissolves in a given volume of solvent at a given temperature 
(6, 12). As presented in Table 1.1, a substance can be categorised from very soluble to 
practically insoluble, depending on how many parts of solvent are required to dissolve per part 
of it (13). Whilst drugs with good solubility are more likely to be absorbed within the gut, those 
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expressing poor solubility get eliminated from the body without being absorbed by the small 
intestine. Thus poorly soluble drugs with low rates of dissolution are candidates that are least 
likely to be absorbed (6, 11, 14). 
 
Table 1.1: USP and BP criteria for in describing the solubility a substance. 
Descriptive term Part of the solvent required per part of 
solute 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 10 to 30 
Sparingly soluble From 30 to 100 
Slightly soluble From 100 to 1000 
Very slightly soluble From 1000 to 10,000 
Practically insoluble 10,000 and over 
 
1.1.2.2.1 Factors affecting the solubility of solids substances in liquids 
 
There are many factors which influence the solubility of a substance and some of these will 
be briefly discussed here. These include temperature, nature of solvent and the solute, 




Generally being an endothermic process, an increase in temperature aids the dissolution 
process. Thus in such endothermic systems, if the temperature is raised, the amount of 
substance which can dissolve increases. However if a substance undergoes the rarer 
exothermic dissolution process, an increase in temperature of the solution would instead 
decrease its solubility (10, 15). 
 
1.1.2.2.1.2 Nature of solvent and the solute 
 
The nature of the solvent and the solute is another factor which impacts the ability of the solute 
to dissolve. This interaction is usually explained with the saying that like dissolves like (16). 
Whereby, if the solvent is made up of polar molecules, such as water, solutes which are also 
polar are much easily dissolved than those which are non-polar (15). This is because of the 
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attraction between the polar solute molecules and the polar solvent molecules. Despite this, 
minute amounts of non-polar solutes can dissolve in polar solvents, probably due to the much 
weaker dipole-induced dipoles attractions induced by polar solvent molecules on non-polar 




Another factor which influences the solubility of a solute is the pH of the solution. This is 
specially the case with weakly acidic, basic and zwitterionic drugs. Since majority of the drugs 
are either weakly acidic or weakly basic, pH of the solution plays a crucial role in their solubility 
(10). Once in solution, these drugs exist as either the unionised or the ionised form in an 
equilibrium where proportion of either is dependent upon the pH of the solution. For weakly 
acidic drugs (HA) and weakly basic drugs (B), this equilibrium is usually expressed using the 
following equations (10, 15). 
 
For a weak acid: 
𝐻𝐴 ⇌ 𝐻+ + 𝐴− 
 
For a weak base: 
𝐵 + 𝐻+ ⇌ 𝐻𝐵+ 
 
The equilibrium between the ionised and the unionised form is dependent upon the pH in 
relation to the pKa of the ionisable sites of the drug (10). pKa is the pH at which 50% of a drug, 
whether weakly acidic or weakly basic, exists in the ionised form whilst the other 50% exist in 
the unionised form. Another simple rule to keep in mind is that an acidic group becomes 
ionised in a more basic pH whilst a basic group becomes ionised in a more acidic pH. This 
means that for weakly acidic drugs, an increase in pH above the pKa of the acidic ionisable 
site, increases the proportion of its ionised form, whilst decreasing the pH has the opposite 
effect. On the other hand, for a drug which is a weak base, an increase in pH above the basic 
group’s pKa will increase the amount in the unionised form whilst decreasing the pH would 
increase the proportion in the ionised form. This means that a formulation scientist can control 
the solubility of weakly acidic or basic drugs by experimenting with the solution pH (10, 15). 
 
Zwitterionic drugs have both an acidic group and a basic group. Therefore, like weakly acidic 
and weakly basic drugs, the solubility of a zwitterionic drug can also be altered by ionising 
either the acidic or the basic group. To add to this, the problem of pH dependent drug 
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degradation is more easily resolved with zwitterionic drugs due to the choice of using acidic 
or basic pH in solubility control. 
 
Although the behaviour of the ionisable sites can be predicted through the study of its pKa 
values and determination of solvent pH, exact degree of the ionisation of a weakly acidic and 
a weakly basic drug can be calculated using the Henderson-Hasselbalch equations below (10, 
15): 
 
For a weak acid: 
 





For a weak base: 
 





Ultimately, the rise of solubility attributed to a rise in ionisable form of a drug is due to the 
ability of the ionised or polar species to interact with polar water molecules. As mentioned 




After becoming dissolved, a drug can now be absorbed into the systemic circulation. At this 
stage, the absorption of the drug can be affected by both physiological factors as well as 
factors relating to the drug. Physiological factors include but are not limited to the availability 
of transport mechanisms through the selective phospholipid membrane and efflux of the drug 
back out from the cells. To add to this, factors relating to the drug also affect its absorption. 
These include lipid solubility, size and number of hydrogen bonds (10). 
 
Like with solubility, poorly permeable drugs will not be absorbed as much as highly permeable 
ones. However, unlike solubility greatly hydrophilic drugs are poorly permeable and thus are 
poorly absorbed through the phospholipid bilayer membrane (17). Since dissociation of weakly 
acidic and basic drugs into its ions makes them less lipophilic and more hydrophilic, the pH 
around the membrane at the site of absorption plays a crucial role in absorption. This has 
been covered in the pH-partition hypothesis by Overton in 1899 and takes into account passive 
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diffusion, the most common route of drug permeation (10). Briefly, only drugs present in the 
unionised form, which exist in an equilibrium whose proportion is effected by the pH around 
the absorption site, will passively diffuse through the membrane. However this hypothesis 
does not explain why drugs that are predicted to exist in the ionised form at physiological pH 
are absorbed through the gastrointestinal tract. One theory put forward for these drugs is the 
formation of ion-pairs, resulting in neutral species which are then able to be absorbed (10). 
 
A drugs ability to be absorbed through the membrane can predicted by determining its 
partitioning behaviour between water and a lipid-like solvent such as octanol (10). Partition 
coefficient (P) of a particular drug under set condition can therefore be calculated using the 
following equation: 
 
𝑃𝑎𝑟𝑡𝑖𝑡𝑖𝑜𝑛 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 =  
𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑜𝑟𝑔𝑎𝑛𝑖𝑐 𝑝ℎ𝑎𝑠𝑒
𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑤𝑎𝑡𝑒𝑟 𝑝ℎ𝑎𝑠𝑒
 
 
The value of P obtained is then converted to logP. Drugs with logP values between 3 and 6 
are optimal for passive diffusion through the lipid membrane (11, 12). 
 
Cell culture techniques using the well-established caco-2 cell line are quite common and well 
accepted model of intestinal absorption (10, 18). Along with permeability data, this cell model 
can provide useful insights into the mechanism of transport. Transport experiments on caco-
2 cells can be done in both apical to basolateral (A-B) direction as well as the basolateral to 
apical (B-A) direction. Passive transport can be assumed if the transport of a drug is equal in 
both directions. On the other hands, efflux by efflux pumps such as P-glycoprotein, is hinted 
by greater transport in the B-A direction (10, 18). 
 
Various other ways for determining the permeability of drugs are available. These include 
tissue studies and perfusion studies both in animals and humans (10). Permeability tests 
directly measure the rate of mass transfer across human intestinal membrane and therefore 
indirectly measure the extent at which the drug would be absorbed in a human (6). 
 
1.1.2.4 The solubility permeability paradox 
 
One of the factors required for a drug to dissolve is also the one which hinder its permeation 
and vice versa. In another words, both very hydrophilic drugs and hydrophobic drugs will have 
poor absorption in the GI tract since they will have very poor permeability and solubility 
respectively. Thus for a drug to be readily absorbed, it must be able to permeate the lipid 
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bilayer whilst also being able to dissolve in water. Optimal requirements therefore are that the 
drug be mainly hydrophobic whilst also being able to dissolve in water. This is one of the 
reasons why majority of the drugs tend to be either weak acids or weak bases (19). 
 
1.1.2.5 Biopharmaceutical classification system 
 
Depending on a drugs solubility and intestinal permeability the Food and Drug Administration 
(FDA) approved Biopharmaceutical Classification System (BCS) classifies it into one of four 
broad categories (20). These classes are presented in the Table 1.2. 
 
Table 1.2: Biopharmaceutical classification system 
 High Solubility Low Solubility 
High Permeability Class 1 Class 2 
Low Permeability Class 3 Class 4 
 
As presented in the table above, class 1 drugs are those which demonstrate both a high 
solubility and a high permeability. In normal circumstance, this allows for rapid uptake into the 
bloodstream and an excellent bioavailability (10). 
 
Having poor solubility, the absorption of class 2 drugs is limited by its low dissolution rate. 
Since solubility and dissolution rate is easier to modulate for a formulation scientist, drugs with 
a low solubility and high permeability are preferred over those with a low permeability and high 
solubility (10). 
 
Class 3 drugs are those which have high solubility but low permeability. Although high 
solubility helps, a formulation scientist can maximise permeation by ensuring very rapid 
dissolution (10, 20). This would allow exposure to the site of absorption for maximum time, 
increasing the total percentage able to permeate (10). 
 
Lastly, out of the four classes, class 4 drugs are the most challenging for a formulation 
scientist. As expected, they exhibit poor bioavailability. For oral delivery, prodrug formation or 
other novel strategies are need to adopted for drugs in this class to attain sufficient 
bioavailability (10). 
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FDA guidelines state that the BCS approach can be used to justify biowaivers for class 1 and 
class 3 immediate release drugs that demonstrate at least rapid in vitro dissolution rates (20, 
21). Biowaivers renders the need for in vivo bioavailability and/or bioequivalence studies 
unnecessary for the drug to be approved. The criteria required for meeting the high solubility, 
high permeability and rapid dissolution requirements of the biowaivers are outlined next. 
 
1.1.2.5.1 High solubility 
 
To meet the high solubility requirement, the highest dose of a drug which a biowaiver is 
requested for must be able to dissolve in 250 ml or less of water throughout the pH range of 
1-6.8 at 37 °C. The 250 ml represents the estimate amount of fluid available after oral dosage 
form ingestion along with a glass of water by a fasting individual. The requirement therefore 
ensures that all the drug within the highest dosage form is able to dissolve easily when taken 
by most patients. 
 
1.1.2.5.2 High permeability 
 
For a drug to be classified as highly permeable, it must demonstrate systemic bioavailability 
or absorption in humans of greater than 85% (20). FDA guidelines stipulate many methods to 
demonstrate high permeability including rate of mass transfer across human intestinal 
membrane and absolute bioavailability along with methods which predict absorption in 
humans including in situ intestinal perfusion using animal models and in vitro permeability 
studies using the caco-2 cell line (10, 20, 21). 
 
1.1.2.5.3 Rapid dissolution 
 
The third requirement for the eligibility of a biowaiver is the demonstration of rapid or very 
rapid dissolution. For this, the drug must be proven to exhibit 85% or more dissolution within 
15 minutes (very rapid dissolution) or 30 minutes (rapid dissolution) using USP apparatus 1 
or 2. Apparatus 1 must be set at 100 rpm whilst apparatus 2 must be set at 50 rpm and 
dissolution must be demonstrated in 500 ml of three different media; 0.1 N HCl, a buffer of pH 
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1.1.2.6 Lipinski’s rule of five 
 
Lipinski et al highlighted that HTS provides higher efficiency in lead generation and more 
therapeutic opportunities, however it is unable to predict for oral activity (22). This results in 
more leads, but they have less favourable physical properties resulting in worse oral activity 
profiles. Because of this, in 1995 Lipinski et al proposed ‘the rule of 5’ as a tool to predict for 
poor absorption or permeation. According to the rule, a formulation scientist should be aware 
of potentially poor lead absorption or permeation when two of the following are met (22): 
 
 “There are more than 5 H-bond donors (expressed as the sum of OHs and NHs)” 
 “The MWT is over 500” in daltons 
 “The Log P is over 5” 
 “There are more than 10 H-bond acceptors (expressed as the sum of Ns and Os)” (22) 
 
These rules are suggestive of solubility or permeability issues for the drug in question (23). It 
is worth highlighting that this rule only applies to such drugs which are not substrates of 
transport proteins (22). 
 
1.1.3 Mechanisms of oral drug absorption 
 
After successful dissolution, a drug must cross the lipid bilayer of the epithelial cells before it 
can reach its site of action. Whilst a comparably small amount of drug is absorbed in the 
stomach, majority of the drugs taken by mouth are absorbed in the small intestine due to the 
greater surface area available for absorption (17). Cell membranes are selective barriers due 
to their hydrophobic core and substrate specific proteins (6, 17). Three main mechanisms are 
well known which enable the transport of drugs across the membranes. These include ATP 
independent transport, active transport and endocytosis (6, 17). 
 
After being transported into the cell, some drugs can undergo efflux back out into the lumen 
of the small intestine. A common efflux transporter responsible for this is P-glycoprotein. This 
will be covered in more detail under the section ‘efflux pumps’. 
 
1.1.3.1 ATP independent transport 
  
Passive diffusion can occur through the lipid membrane (lipid diffusion) or aqueous channels. 
It is the mechanism through which most of the drugs are absorbed from the GI tract. Since 
Page 37 of 252 
this mechanism is passive, no energy is expended and the driving force for this mechanism is 
the concentration gradient. Drugs diffuse from an area of high concentration to an area of low 
concentration until equilibrium is reached. Other than concentration gradient, the main drug 
characteristics governing the diffusion rate are molecular size and shape, degree of ionisation, 
lipid solubility. Passive diffusion generally only enables small molecules to diffuse through. A 
specific type of passive diffusion, known as facilitated diffusion is the mechanism through 
which larger molecules are able to diffuse into the cell (7, 12, 17). 
Lipid soluble drugs show the highest rate of passive diffusion. However this relationship is not 
linear. This is because for a drug to passively diffuse across a lipid membrane, it must not only 
be able to partition into the membrane but back out of it from the other side (Figure 1.1). In 
other words, hydrophilic (LogP <3) drugs would find it difficult to partition into the membrane 
bilayer. On the flip side although drugs that are very hydrophobic (LogP >6) would rapidly 
partition into the membrane, they would find it difficult to partition out from the other side into 
the cell (11, 12). Membranes also contain aqueous channels through which drugs with higher 
hydrophilicity can penetrate (17). 
Figure 1.1: Polar drugs would find it difficult partitioning into the membrane bilayer, whereas very nonpolar 
drugs would find it as had to partition out the membrane, once in it (12). 
Since most drugs are weak acids or bases, in aqueous GI fluids they exist as both ionised and 
the unionised form, with the equilibrium dependent upon the pH of the surroundings. The 
ionised form is hydrophilic and thus is unable to be absorbed through passive diffusion 
whereas the unionised form is largely lipid soluble and is therefore able to be transported 
(Figure 1.2) across the membrane (12, 17). 
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Figure 1.2: Ionised form of the weak acid (A) and weak base (B) is passively able to diffuse through the 
membrane whereas the unionised version of the weak acid (B) and weak base (B) is not (17). 
Although facilitated diffusion utilises specialised transmembrane carrier proteins, like simple 
passive diffusion it also does not require any energy. The proteins enable the passage of 
larger molecules into the cell, again down the concentration gradient. During the process of 
transportation the carriers are able to undergo conformational changes to facilitate the 
passage of large molecules such as glucose (12, 17). 
1.1.3.2 Active transport 
Active transport utilises specific carrier proteins. Since these transmembrane proteins require 
energy, unlike in passive diffusion, active transport enables the passage of molecules against 
their concentration gradient. The energy for the process is derived from hydrolysis of 
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adenosine triphosphate. Drugs that are similar to natural endogenous metabolites are able to 




Endocytosis enables the transport of very large drugs into the cell. In this process, the drug is 
engulfed by part of the cell membrane which then gets pinched off inside the cell and forms a 
vesicle containing the drug. Like active transport, this mechanism also requires energy (17). 
 
1.1.4 Challenges and strategies for oral drug absorption 
 
Oral drug delivery is the most widely used route of drug administration due to its cost 
effectiveness as well as the comparably high patient compliance it offers as a consequence 
of its convenience in use. One of the most challenging hurdles is attaining a sufficient solubility 
which about 40-70% of all new chemical entities (NEC’s) fail to reach (8, 9). 
 
1.1.4.1 Oral drug delivery 
 
A drug can be administered to a patient through various routes, the choice of which is 
influenced by many factors. These routes include the oral route, parenteral route, topical route, 
respiratory route as well as the rectal and vaginal route. However oral drug administration is 
often the route utilised and preferred by both the patient and the physician. From the patient’s 
perspective, taking the drug orally is often more convenient, simple, safe as well as less time 
consuming. Whereas from a physician’s perspective the preference of the oral route is 
influenced by cost effectiveness as well as patient compliance which results from the ease of 
use this route presents to the patient (6, 12, 17). Thus this route offers convenience to the 
patients and a higher adherence rate is expected, which is mutually beneficial to both the 
patient and the health care system. 
 
However formulating a drug for oral administration is not always simple. The drug must be 
able to withstand enzymatic degradation within the gut while being stable in both acidic and 
alkaline pH. It must also show good level of stability with the food it will inevitably come in 
contact with. It must be resistant to efflux from the small intestine as well as survive first pass 
metabolism. Importantly, before the drug becomes available it must solubilise in water for it to 
be absorbed, and then be able to permeate through the gut lining into the blood stream (7, 
17). 
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1.1.4.2 The challenges 
 
Low solubility and low permeability are the most common causes of low oral bioavailability. 
Around 40-70% of NEC’s that are discovered, do not reach the market due to their poor water 
solubility profile. Thus herein lies one of the biggest challenges for a formulation scientist of 
today (8, 9). 
 
Even though challenging, enhancing the apparent solubility of drugs is therefore a crucial 
research area. Many methods have been developed in a bid to tackle this problem. When 
enhancing the solubility of a drug, the method chosen is dependent upon the drug 
characteristics and dosage requirements. These methods can be divided into three main 
categories; physical modifications, chemical modifications and other methods. Physical 
modifications include particle size reduction and solid dispersions. Chemical modifications 
include salt formation. Other methods such as supercritical fluid process and use of adjuvant 
like surfactant are also available (8, 9). 
 
1.1.4.2.1 Ways of overcoming challenges with solubility 
 
1.1.4.2.1.1 Self-emulsifying drug delivery systems 
 
Mohsin et al optimised self-nanoemulsifying drug delivery system (SNEDDS) to improve the 
solubility and bioavailability of the anticholesterol drug fenofibrate (24). Highest solubility was 
obtained with formulations containing mixed glycerides. They showed in vivo studies that the 
oral bioavailability of fenofibrate improved 1.7 times using SNEDDS as compared to the pure 
drug itself (24). 
 
Balata et al used self-emulsifying drug delivery system (SEDDS) to improve the solubility of 
resveratrol. The optimal formulation was then used to determine the effect of the formulation 
on the efficacy of the drug through in vivo studies (25). Various oils, surfactants and 
cosurfactants were screened for their individual effect on the solubility of resveratrol. Olive oil, 
Tween 80 and propylene glycol were found to be the best oil, surfactant and cosurfactant 
respectively in solubilising the drug. Therefore these components were combined with the 
drug to form the most optimal system. 
 
They found that the solubility of the drug was dependent on the concentration balance of the 
oil, surfactant and cosurfactant used. The proportion of each component effected the size of 
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the droplets; the smaller droplets with more surface area to volume ratio was generally found 
to solubilise more drug. The composition of oil to surfactant to cosurfactant weight ratio of 
200:266.7:533.3 was determined to be the best formulation and was used for further studies. 
In vivo studies showed significant results; the new formulation was nearly as effective as the 
unprocessed drug in decreasing the total cholesterol (25). The hypoglycemic effect of the drug 
followed a similar pattern and is likely due to higher bioavailability of the drug through the use 
of optimised SEDDS (25). 
 
Alqahtani et al prepared mixed micelles using cremophor EL, labrasol, captex and ethanol as 
a surfactant, co-surfactant, oil and co-solvent respectively. This SEDDS was prepared to 
increase the solubility and bioavailability of the poorly soluble and permeable drug ɣ-
Tocotrienol (26). To assess solubility, lipolysis was used to release the entrapped drug in the 
system. The drug was then quantified using HPLC. The group found that SEDDS formulation, 
had a better release profile (60% at 120 min) compared to the commercially available product 




Wang et al used the thin film hydration method to prepare liposomes which they loaded with 
naringenin to increase the solubility and bioavailability of poorly soluble drug. The liposomes 
consisted of phospholipid, cholesterol, sodium cholate, and isopropyl myristate. Liposomal 
characterisation studies revealed that stable liposomes were formed (27). 
 
Dynamic light scattering measurements using particle size/zeta potential analyser revealed 
an average particle of liposome to be 70.53nm whilst transmission electron microscopy 
showed that these naringenin loaded particles were spherical in shape. Furthermore since the 
average particle size of free naringenin particles was 21.35µm, 0.22µm filters were used to 
remove the naringenin which was not encapsulated into the liposome. This enabled the 
quantification of remaining encapsulated drug within the samples, using HPLC, and allowed 
the encapsulation efficiency of the liposomes to be determined. The results indicate majority 
(72.2%) of the drug was entrapped in the liposome (27). 
 
In vitro release profile revealed the dissolution rate of liposome loaded drug to be much higher 
(>90% in 72 hours) than free drug (<32%). It is likely that the dissolution rate was enhanced 
due to higher solubility of the drug in the liposome formulation compared to the free drug (27). 
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For tissue distribution study, fasted Kunming mice were orally administered with free and 
liposome loaded drug. Next the tissues of interest were dissected and the amount of drug in 
the respective tissue quantified. The study found that the liposome loaded drug, had a 
significantly higher distribution throughout all tissues compared to the free drug (27). 
 
1.1.4.2.1.3 Solid Dispersion 
 
Fong et al used freeze drying to formulate solid phospholipid dispersions for the poorly soluble 
drug celecoxib in order to increase its solubility and its effect on permeability. In the 
formulations, different concentrations of phospholipids were used to form the matrix around 
the drug (28). 
 
They found that the enhancement of solubility of the drug depended upon the concentration 
of the phospholipid in the formulation. Greater than 200 fold increase in solubility was 
observed for the formulations. The reason for the apparent enhancement in this solubility is 
twofold. Firstly the solubilising effect of liposomes contributes to this enhanced solubility. 
Secondly, freeze drying changed the state of the drug from the crystalline state to an 
amorphous state. Since the forces between the molecules of a substance in the amorphous 
state are weaker than those in the crystalline form, it is more easily dissolved. Due to this 
reason, they also found that freeze drying on its own caused a seven fold increase in the 
apparent solubility of celecoxib (28). 
 
Choonara et al used various concentrations of the hydrophilic substance menthol to make 
solid dispersions of sulfamethoxazole. This drug has low solubility and high permeability and 
therefore falls under class II of the BCS (29). 
 
The group used the co-melt technique in which heat and mixing was utilised to mix menthol 
and the drug to form the solid dispersions. They used various concentrations of menthol 
ranging from 1g to 10g, whilst the concentration of the drug was kept constant at 50mg per 
solid dispersion. They melted the menthol at 37°C, after which they added the drug to the 
melted menthol and raised the temperature to 160°C to melt the drug. Throughout this process 
magnetic stirring was utilised to ensure homogenous mixture of the two components in the 
melt state as well as when the solid dispersion is formed. Next 5% sucrose was added as a 
cryoprotectant; to prevent freezing and desiccation of menthol during the freeze-drying 
process. The resultant mix was freeze-dried and later mixed with hydroxypropyl 
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methylcellulose, sodium carboxymethyl cellulose and magnesium stearate before being 
compressed into tablets (29). 
 
To determine change in solubility of the drug through the formation of the drug loaded solid 
dispersion, as compared to the drug own its own, both the control and the solid dispersion 
were mixed for 48h in simulated human intestinal fluid and quantified thereafter. They found 
that the solubility of the drug was higher in the drug-loaded solid dispersions compared to 
control. Furthermore, the higher the content of menthol in the dispersion, the higher the 
resulting solubility was (29). The increase in menthol concentration and solubility was also in 
line with a decrease in crystallinity and therefore and increase in amorphous form of the 
product as well as decrease particle size and therefore an increase in surface area to volume 
ratio (29). 
 
1.1.4.2.1.4 Complex formation 
 
Sanka et al used skimmed milk as the host to form inclusion complexes with the poorly soluble 
drug piroxicam. They made this complex using the rotary evaporator technique. They found 
that skimmed milk was a good carrier in not only increasing solubility (2.5 times) but it also 
significantly decreased the gastric side effects, such as ulceration, associated with such non-
steroidal anti-inflammatory drugs (30). Milk contains amino acids so it may be possible that 
interaction of the drug with these amino acids may be one of the potential underlying causes 
for the enhancement of solubility. 
 
1.1.4.2.1.5 Supersaturated Drug Delivery System 
 
Ganesh et al developed a supersaturated drug delivery system (SDDS) where chitosan was 
used to form cocrystals of aceclofenac which were embedded within alginate beads. The aim 
was to enhance the solubility of the drug through co crystal formation to enable controlled 
released through the formation of an alginate matrix around the cocrystals (31). Various 
mechanisms are underplay in the enhancement of dissolution rate through the use of chitosan. 
These include particle size reduction, enhanced wettability of the system as well as alteration 
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1.1.4.2.1.6 Other solid dispersions 
 
Rashid et al conducted a study to compare the effectiveness of various solubility enhancing 
techniques in enhancing the physicochemical characteristics of the drug ezetimibe. In this 
study the group compared SNEDDS, surface modified solid dispersions (SMSD) as well as 
solvent evaporated solid dispersion (SESD). All systems were loaded with the drug and 
aqueous solubility, dissolution and oral bioavailability was investigated (32). 
 
Spray drying techniques were used to prepare all formulations. The group found that SNEDDS 
were the best in improving the physicochemical characteristics of the drug followed by SESD 
and lastly but not least, since it also improved the characteristics, SMSD. This pattern 
correlates with the particle size achieved with each formulation; SNEDDS gave the smallest 
particle size (6 µm) whilst SMSD gave rise to the larges particle size (24µm). Also of interest 
is that the drug was present as an amorphous form in SNEDDS and SESD but as a crystalline 
form in SMSD formulations (32). 
 




Yousaf et al developed nanoparticles (referred to as nanospherule) using the electrospraying 
technique. These nanoparticles were loaded with a BCS class II drug fenofibrate to increase 
the solubility of the drug (33). The matrix composed of the polymer polyvinylpyrrolidone (PVP) 
and the surfactant Labrafil M 2125. 
 
Increasing the concentration of Labrafil in the formulation was seen to enhance the apparent 
solubility and hence also the dissolution rate of the drug. Thus the highest drug to Labrafil 
weight ratio of 1:0.5 was chosen to determine the effect of changing PVP concentration on the 
formulation. Like with Labrafil, increasing the PVP concentration also raised the solubility, but 
only up to a drug to PVP weight ratio of 1:4. Further increasing the PVP concentration did not 
give rise to any significant advancement in solubility. Finally the optimal formulation was 
chosen to be drug/PVP/Labrafil 1:4:0.5 and was used to do characterisation studies as well 
as in vivo oral bioavailability in rats. The oral bioavailability was found to be 2.5 times greater 
in the optimised formulation compared to the free fenofibrate (33). 
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1.1.4.2.2.2 Hot melt extrusion 
 
Ashour et al utilised the hot melt extrusion technique to increase the solubility, permeability 
and oral bioavailability of piperine using various polymers. Soluplus was found to be the most 
optimal polymer, enhancing the apparent solubility of piperine by 160 fold with the formulation 
containing 10% w/w piperine/Soluplus (34). 
 
1.1.4.2.2.3 Antisolvent Precipitation 
 
Sadeghi et al used the antisolvent precipitation or crystallisation technique to increase the 
solubility of curcumin which is an anticancer drug with poor solubility. They did this in the 
presence of polyvinylpyrrolidone K30 (PVP). Untreated curcumin was used as the control, 
whereas physical mixture of curcumin and PVP were used to distinguish the difference of 
effect of just PVP and the effect of antisolvent crystallisation on curcumin (35). 
 
For crystallisation, curcumin which was dissolved in acetone was added dropwise to aqueous 
solutions containing different amounts of PVP to give final weight ratios of curcumin to PVP of 
1:0, 1:1, 1:2 and 2:1. The resulting suspension was frozen and 24 hours later freeze dried. 
Physical mixtures of curcumin and PVP were prepared using a tumbling mixture using 
appropriate ratios of both substances (35). 
 
Solubility studies showed that curcumin in precipitated samples of curcumin and PVP had up 
to a twenty fold higher solubility compared to curcumin on its own or to the physical mixtures 
of curcumin with PVP. Curcumin which has been precipitated with PVP displays an amorphous 
state as compared to the curcumin precipitated without PVP or the untreated curcumin, both 
of which displayed crystalline structures (35). 
 
1.1.4.2.3 Ways of overcoming challenges with permeability 
 
1.1.4.2.3.1 Inhibition of efflux pumps 
 
Having been solubilised and absorbed into or through the membrane, the drug may be 
susceptible to efflux. Hence low bioavailability due to efflux of drugs is another challenge faced 
in oral drug delivery. Apart from low bioavailability, increased luminal concentration of the drug 
resulting from its efflux into the intestine can lead to intestinal toxicity. This highlights the need 
to overcome drug efflux to improve bioavailability. 
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A novel application of phospholipids were investigated by Simon S et al (36). They showed 
that two phosphatidylcholine (PC) derivatives 1,2-dicotanoyl-sn-glycero-3-phosphocholine 
(8:0 PC) and 1,2-didecanoy-sn-glycero-3-phosphocholine (10:0 PC) had significant in vitro P-
glycoprotein (P-gp) inhibitory activity (36). In this study the group only used phospholipids 
which demonstrated good formulation and no cytotoxicity to assess their interferences with P-
gp activity. They also suggest that the lipid molecules themselves were accountable for the 
inhibition of P-gp, whilst the shape and size of the aggregates and whether they formed 
liposomes or not did not seem to influence P-gp activity. They also concluded that intact 
phospholipids were required for their inhibitory effect on P-gp; free fatty acids, on the other 
hand, either did not have a significant inhibitory effect or led to decreased monolayer integrity 
evident from a significant drop in transepithelial electrical resistance (TEER) values. Further 
evidence to confirming P-gp inhibition by these phospholipids was found when Papp ratio 
decreased in P-gp transfected MDCKII mdr1 cell line to a much higher degree compared to 
those that were not transfected with P-gp (wild type) (36). 
 
Two main methods were used to determine a phospholipids inhibitory effects. The first 
involved the study of the transport of Digoxin, whilst the second was the calcein accumulation 
assay (CAA). In these studies the inhibitory effect of verapamil was taken to be 100%. The 
results for the test compounds were thus expressed as the relative inhibition compared to 
verapamil. In CAA, 8:0 PC displayed a relative inhibition of 50% and 80% in caco-2 and 
MDCKII mdr1 cell lines respectively. For 10:0 PC, the relative inhibition of P-gp was 80% in 
caco-2 cell lines, whilst the inhibitory effect of this phospholipid was 20% better then verapamil 
in MDCKII mdr1 cell lines at 120% relative inhibition (36). 
 
They showed using wildtype MDCKII cell lines that the P-gp inhibition was the mechanism 
involved. After incubation with the test phospholipids and as compared to control the 
fluorescence of calcein increased dramatically (up to 9 fold) in cells with P-gp expressed 
(MDCKII mdr1) as compared to wildtype cells which do not express P-gp (36). 
 
The P-gp ATPase activity studies showed that the mechanism of p-gp inhibition of cis-22:6 
PC was indirect, since this phospholipid did not affect P-gp ATPase activity. 8:0 PC and 10:0 
PC on the other hand both reduced the P-gp ATPase activity which was induced by verapamil. 
Furthermore, 10:0 PC was also shown to reduce basal activity of P-gp ATPase. The group 
concludes that both 8:0 PC and 10:0 PC act through a direct mechanism to induce P-gp 
inhibition (36). 
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Further in vivo work by the same group showed that these phospholipids can also be used to 
increase bioavailability (37). They investigated the effect of incorporating phospholipids on the 
bioavailability of orally administered ritonavir. To do this they used the animal model Wistar 
rats and administered 20mg/kg suspension of ritonavir along with 1mM of test compound into 
their stomach. 
 
Although 8:0 PC and 10:0 PC did not match the P-gp inhibiting effects of verapamil or Tween®, 
nevertheless they exhibited a significant increase in bioavailability of ritonavir represented by 
an 18 and 14 fold increase in the area under the curve respectively (37). 
 
Derivatives of PC are present in a normal diet and thus it is hoped that as long as the total 
administrated lipid is not more than that which classifies it as a xenobiotic, it is unlikely to have 
any adverse effects. It is also suggested that a systemic side effect of using phospholipids is 
unlikely due to their degradation by digestive enzymes. The author highlights that use of 
surfactants such as Tween® may have adverse effects. Thus it is suggested that the 
phospholipids, although less effective then Tween®, may be a safer option since although 
synthetic, they are made up of moieties natural to the body (37). 
 
1.1.4.2.3.2 Balancing toxicity verses permeability approach 
 
Intestinal permeation enhancers offer a good way to improve bioavailability. However their use 
has been limited due to a somewhat toxicity concerns. Whitehead et al studied 51 permeation 
enhancers generating a database highlighting their potency and toxicity (38). 
 
Whitehead et al studied 51 different permeation enhancers at three different concentrations 
(0.01%, 0.1% and 1% w/v); thus a total of 153 formulations were studied. Whitehead et al 
found that both permeation enhancement and toxicity of the 51 chemical permeation 
enhancers (CPEs) were dependent upon their concentration. However they also found that 
the extent of permeation enhancement and toxicity significantly varied across all chemical 
categories (38). 
 
Their study confirmed the commonly held perception that if CPEs are strong enhancers of 
permeability, they are also very toxic or that if CPEs are not very toxic, they are weak 
enhancers of permeability. However the production of this database allows the recognition of 
a few formulations that are potentially best of both; significantly low toxicity whilst having a 
significantly high permeation enhancement effect (38). Thus considering both the 
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enhancement potential and toxicity, the authors created a new parameter called overall 
potential (OP). The largest OP was observed for the chemical category of anionic surfactants 
and was followed by zwitterion surfactants. Furthermore, using OP values the authors were 
able to rank the formulations and found that six out of the top ten best and safest enhancers 
were of the low concentration (0.01% w/v). According to the author this highlights the need to 
study a chemical enhancer at different concentrations before ruling it out (38). 
 
The highest OP value was obtained for Phenyl piperazine (PPZ) which identified it as the most 
optimal permeability enhancer. 0.1% PPZ was found to enhance the permeability of mannitol 
and dextran by 14 and 11 fold respectively. Furthermore TEER values returned to original with 
24 hours of removal of PPZ from the media. This shows the potential applicability of not only 
PPZ but also the database to pinpoint the most safe and effective CPEs (38). 
 
1.1.4.2.3.3 Ion-pair formation 
 
Isabel et al used the concept of ion-pairing to improve the permeability of atenolol at the colon. 
The counterions used were acidic, brilliant blue and bromophenol blue (39). Histological 
assessment was carried out using microscopy to determine membrane integrity (39). No 
significant damage to the colon was observed through microscopy and therefore it is likely that 
the enhancement in permeability was due to ion pairing and not due to loss of membrane 
integrity (39). 
 
Since majority (>87%) of atenolol was present in the aqueous phase for each assay, whether 
or not ion pairing occurred was unclear form the partitioning studies (39). 
 
Nevertheless, In situ permeability studies were carried out on the male Wistar rats. 500µM 
concentrations of both atenolol and the counterions were used in the study; that is a 1:1 molar 
ratio. The use of these counterion did attain the desired outcome of enhancing the permeability 
of atenolol. Of particular note is that permeability was found to be better in brilliant blue (Papp 
0.508 X10-4 cm/s) compared to bromophenol blue (0.405 X10-4 cm/s). Bromophenol blue has 
previously been found to be a suitable counterion, however it is toxic. This study therefore 
shows that brilliant blue, a food additive, may be a suitable counterion. However, the author 
states that majority of brilliant blue is excreted without being absorbed (39). Therefore, if the 
lack of toxicity associated with brilliant blue is due to lack of its absorbance, this formulation 
may lead to brilliant blue associated toxicity since ion pairing will increase its absorption from 
the colon. 
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Interestingly, ion-pair formation is not only linked to permeability enhancement, but has shown 
evidence to overcome both solubility and permeability. To add to this, the same substance 
which enhances solubility has also been linked to the enhancement of permeability. ElShaer 
et al, has used the concept of ion pairing to assess its impact on the apparent solubility and 
permeability of model drugs. The concept utilises amino acids as counterions to drugs with 
the aim that the drug would form an ion pair with an oppositely charged amino acid in solution, 
thereby modifying the drugs physicochemical characteristics. ElShaer et al, has shown that 
the apparent solubility and permeability of drugs can be improved through the use of amino 
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1.2 Drug delivery in bacteria 
Challenges with delivering drugs are not restricted to just absorption of orally administered 
drugs through the GI tract. Bacteria present a more sophisticated level of barrier to 
antimicrobial agents, a barrier which is also ever evolving. The effectiveness of the bacterial 
envelop to function as a barrier differs depending on which two of the broad class of bacteria 
it belongs to; gram-positive or gram negative. This is because of the difference in bacterial 
envelop between these two classes, some of which, along with mutual features are presented 
in Table 1.3 (41). 
Table 1.3: Features of gram-positive and gram-negative bacterial envelop. 
Gram-positive Gram-negative 
Peptidoglycan Thick Thin 
Outer membrane Absent Present 
Periplasm Absent Present 
Inner membrane Present Present 
Although gram-positive bacteria have a thicker cell wall comprising of peptidoglycan, it does 
not present much resistance to diffusion of antimicrobial agents. The outer membrane of gram-
negative bacteria on the other hand confers substantial resistance acting as an effective 
barrier. The diffusion of otherwise permeable hydrophobic molecules is greatly hindered by 
the outer membrane due its outer leaflet being composed of lipopolysaccharide (LPS) (42). 
There is a presence of asymmetry in the outer membrane, caused by LPS being exclusively 
present in the outer leaflet, whilst the inner leaflet is composed of the typical phospholipid (43). 
Along with this asymmetry, the saturated fatty acid chains of LPS drastically reduce the fluidity 
of the interior of the outer membrane, which in phospholipid bilayers is fluid (41). Ultimately, 
this reduction in fluidity is understood to be the cause of reduced permeation (44, 45). 
1.2.1 Antimicrobial resistance 
Along with the barrier, bacteria themselves are ever evolving. This evolution has given rise to 
antimicrobial resistance (AMR) to such extents that it has become a threat to global public 
health with the World Health Organisation (WHO) referring to it as a crisis (46). Fearing a post-
antimicrobial era, where even common infections may prove fatal, the World Health Assembly 
held on May 2015 implemented a global action plan outlining the following five objectives (46): 
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 “to improve awareness and understanding of AMR through effective communication,
education and training;
 to strengthen the knowledge and evidence base through surveillance and research;
 to reduce the incidence of infection through effective sanitation, hygiene and infection
prevention measures;
 to optimize the use of antimicrobial medicines in human and animal health;
 to develop the economic case for sustainable investment that takes account of the
needs of all countries and to increase investment in new medicines, diagnostic tools,
vaccines and other interventions (46).”
To add to this WHO has published a list of priority pathogens to focus research and 
development. After declaring Mycobacterium tuberculosis caused infection tuberculosis to be 
the number one killer, WHO provides a list of 12 pathogens grouped into critical, high and 
medium priority (47). This list is presented in the Table 1.4. 
Table 1.4: List of priority pathogen proposed for research and development published by WHO (47). 
Critical Priority High Priority Medium Priority 
Acinetobacter baumannii Enterococcus faecium Streptococcus pneumoniae 
Pseudomonas aeruginosa Helicobacter pylori Haemophilus influenzae 




1.2.2 Origin of antimicrobial resistance 
The role of human use of antibiotics as a cause of AMR is well established and links between 
antibiotic consumption and AMR shows strong correlation (3). However, it seems that all AMR 
does not have to be anthropogenic in origin. Bacteria strains resistant to as many as 14 distinct 
antibiotics have been discovered in caves isolated from apparent human influence for 4 million 
years (48). Thus, AMR is an ancient, naturally occurring by-product of bacteria fighting to 
survive in various environments and communities. To add to this, resistance is not always 
acquired. Bacteria also exhibit intrinsic resistance, which is resistance conferred by genes 
which are already present in the genome of a species or genus (49). Acquired resistance on 
the other hand occurs in the presence of selection pressure, most likely due to exposure to 
antibiotics. These antibiotics also include naturally secreted substances by neighbouring 
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species. Nevertheless, the selection pressure can confer resistance by two different 
mechanisms; mutation of genes to a more resistance genotype and acquisition of resistance 
DNA through horizontal gene transfer (50). 
 
1.2.2.1 How does mutation lead to resistance? 
 
During natural cell division, mutations in genes are likely to occur. Since bacteria generally 
have a much higher rate of cell division compared to eukaryotic cells, this confers them high 
rates of mutation also. Ultimately mutations in genes can lead to a phenotype which can affect 
the activity of a particular drug (50). In the presence of such a drug all susceptible bacterial 
cells would be wiped out, leaving only those with the mutation to survive. Finding no 
competition and no drug to kill them, these resistant cells continue to divide and ultimately 
become the dominant phenotype, giving rise to resistance. This shows that use of 
antimicrobial agents selects for the resistant phenotypes, since without it the natural 
phenotype would predominate and the mutated cells would eventually die out. Misuse of 
course would only speed up this process; bringing to light why WHO in their global action plan 
hope to optimise antibiotic use (46). The exact mechanism of resistance will be covered under 
the section ‘conventional resistance mechanism’. 
 
1.2.3 Extent of the crisis of antimicrobial resistance 
 
Table 1.5 presents some of the common antimicrobial agents along with their mechanism of 
action, classification, aqueous solubility, type of bacteria it is effective against, known 
mechanisms of resistance, whether it is effluxed or not and also the route of administration. It 
also serves as a reminder that resistance has been established for all common antibiotics.  
 
To add to this, AMR is not restricted to particular locations. Instead it is a global threat. The 
WHO first published a report on the global surveillance of AMR in 2014, stating that AMR 
resistance has reached “alarming levels” in many parts of the world (51). Realising global AMR 
surveillance to be the key in deploying global strategies, in 2015 the WHO initiated the Global 
Antimicrobial Resistance Surveillance System (GLASS) (51).  
 
Despite this, most of the pharmaceutical companies have stopped research into new 
antimicrobial agents (46). This in combination with increasing rise in clinical resistance to 
antibiotics highlights why the 5th objective of the global action plan was necessary and 
reiterates the need for research into novel strategies in combating AMR globally. 
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Table 1.5: List of common antimicrobial agents including their mechanism of action, classification, 
aqueous solubility (E: experimental, P: predicted), type of bacteria it is effective against, mechanisms of 
resistance, whether it is effluxed or not and also the route of administration (3, 52-54).  
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1.2.4 Conventional resistance mechanisms 
 
Resistance in bacteria whether intrinsic or acquired through mutation, vertical gene transfer 
or horizontal gene transfer can be looked at mechanistically. Some of the more conventional 
mechanisms of antimicrobial resistance will be covered in this section, whilst the following 
section will explore resistance of bacteria within biofilms. 
 
1.2.4.1 Enzymatic inhibition, deactivation or destruction of the antibiotic 
 
Being one of the most common and successful forms of antimicrobial resistance mechanisms, 
enzymatic action on the antimicrobial agent refers to the process where the antibiotic is 
inactivated by modification or destruction through the aid of enzymes. These processes 
include hydrolysis, transference of functional groups as well as other chemical modifications. 
The end result is that the drug is unable to function as intended. 
 
Aminoglycoside modifying enzymes (AMEs) are a prime example of enzymes which 
chemically modify the aminoglycoside antibiotics. Covalent modification of the hydroxyl or 
amino groups of the aminoglycoside antibiotics leads to such an alteration which renders the 
antibiotic inactive (50). Likewise, enzymes which destroy the antibiotic also exist. β-
lactamases such as penicillinases are well known examples for this category and they pose 
major problems specially in gram-negative bacteria (50, 55). Breakdown of the amide bond by 
these enzymes leads to destruction of the β-lactam ring in antibiotics possessing these rings 
(50). 
 
1.2.4.2 Decreased drug influx or increased efflux 
 
Since majority of antimicrobials have targets within the cell or on the inner membrane, to illicit 
the desired effect, the drug must be able to penetrate through at least one or in some cases 
through both of the membranes (50). This presents bacteria for another opportunistic route to 
develop resistance. A decrease in intracellular levels of the active compound can be either 
due to a decrease in its uptake or an increase the rate at which it is pumped back out. Efflux 
will be covered later in its own section. Since one of the mechanism of drug penetration into 
the cell is via porins, a reduction in their expression can lead to reduced uptake as is the case 
with β-lactams and fluoroquinolones (54). Being hydrophilic, these antibiotic generally prefer 
to use the water-filled porins to migrate into cells (50). 
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1.2.4.3 Interference with the target site 
 
Another common mechanism of resistance bacteria utilise is preventing the interaction 
between the drug and its target. They do this in two primary ways; target protection and target 
modification. Examples of target protection are the TetO and TetM proteins which dislodge 
tetracycline from its binding site on the ribosome (50). 
 
Target modification can be due to mutation of the target site, target site alteration via enzymes 
or complete replacement or bypass of the target. Some bacteria are also able to become 
resistant by overproducing the target of the antibiotic, requiring no modification of the target 
site (50). Mutation of the genes coding for a specific target site greatly reduces the affinity of 
the antibiotic. Rifampin is an antibiotic effected by this mechanism of resistance. Mutation in 
the genes coding for RNA polymerase reduce the affinity of Rifampin for the enzyme, the 
binding of which would otherwise interrupt transcription (50). Thus mutation leading to binding 
site alteration allows transcription and hence protein production and normal cell physiology to 
continue, leading to resistance. 
 
Enzymatic modification of the target site leads to resistance in a similar manner. A good 
example which represents this mechanism is the enzyme coded by the erm (erythromycin 
ribosomal methylation) genes (50). Macrolides are a class of antibiotics which prevent protein 
synthesis by binding to the 50s subunit of the ribosome (56). The enzyme causes mono- or 
demethylation of a residue of the 50s ribosomal subunit. This modifies the target site 
preventing binding of macrolide antibiotics to its target, and resistance ensues (50). 
 
The final mechanism which can be grouped under target modification is complete replacement 
of the target. It refers to the ability of bacteria to no longer require a component which is a 
target of an antibiotic. This is achieved by the production of new components which serve the 
same function as the original component (50). Meaning that antibiotic inactivation of the 
original component is unable to hinder normal functioning of the bacteria. To demonstrate this, 
the example of penicillin binding proteins (PBPs) will be used. PBPs play a crucial role in the 
synthesis of peptidoglycan through transpeptidation and transglycosylation of peptidoglycan 
units. Peptidoglycan is a major component of bacterial cell wall and since β-lactam antibiotics 
function by binding to PBPs, this leads to incomplete and thus unstable cell wall, unable to 
sustain the life of the bacteria. Returning back to the mechanism of resistance, horizontal gene 
transfer resulted in Staphylococcus aureus (S. aureus) to acquire the gene mecA, a gene 
which codes for the production of PBP2a. Not only do β-lactams have low affinity for PBP2a, 
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the protein can also replace the function of PBPs (50). Thus although the antibiotic can still 




Biofilms utilise a unified behaviour of its microbes to facilitate their survival in an otherwise 
adverse environment. Biofilms are increasingly gaining attention because of their role in 
antimicrobial resistance (57). They are communities of sessile microorganisms (bacteria or 
fungi) living in a self-produced matrix (matrix of extracellular polymeric substances) which aids 
the survival of these microorganisms (58). Biofilms are not restricted to comprising of one 
species, instead they can contain communities of multiple species. Yet these communities 
within biofilms are highly organised and function cooperatively (59). Lawrence et al, showed 
through scanning confocal laser microscopy, the structure of biofilms to be micro-colonies 
separated by a network of open water channels (59, 60). This simple example demonstrates 
the level of interspecies and intercolonial signalling required to direct colonial growth in a 
structured way that it does not obstruct the water channels (59). Even though researchers 
have only begun to look into the interspecies communication that result in such highly 
functional and thriving multispecies communities; yet it is clear that a level of interspecies 
cooperation and tolerance is undoubtedly in play (59). 
 
The formation of biofilm can be divided into stages. Firstly planktonic bacteria attach to a 
surface reversibly (58). At this stage the bacteria are still susceptible to antibiotics; hence 
prophylaxis in alloplastic surgery proves very useful as at this stage the bacteria are able to 
act on the planktonic forms which become reversibly attached (57). In the next stage, the 
bacteria become irreversibly attached through self-adhesion structures such as pili, multiplying 
and forming colonies. Furthermore, extracellular polymeric substances, which form the matrix, 
then become secreted and become deposited around the colonies (57). The matrix is very 
resourceful for the communities and consists of water, polysaccharides, proteins, lipids and 
DNA (57). Hydrogen bonding between water molecules and hydrophilic polysaccharides holds 
water within the biofilms whilst polymers such as glycopeptides, lipids and lipopolysaccharides 
aid in scaffolding and holding the biofilm together (57). As the biofilm grows thicker, it becomes 
mature; a process which is coordinated through quorum sensing and other signalling (57). 
Finally, the sessile bacteria in the biofilm are able to become free and spread to other surfaces 
to form new biofilms (57, 58). 
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These functional and structural adaptations which lead to the interrelationships present in 
biofilms are due to expression of genes which make the phenotypes of the bacteria within 
biofilms profoundly different from the planktonic forms of the same species (59). Biofilms are 
highly evolved systems, so much so that on estimate >99.9% of microbes are present as the 
biofilm form whilst planktonic phenotypes only account for <0.1% of the total microbial biomass 
(59). This demonstrates the survival advantage that bacteria in biofilms have compared to 
planktonic forms and hints at their clinical significance. Bacteria within biofilms can exhibit 
resistance to antibiotics, disinfectant chemicals and many components of the immune system 
(57). Furthermore biofilms can grow in many environments and on both biotic and abiotic 
surfaces (57). The survival advantage due to the adaptations ultimately enables biofilms to 
exhibit harmful clinical manifestations. 
 
Resistance to antibiotics can be up to 1000 times higher for bacteria in biofilms and the 
underlying mechanisms of resistance are likely to be a combination of conventional resistance 
mechanisms found in planktonic phenotypes as well as those specific to biofilm phenotypes 
(58). Such specific mechanisms include retardation of antibiotic diffusion by the biofilm matrix 
as well as slowed growth of bacteria due to decreased metabolic rate in biofilms (57). The 
latter leads to resistance because most antibiotics have their effect on rapidly dividing cells 
(58). 
 
Another theory which may bring light to the resistance observed within biofilms is that of 
persisters (61). These are a small population of bacterial cells which are able to survive despite 
aggressive antibiotic exposure (61). Whereas small populations of planktonic forms, which 
may remain after antibiotic therapy, would be eliminated by the immune system, in biofilms 
these would survive and lead to the restoration of the biofilm post-antibiotic therapy (62). It is 
proposed that these persisters are able to survive within biofilms due to damaged apoptotic 
mechanisms (63). Although other mechanisms mentioned above specific for biofilm resistance 
are likely to also be involved. 
 
Biofilms forming bacteria are commonly associated with chronic infections, which are 
infections that persist despite antibiotic therapy and the body’s immune response (57). The 
sessile communities in biofilms can give rise to planktonic forms, which in turn give rise to the 
disease state (58). Since the bacteria in biofilms are highly evolved in survival, biofilms act as 
a base which poses constant threat to the body through continuous release of virulence factors 
and planktonic forms (57). Hence a chronic state of infection is maintained due to the inability 
of the immune system or drugs to eradicate the biofilm.  
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Their ability to grown on abiotic surfaces can result in complications with implants as well as 
catheters. A good example which highlights the danger associated with biofilms is a biliary 
stent in which the growth of Escherichia coli (E.coli) biofilm led to repeated incidents of sepsis. 
Antibiotic therapy was of no avail and the second episode of sepsis proved fatal. DNA typing 
revealed that the same E.coli clonal type was present in the biofilm as the one responsible for 
sepsis (57). 
 
There is an urgent need therefore for strategies which can successfully and safely prevent as 
well as those which can treat a biofilm infection. The strategies studied can be divided into 
four major categories; prevention of biofilm formation, weakening of the biofilm, disruption or 
dispersal of the biofilm and killing of bacteria specially the subpopulation which persists (58). 
 
One strategy utilises D-amino acids to inhibit and disperse biofilms. Their role was seen after 
factors D-leucine, D-methionine, D-tryptophan and D-tyrosine, isolated prior to disassembly of 
Bacillus subtilis were found to prevent biofilm formation as well as cause its dispersal. It was 
found that D-amino acids caused cells in the biofilm to release amyloid fibres which were 
involved in linking cells in the biofilm together. YqxM was found to be the protein required in 
the formation and anchoring of the Tas A amyloid fibres to the cells (64). Strains with mutations 
in this protein were able to form biofilms in the presence of D-amino acids (65). 
 
Since this understanding, D-amino acids have also proved to be effective as strategies for the 
prevention and dispersal of biofilms in other bacteria (66). It has been observed that using L-
amino acids has no effect (65). They have also been studied and proved effective in 
combination with antimicrobials in a bid to overcome the antimicrobial resistance of biofilms. 
 
1.2.6 Combinatorial therapy 
 
One of the strategies used by clinicians with the aim of overcoming AMR is the use of antibiotic 
combinations (67). Though this was effective, and also holds the benefit of decreasing the 
chance of AMR occurrence, resistance can still occur (67). An issue related to using multiple 
antibiotics in combination is that bacteria can emerge with resistance to multiple drugs instead 
of just one. Dependent on extent, this can give rise to what is known as multidrug resistance, 
extensive drug resistance and pan drug resistance (68). 
 
Another way to enhance the efficacy of antibiotics prone to resistance is the use of adjuvants. 
Antibiotic adjuvants are substances that can enhance the activity of a drug, most likely by 
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interfering with the resistance mechanisms. Generally, they show no antibiotic activity on their 
own (67). One example of antibiotic adjuvants which are in use and in clinical development 
are β-lactamase inhibitors (69, 70). Bacteria can develop resistance to the class of β-lactam 
antibiotics by producing enzymes (β-lactamases) which are able to hydrolyse the antibiotic 
rendering it ineffective (70). Knowing this however, opens the opportunity to develop 
compounds which can inhibit the enzymes. Thus, β-lactamase inhibitors structurally mimic the 
β-lactam and work by irreversibly or reversibly binding on or near the active site of the enzyme, 
thus rendering the enzyme ineffective, and overcoming resistance to β-lactam antibiotics (70). 
However, given the nature of resistance, it is probably not long before enzymes that are 
resistant to these inhibitors are produced by bacteria, leaving room for research into adjuvants 
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1.3 Ion Pairs 
 
Ion pairs are neutral species formed in a solution through the columbic (electrostatic) attraction 
between oppositely charged ions. They are often sufficiently lipophilic, enabling them to 
dissolve in non-aqueous solvents (72). Since ion-pair formation can be used to enhance 
solubility and permeability of drugs, they are looked at in some depth here. 
 
1.3.1 Ion pair formation 
 
In a solution, the charge of a free ion polarises the surrounding solvent molecules. This leads 
to a solvent-ion interaction between the newly polarised solvent molecules and the ion. Once 
this interaction is strong enough, the ion is said to exhibit a tight solvation shell (72, 73). 
 
Once a counterion approaches an ion possessing a solvation shell, one of the two outcomes 
are possible. First possibility is that the solvation shell is maintained and the association is that 
of a loose ion pair. These can be of two types depending on whether the primary solvation 
shells of both ions are maintained (solvent separated ion pair) (Figure 1.3A) or both ions share 
one solvation shell (solvent shared) (Figure 1.3B) (74). In the second case, the solvent 
molecules (of the solvation shell) separating the two ions are pushed aside, leading to a 
stronger interaction and the formation of a tight (contact) (Figure 1.3C) ion pair (73, 74). 
 
A B C 
 
Figure 1.3: Types of ion pairs. A) Solvent separated ion pair. B) Solvent shared ion pair. C) Contact ion 
pair. 
 
Therefore one of the requirements for the formation of a loose ion pair is the availability of 
solvent molecules with which the free ions can form a solvation shell. If such medium is not 
present, only tight ion pairs will form (72-74). 
 
The two ions must breach a critical separation distance (D) in order to form and be classified 
as an ion pair. This distance is dependent upon the cationic charge (Z+), anionic charge (Z-), 
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electron charge (e), dielectric constant (ε) and absolute temperature (T) (72, 73). The 
relationship of these values to the critical separation distance can be seen through the 
Bjerrum’s equation (where k is the Boltzmann’s constant): 





The dielectric constant is therefore an important parameter in ion pair formation. According to 
the above equation, ion pairs would form more readily in solvents with a lower dielectric 
constant, corresponding greater critical separation distance in such medium (72, 73). 
 
1.3.2 Ion pair solubility 
 
The solubility of an ion pair is dependent upon the charge accessibility on the ion pair by the 
solvent molecules. Utilising this concept, Higuchi proposed the solvation of ion pairs through 
three (Figure 1.4) distinct cases (74). Case one (Figure 1.4A) represents an ion pair with a 
large cation (mainly lipophilic except the positively charged centre) and a small anion. Due to 
their size, the anion carries a relatively high charge per unit area compared to the cation. 
Therefore, this ion pair would be solvated by lipophilic molecules carrying exposed positively 
charged surfaces (alcohols and dipolar molecules with acidic protons e.g. phenol). Being next 
to the anion, these positive charges would be ‘buried’, portraying this system as relatively 
nonpolar (74). 
 
Complete opposite was proposed for the second case (Figure 1.4B) of ion pairs; the ion pair 
would be solvated by lipophilic molecules with exposed negatively charged surfaces, 
surrounding the cation (74). Third case (Figure 1.4C) represents an ion pair with no exposed 
polar surfaces due to deeply buried charges, and hence cannot undergo solvation in polar 
media. This ion pair can be extracted by non-polar solvents (74). 
 
A B C 
 
Figure 1.4: Three cases of ion pair solvation. A) Large cation and a small anion. B) Large anon and a small 
cation. C) Both cation and anion are large. 
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1.3.3 Ion pair aqueous solubility 
 
Despite water having a high dielectric constant (ε = 78.5) Diamond used the term “Water 
structure enforced” to explain the formation of ion pairs in such medium (75). Ion pairs in water 
can form if both the cation and the anion are large and hydrophobic. In such a case the ions 
are forced together due to the hydrophobic interactions between ions and the hydrogen-
bonded water structure. Ion pair formation in water is therefore due to solvent mediated effect 
as well as electrostatic attraction, with relative contribution of either depending upon the 
properties of the ions and solvents in question. Given that this electrostatic interaction is likely 
to be comparatively weaker, and that ion pairing is limited to low concentrations (due to low 
solubility), the usefulness of ion pairing in aqueous solutions is questionable (73, 75). Yet as 
evident of ion-pairing in aqueous solutions and its role in transport across membranes, ion 
pairing in water does occur. As will become apparent later, ion pairs forming in water are 
probably solvent-separated. This would be ideal as after permeation, the formulation scientist 
generally hopes for ion pair dissociation, enabling the active substance to carry out its intended 
function. 
 
1.3.4 Formation of tight or loose ion pairs 
 
Grunwald has described that as two ions approach each other, the potential energy slowly 
decreases (76). This occurs until the solvation shells come in contact, or one of the ions comes 
into contact with the others solvation shell (76). Considerable energy would be required to 
overcome this barrier, if a tight ion pair was to form. Considering Coulomb’s law, the electrical 
force between the two ions would increase as their separation decreases. Therefore, if at this 
point the attraction is strong enough, the interionic distance would slowly decrease and 
potential energy rapidly increase, until in line with Coulomb’s law the attraction becomes 
strong enough, to overcome the energy required in penetrating the solvation shell (76). 
 
Increase in the solvents dielectric constant and ion-solvating power favours solvent-shared 
and solvent-separated ion pair (72, 73, 76, 77). It is therefore deducible that a solvent with a 
lower dielectric constant and a lower solvating power would favour the formation of contact 
ion pairs. 
 
Furthermore, Naseer Ahmad and Day found that the higher the donicity (effectiveness as 
electron pair donors) of a solvent, the greater their ability to transform contact ion pairs into 
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solvent-separated ion pairs. This transformation was not observed in solvents with a lower 
donicity such as diethyl ether (78). 
 
1.3.5 Amino acids as ion pairs 
 
ElShaer et al, has been investigating both anionic (glutamate, aspartate) and cationic 
(arginine, lysine and histidine) amino acids as counterions for various model drugs. It has been 
found that both solubility and permeability of model drugs can be increased utilising this 
concept (40, 79). 
 
1.3.6 Molar conductivity 
 
Decrease in molar conductivity is a useful method for the detection of ion pair formation since 
ion pairs do not contribute to both ionic strength and electrical conductivity (80). 
 
Ohm’s law: 
𝐸 = 𝑖𝑅 
 
Where E represents the applied potential, i is the measured current and the resistance 
between the two electrodes is denoted R (81). 
 
While resistance quantifies the difficulty by which an electric current passes through a 
conductor, conductance (Symbol: S, Units: siemens – S) is the opposite and measures the 






Conductivity is a quantity expressed by the symbol κ (S cm-1). The ratio (d/A) of the distance 
between the two electrodes (d) and the surface area (A) of each electrode is a constant for a 
particular measurement cell and is called the cell constant (θ) (81). Conductivity can be given 
as: 
𝜅 = 𝑆𝜃 
 
For comparison between two samples, conductivity can be converted into molar conductivity. 
Molar conductivity Λ (S cm2 mol-1) is given by the following equation where C (mol/cm3) the 
total ionic concentration (81): 







The following equation can also be used for simplicity (less unit conversion is needed and the 






1.3.7 Enhancing permeation through ion pair formation 
 
The concept of enhancing the permeation of ionised drugs, through the use of counterions, 
rests in the ‘burial’ of charges that occurs with the formation of an ion pair. In other words the 
formation of ion pairs transforms the hydrophilic drugs into more lipophilic complexes, thus 
enhancing their transport through hydrophobic membranes. This was first tested by Irwin et 
al, and found support in many later studies (73, 82). 
 
However, some studies indicated that ion pair formation may not always be the cause of 
enhanced drug absorption and instead other mechanisms relating to the counterion may be 
involved. Thus to exclude the direct effect of counterions, neutral molecules (which cannot 

















Page 65 of 252 
 




Transporters are not only restricted to transporting substances into a cell. Often they are 
involved in transporting substances, including drugs, out of cells. These transporters are 
generally termed efflux pumps. This evolutionary trait which functions to keep the body safe 
from harmful substances, has also become one of the major challenges in the field of health 
today. Efflux pumps in humans and efflux pumps in microorganisms are big contributors to the 
resistance to chemotherapy and antimicrobials respectively (83). This section will cover one 
well studied and clinically relevant efflux pump in humans and one in bacteria. 
 
Three main criteria can be used for the classification of transporters; the energy source, 
phylogenic relationship, substrate specificity (84). There are two main classes of active 
transporters. Primary active transporters account for majority of drug efflux pumps in 
eukaryotic cells and utilise various forms of energy for their function. The energy source 
classically utilised is ATP. Secondary active transporters on the other hand are predominant 
in bacteria and function by acting as symports and antiports (84). Within these two classes 
three subclasses have been formed; superfamilies, families and clusters. These subclasses 
are divided in accordance with their substrate specificity (84). Even then, amazingly, most 
drug efflux pumps exhibit a multi-drug resistance phenotype. 
 
1.4.2 Substrate specificity 
 
Interestingly minimal common structural properties are necessary to obtain detectable efflux 
(Table 1.6). It is a commonly agreed hypothesis that most transporters recognize molecules 
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Organic, anionic substrates 
(sometimes, hydrophobic, 
neutral or mildly cationic 
substrates) 
 
Since majority of drug efflux pumps have a broad substrate specificity, this enables them to 
deal with many drugs of potentially unrelated pharmacological classes (84). Furthermore, 
efflux pumps are not restricted to bacteria; they have been recognised in almost all cell types 
(84). One of the way efflux pump activity can be bypassed, and which may be relevant is by 
increasing intracellular antibiotic concentration by enhancing permeability. A novel way of 
bypassing efflux pumps is being explored in this study through the utilisation of amino acid 
counterions. 
 
1.4.2.1 Basis of substrate specificity 
 
Proton motive force (PMF) dependent efflux proteins of the SMR, MFS and RND superfamilies 
tend to possess broad substrate specificity. However the molecular basis underlying their 
specificity is not yet clear. Currently studies indicate that instead of substrate structure, 
physical properties such as charge, hydrophobicity or amphipathicity may be the key 
determinants for the recognition of substrates by these proteins (84). 
 
For the MFS transporters VMAT1 and VMAT2 the common substrate characteristics were the 
presence of a cationic moiety and an aromatic ring. Interestingly, the introduction of a negative 
charge to some VMAT substrates impressively decreased their affinities for the transporter 
binding site (84). 
 
1.4.3 Efflux pumps in bacteria 
 
Evolution is a fascinating phenomenon, one which has enabled the humans to flourish into the 
most advanced species witnessed today. Yet, evolution in the smallest of scales continues to 
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present us with some of the greatest challenges in combating infectious diseases. Microbes 
such as bacteria, utilise evolution to survive in otherwise lethal environments, resulting in 
devastating consequences in an infected individual. One of the key mechanisms is the active 
removal of antibiotics through the overexpression of efflux pumps. This results in sub-lethal 
concentrations of the antibiotic within the organism, which in turn can lead to emergence of 
antibiotic resistance. Although efflux pumps are nothing new, increasing insight into their 
structure and function make them attractive targets for restoring antibiotic susceptibility to 
resistant strains (84). However given the nature of evolution, it may be fair to say that 
resistance will find a way to persist. 
 
Drug efflux pumps present in bacteria are categorised into five superfamilies: ABC (ATP-
binding cassette superfamily), MFS (major facilitator superfamily), MATE (multidrug and toxic 
compound extrusion family), SMR (small multidrug resistance family) and RND (resistance-
nodulation-division superfamily) (84). Efflux pumps in Gram-positive bacteria belong to the 
MFS, SMR, ABC and MATE families whilst the RND family exporters play a key role in 
clinically relevant Gram-negative antibiotic resistance (84). For now this section will look at 
some detail into RND transporters. 
 
1.4.4 RND Transporters 
 
RND efflux pumps are found throughout Prokaryotes and Eukaryotes. These are widespread 
in Gram-negative bacteria, but are not the only family of efflux pumps found in these bacteria 
(85). They function as proton/drug antiporters, catalysing the efflux of a wide variety of 
substrates including antibiotics and chemotherapeutic agents. Extensive studies have been 
done with most typical RND pump complexes: AcrAB-TolC of E-coli and MexAB-OprM of 
Pseudomonas aeruginosa (P. aeruginosa) (86). 
 
1.4.4.1 Structure and Function 
 
In Gram-negative bacteria the RND efflux pump complex (Figure 1.5) spans the inner and 
outer membrane. The RND efflux pump AcrB is situated within the inner membrane and 
functions in complex with two other proteins: AcrA and TolC (87). AcrA is a periplasmic adaptor 
protein and TolC is an outer membrane channel. These together form a tri-partite efflux pump 
(87). AcrB functions as a PMF dependent transporter, catalysing drug/H+ antiport (87). AcrB 
is also responsible for drug selectivity. AcrA on the other hand connect the other two proteins 
together (86, 87). 
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AcrB is associated with the drug efflux pathway from the periplasm/outer leaflet (inner-
membrane) through the periplasmic domain of AcrB. MexB on the other-hand may have the 
ability to remove antibiotics from the cytoplasm/inner leaflet (inner-membrane) (86, 87). 
Figure 1.5: Structure and function of the RND efflux pump (86). 
Key residues (Asp407, Asp 408, Lys940 and Thr978) in the transmembrane domains of AcrB 
have been identified which likely function as the proton relay network (86). 
Mutations around the residues Phe178 and Phe615 in the periplasmic domain of AcrB can 
lead to no change, or an increase or a decrease in resistance to various substances (86). This 
hints to the involvement of the periplasmic domain in substrate recognition (86, 87). Studies 
on the AcrD exporter showed that substrates could be captured from the cytoplasm as well as 
the periplasm, suggesting the presence of binding sites on both regions of the protein (86). 
The AcrB is a homotrimer consisting of three organized protomers. The pump action is now 
understood to utilise a three-step functionally rotating mechanism (86). The protomers are 
however asymmetrical, with their conformation depending upon what state of the transport 
cycle they are in (86). These functional states are access (loose), binding (tight) and extrusion 
(open). It is suggested that the extrusion of a substrate bound at the periplasm is triggered by 
the protonation of one of the residues of the proton relay network (86, 87). 
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1.4.5 Efflux pumps in humans 
 
Development of multi drug resistance is not only an issue in infectious diseases but also in 
oral bioavailability in general as well as in cancers (83). The physicochemical properties which 
allow for active transport of substances also render those substances more susceptible to 
recognition by efflux pumps (88). If a drug is being effluxed back out of GI tract endothelial 
cells, it will lead to poor bioavailability, whereas if the drug is effluxed out of a cancer cell it 
would lead to refractory disease. 
 
One of the most implicated and well-studied efflux pump superfamily is the ABC superfamily 
(83). They are present in cellular and intracellular membranes and show a wide tissue 
distribution. They transport substances against the concentration gradient and therefore are 
energy dependent; energy is obtained from the hydrolysis of ATP. The genes coding for ABC 
superfamily are further subdivided into seven families from ABCAA to ABCG (89). Three of 
these families, ABCB, ABCC and ABCG, are the most important because they code for the 
proteins P-glycoprotein, multidrug resistance proteins (MRP) and ABCG2 (also known as 
breast cancer resistance protein) respectively. The following section will look at some detail at 
the efflux pump P-glycoprotein (83, 88, 89). 
 
1.4.5.1 P-glycoprotein  
 
P-glycoprotein has a wide tissue distribution and as well as being present in cancer cells is 
also found in normal tissues such as the blood-brain barrier, intestine, kidneys, liver along with 
others (89). P-glycoprotein (P-gp) is coded by the ABCB1 gene and is sometimes also referred 
to as PGY1 or multidrug resistance protein-1 (MDR1) (89). This is because the transporter 
has broad substrate specificity, recognising amphiphilic, neutral or positively charged drugs; 
that is it recognises and is involved in the efflux of multiple drugs of unrelated chemical 
structure and function. P-gp shares this broad substrate specificity with cytochrome P450 3A4 
(88). Considering the wide tissue distribution, the broad substrate specificity and the function 
of P-gp and cytochrome P450, it is hypothesised that both work in a united fashion to protect 
the host from harmful and xenobiotic substances. Drugs that associate with P-gp can act as 
substrates or inhibitors, or as is the case with cyclosporine, both as a substrate and as an 
inhibitor (88, 89). 
 
P-glycoprotein has been implicated in both limiting oral drug absorption and resistance to 
chemotherapy (88). Studies with human Caco-2 cells show that drug absorption is increased 
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upon inhibition of the pumps function via verapamil (88). It has also been observed that the 
expression of P-gp increases in cancer cells after chemotherapy and its expression has been 
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1.5 Amino Acids 
Proteins are composed of up to twenty amino acids, varying in size, shape, charge and 
chemical reactivity (90). There are two naturally occurring acidic (aspartic acid and glutamic 
acid) amino acids and three naturally occurring basic (arginine, lysine and histidine) amino 
acids (90, 91). The general chemical structure of these amino acids is the same; they only 
differ in their side chain (R group). The consistent part of the amino acid structure which is the 
same in all of these amino acids, is known as the backbone and is composed of an alpha 
carbon, an amino group (NH2), a carboxyl group (COOH). All three of the groups, the amino 
group, the carboxyl group and the R-group are attached to the central alpha carbon (92). 
All amino acids apart from glycine can occur in two isomeric forms; the L-isomer or the D-
isomer. This is due to the presence of a carbon atom with four different groups attached (chiral 
centre), allowing the formation of two different non-superimposable structures differing only in 
the spatial orientation of their groups in three-dimensional space (90, 91). 
Since amino acids possess both a basic (amino group) and an acidic (carboxyl group) group, 
they can exist as zwitterions. A zwitterion can be defined as a species carrying both a negative 
and a positive charge. Presence of both acidic and basic centres allows amino acids to remain 
ionised at any given pH, as a cation, anion or a zwitterion. This makes amino acids ideal 
candidates as counterions for the model drugs which will be studied. Even though zwitterions 
carry zero net charge, a truly neutral species does not exist (90, 91, 93). 
Table 1.7: Acidic and Basic amino acids with their pKa and isoelectric points (pI) (91). 
Amino Acid α-carboxylic 
acid pKa 
α-amino pKa Side chain pKa pI 
Aspartic Acid 1.88 9.60 3.65 2.77 
Glutamic Acid 2.19 9.67 4.25 3.22 
Arginine 2.17 9.04 12.48 10.76 
Lysine 2.18 8.95 10.53 9.74 
Histidine 1.80 9.33 6.04 7.69 
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1.6 Aims and Objectives 
 
It is clear that once discovered, getting the drug to its sight of action is a challenge. Challenges 
range from generally the solubility and permeability of the drug to, more specifically, resistance 
of the drug where possible. The overarching aim of this project was to study the 
physiochemical and physiological, both in mammalian cells and in bacteria, effects of using 
naturally occurring acidic and basic amino acids as counterions for various model drugs. The 
underlying hypothesis being that amino acids can enhance drug solubility, and therefore 
indirectly lead to enhanced drug permeability and decreased drug resistance. Formulation of 
the hypothesis also considered that amino acids can directly enhance permeability and 
decrease drug resistance through potential mechanisms including, but not restricted to ion 
pairing and utilisation of amino acid transport channels. 
 
Thus the overall objective of the project was to determine the use of amino acids as solubility 
and permeability enhancers and as anti-resistance agents. Considering that permeation into 
the body was not enough, since the inevitable resistance would render this effort useless, both 
a permeability (Caco-2 cell line) and resistance model (bacteria) was used. Tetracycline (TC), 
ciprofloxacin and digoxin were chosen as model drugs along with acidic and basic amino acids 
as counterions. 
 
The following were the objectives of this project: 
 To investigate the solubility and octanol-water partitioning of tetracycline in the 
presence of amino acids 
 To investigate the effect of using amino acids as counterions to tetracycline, on the 
accumulation of the drug in planktonic S. aureus and P. aeruginosa cells and 
determine whether this translates to an effect in growth of the bacteria, whilst 
elucidating any synergy between the drug and the amino acids 
 To investigate the effect of using amino acids as counterions to ciprofloxacin, on the 
accumulation of the drug in planktonic S. aureus and P. aeruginosa cells and 
determine whether this translates to an effect in the growth of bacteria, whilst 
elucidating any synergy between the drug and the amino acids 
 To investigate the effect of using D-isomers of acidic amino acids on biofilm inhibition 
and dispersal whilst delving to their effect on biofilm architecture and determining 
synergy between the amino acids and ciprofloxacin 
 To investigate the solubility, caco-2 monolayer permeability and efflux ratio of digoxin 
in the presence of amino acids 

















Chapter 2: Tetracycline: Evaluation of the impact of 
acidic and basic amino acids on solubility, octanol-
water partitioning and bacterial efflux 
_________________________________________________________________________ 
 
The work presented in this chapter comprises of two subchapters. The first subchapter 
investigates the role of charged amino acids on solubility and octanol water partitioning of 
tetracycline. The second subchapter evaluates the impact of optimised counterions on 
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2.1 Investigating the effect of acidic and basic amino acids as 
counterions on the solubility and octanol-water portioning of the 




Tetracyclines are a class of bacteriostatic antibiotics which inhibit protein synthesis by binding 
to the 30s ribosomal subunit (94). Tetracycline (TC) is one of the oldest antibiotic of this class, 
and was first introduced into clinical practice in the 1950s (95). In 1966 tetracycline was the 
second most dispensed antibiotic after penicillin with  prescriptions reaching an estimated 12.6 
million (96). 
 
Tetracycline is prescribed as a tetracycline hydrochloride salt, with percentage absorption 
ranging from 77-88%. It is usually administered as an oral formulation although intravenous 
formulations are also available (95). Being administered in doses of 250 or 500mg, TC serum 
peak concentrations vary between 2 and 5mg/L with the dose. Time to peak concentration 
(tmax) of 2-4h indicates that serum concentrations of TC rise slowly (95). 
 
Being amphoteric TC is able to act as an acid and a base. Three pKa values (3.3, 7.7 and 9.7) 
are revealed upon titration (Figure 2.1), while a fourth pKa value of 12 is also possible (97, 
98). TC has an isoelectric point of around pH 5 (97). In accordance with the USP and BP 
solubility criteria TC is only ‘very slightly soluble’ in water, with 1 part TC requiring 2500 part 
water to dissolve (99). At 25°C TC has a solubility of 231 mg/L in water whereas in methanol 
it has a solubility of 20 mg/ml at 28°C (100). This is why it is generally prescribed as the salt 
tetracycline hydrochloride, which is freely soluble in water (101). 
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Figure 2.1: Chemical structure of TC with its functional groups highlighted which give rise to pKa values 
of 3.3, 7.7 and 9.7. Image adapted from British Pharmacopeia (102). 
 
The stability of tetracycline (TC) has been studied in detail in aqueous solutions while its 
stability in methanol has also been examined. The best understood scheme of TC instability 
is epimerisation followed by dehydration (103, 104). Both have been described as degradation 
by many papers and their products as degradation products. Although many degradation 
products of TC have been suggested, three are well recognised (103). These are 4-
epitetracycline (ETC), anhydrotetracycline (ATC) and 4-epianhydrotetracycline (EATC) (105). 
 
Most likely drugs to undergo epimerisation are of the TC family (106). Epimerisation occurs 
most rapidly in solution between pH 2 and 6 (although also possible above pH 7.5) and results 
in the formation of its epimer ETC (107). The equilibrium is pH dependent and favours TC at 
higher pH values (104). Although ETC has a much lower antibiotic activity (5% of natural 
epimer), it is not known to be toxic (105, 107). Furthermore, this epimerisation is a reversible 
process meaning that ETC can turn back into the more potent epimer (107). 
 
At lower pH values, a toxic degradation product is formed via two pathways (Figure 2.2). TC 
can undergo dehydration and form ATC which can in turn undergo epimerisation to become 
EATC. Along with this, ETC can also dehydrate to form EATC (97, 105). EATC is toxic to 
kidneys and is associated with Fanconi-like syndrome which may be fatal in extreme 
circumstances (97). Therefore a limit has been placed on the permitted quantity of these 
degradation products in the pharmaceutical dosage forms (tablets and capsules) containing 
tetracycline hydrochloride (the prescribed form) by British Pharmacopoeia (BP) (102).  
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Figure 2.2: Epimerisation of TC and its instability in acidic pH. Image taken from Foye's principles of 
medicinal chemistry (97). 
The table below (Table 2.1) highlights the limit established by British Pharmacopoeia for these 
degradation products (102). The limit established for EATC by United States Pharmacopeia 
is 2.0% (108). 
Table 2.1: Limit of impurities in TC by British Pharmacopeia (102). 





ETC 2.0 5.0 
ATC 0.5 1.0 
EATC 0.5 0.5 
Stereoisomers are molecules that have the same molecular formula and bonding connectivity 
but differ only in the relative spatial orientations of their atoms and groups. Epimers are 
stereoisomers which are not mirror images of each other and convert from one epimer to 
another by the process of epimerisation. Epimerisation is the configurational inversion of one 
of the chiral centres in a molecule exhibiting more than one chiral centre. This process yields 
an epimer of the original molecule (109). 
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The C-4 dimethylamino functional group is the most studied moiety in TC since its stereo 
orientation is essential for antibacterial bioactivity (107). Epimerisation of TC is made possible 
due to the presence of the tricarbonyl system of ring A. This system allows enolization (enol 
formation) which involves the loss of C-4 hydrogen. Once reprotonation occurs either TC is 
reformed or ETC is formed (Figure 2.3), depending upon whether reprotonation occurred from 
the top (TC) of the enol or bottom (ETC) (97). 
Figure 2.3: Diagram depicting that reprotonation of tetracycline can lead to epimerisation depending on 
whether the reprotonation was from the top or bottom of the enol. Image taken from Foye's principles of 
medicinal chemistry (97). 
Adverse storage conditions such as light exposure, high temperature and humidity can 
increase TC degradation (110). 
Various studies have shown ETC to be eluted first followed by TC and according to the British 
Pharmacopoeia the 1st, 2nd and 3rd peaks represent ETC, TC and EATC (in a sample 
containing these molecules) respectively (102, 103, 105). 
The rational for choosing tetracycline base form was that it is a zwitterion and therefore able 
to potentially form ion pairs or at least become ionised by both acidic and basic amino acids. 
Furthermore working with tetracycline enables us to use bacteria as a model for investigating 
the impact of amino acids as counterions in studying drug efflux (Chapter 2.2). 
Thus the aim of this study was to investigate the effect of acidic and basic amino acids on the 
solubility of TC and its partition behaviour from aqueous to an organic phase. For this, first a 
HPLC method able to precisely quantify TC was validated. Then TC saturated solubility was 
investigated at different concentrations of amino acids in aqueous medium. Finally, octanol-
water partitioning studies were conducted to determine the effect of optimised amino acids on 
the partitioning of TC from water to octanol. 
Page 78 of 252 
 




Tetracycline ≥98.0% (NT), Oxalic Acid Dihydrate ≥99.0% (GC), L-Aspartic Acid 98%(T) and 
L-Glutamic Acid (N) were purchased from Sigma Aldrich, UK. HPLC grade Methanol and 
Aacetonitrile were both purchased from Fisher Scientific UK. 
 
2.1.2.2 HPLC analysis 
 
Calibration curve and sample quantification was carried out using a HPLC system; Dionex 
1100 system consisting of an autosampler (AS50), gradient pump (GP50), UV detector (UVD 
170U). Gemini 5µm C18 110Å 150 x 4.6 mm column was purchased from Phenomenex. The 
method was adapted from Castellari et al., (111). Mobile phase consisted of aqueous Oxalic 
acid dihydrate 0.01 M: Methanol: Acetonitrile (75:12.5:12.5 v/v/v). Analysis was carried out at 
ambient temperature with the flow rate of 1 ml/min and an injection volume of 60 μL. λmax for 
TC was determined using Genesys 10s UV-Vis Spectrophotometer to be 364 nm and the UV 
detector for HPLC analysis was set at 364 nm. 
 
To obtain the calibration curve, single stock solutions were prepared by dissolving Tetracycline 
in methanol with a concentration of 1 mg/ml. This stock solution was used to make 
chromatographic standard solutions by diluting with appropriate volume of the mobile phase, 
as and when required. 
 
2.1.2.3 Tetracycline solubility study 
 
Saturated solubility of TC in different concentrations of amino acids were determined. Stock 
solution of amino acids (glutamic acid and aspartic acid) with a concentration of 1 mg/ml was 
prepared. Serial dilutions were prepared from this stock solution ranging from 1000 µg/ml 
down to 62.5 µg/ml in screw-capped tubes. Excess amounts of TC was added to each amino 
acid solution and pH recorded (Xisherbrand Hydrus 500 pH meter). The mixture was stirred 
at ambient temperature for up to 24 hours until excess TC had deposited. The pH was 
obtained again after which the tubes were left to rest for 2 hours. The supernatant was filtered 
through 0.45 µm syringe filter. The filtrate was diluted adequately with the mobile phase and 
the concentration determined through HPLC. 
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2.1.2.4 Preparation of Mutually saturated 1-octanol and distilled water 
 
Shake flask method outlined in the Organisation of Economic Cooperation and Development 
(OECD) guidelines was used for the octanol-water partitioning experiment (112). Since water 
and octanol are not fully immiscible, mutually saturated solutions of octanol saturated with 
water and water saturated with octanol were prepared (113). Stock solution of octanol 
saturated with water was prepared by adding sufficient amount of water and stirring overnight 
with a magnetic stirrer. The solution was then left long enough for the octanol and water to 
separate. The water saturated octanol was then separated from water using a separating 
funnel. Stock solution of octanol saturated water was prepared in the same manner. 
 
2.1.2.5 Octanol-water partitioning experiment 
 
TC concentration of 100 µg/ml used based on the average of the controls for L-aspartic acid 
and L-glutamic acid solubility profiles. 100 ml stock solution of 200 µg/ml TC was made in 
octanol saturated distilled water. Stock solutions for L-aspartic acid and L-glutamic acid were 
made with the concentrations representing the molar ratio of TC to amino acid of 1:32, where 
the concentration of TC is 100 µg/ml. 2.5 ml of amino acid solution was mixed with 2.5 ml of 
200 µg/ml TC solution to achieve a 5 ml solution with molar ratios of TC to amino acid of 1:16. 
At each stage of serial dilution from the stock solution of the amino acid, 2.5 ml of TC stock 
solution was mixed with 2.5 ml of amino acid solution to obtain the molar ratios of TC to amino 
acid of 1:16, 1:8. 1:4, 1:2 and 1:1. 5 ml of this TC with amino acid solution was mixed with 5 
ml of water saturated octanol. The two phases were then stirred overnight with a magnetic 
stirrer, after which the two phases were left to rest for separation. A sample of the aqueous 
phase was obtained using a needle and syringe and used to determine the TC concentration 
using HPLC. 
 
2.1.2.6 Calculation of percentage ionisation 
 
The percentage ionisation of TC and the amino acids were calculated using equations derived 
from the Henderson-Hasselbalch equation below (97). 
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Equation for percentage ionisation is given below, where x is -1 for an acidic site and 1 for a 







Since both the drug and the amino acids are zwitterions, percentage ionisation at any given 
pH was calculated for individual ionisable groups. After this, the percentage ionisation of both 
acidic groups and both basic groups were added together before subtracting with the opposite. 
This enabled the calculation of the overall percentage ionisation. 
 
2.1.2.7 Mass spectrometry analysis of degradation products of TC 
 
In order to investigate what each peak in the chromatogram represents, samples were run 
through the column using the HPLC system mentioned above. Fractions representing each 
peak on the chronograms were collected as they were separated through the column. These 
fractions were then used for mass spectrometric (MS) analysis, and m/z spectra for each 
fraction was obtained. Positive ion mode was used to ionise the samples using the 




Statistical analysis was conducted using GraphPad Prism. One way ANOVA was used to see 
whether there was overall statistical significance in the results. This was followed by Dunnett’s 
multiple comparisons test to see which treatment was significantly different to the control. 
Dunnett’s procedure was used over other multiple comparison tests because it is specialises 
in comparing each treatment against the control. P values below 0.05 for the results were 












2.1.3.1 Validation of tetracycline HPLC method 
 
2.1.3.1.1 Specificity and selectivity 
 
 
Figure 2.4: Three peaks of TC analysis through HPLC. Peak one (left), two (middle) and three (right) 
represent 4-epitetracycline, TC and 4-epianhydrotetracycline respectively. 
 
In the analysis of TC three peaks (Figure 2.4) were observed on the chromatograms. 
According to the British Pharmacopoeia the 1st, 2nd and 3rd peaks represent ETC, TC and 
EATC (in a sample containing these molecules) respectively (102). Studies have shown the 
elution order of TC and its major degradation products to be ETC, TC, EATC and ATC from 
first to last (103, 105). ETC has a much lower antibiotic activity compared to TC. However, 
since ETC is not associated with toxicity and under some conditions can convert back into TC, 
the sum of the two peaks representing ETC and TC was used in quantifying the total amount 
of TC in a sample (105, 107). This total was used in plotting the calibration curve as well as in 








1 2 3 
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2.1.3.1.2 Linearity and range 
 
 
Figure 2.5: Calibration curve for TC with concentrations of TC ranging from 1.56 to 100 µg/ml; n=3. 
 
Standard solutions of tetracycline at concentrations of 0.098, 0.20, 0.39, 0.78, 1.56, 3.13, 6.25, 
12.5, 25, 50 and 100 µg/ml were prepared as described in the method. Calibration curve 
(Figure 2.5) was obtained with tetracycline standard solutions of concentration above the limit 
of visual detection; concentration ranging from 1.56 to 100 µg/ml. The equation of straight line 
and coefficient of determination (R2) were obtained: 
 
y = 0.8591 x 
R2 = 0.9993 (n = 27) 
 
The Centre of Drug Evaluation and Research (CDER) recommends that criteria for 
establishing good linearity should be equal to or above a coefficient of determination of 0.999 
(115). Therefore the obtained value for R2 indicates good linearity since it is above 0.999. 
 
2.1.3.1.3 Limit of detection (LOD) and limit of quantification (LOQ) 
 
Visual evaluation was used to identify the concentration at which the limit of detection is 
achieved. The data for the mentioned range of concentrations obtained was then used to plot 
the calibration curve and establish the slope of the calibration curve (S) and the standard 
deviation of the response (σ). The standard deviation of the regression line was used as the 
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Precision was determined by testing two batches of six replicates at 100% of the test 
concentration; 100 µg/ml. One batch was tested twice in one day to determine the intra-day 
(intra-batch) precision (Table 2.3) whilst a second batch was tested on a different day allowing 
the determination of inter-day (inter-batch) precision (Table 2.2). The inter-day % relative 
standard deviation (RSD) was 5.86 and 6.47 for the first and second day respectively. The 
intra-day %RSD was 3.26 and 6.47. It is recommended that %RSD should not exceed 15%, 
therefore these results suggest good precision of the method (116). 




Day Mean measured 
concentration 
(µg/ml) 
SD RSD (%) 
100 1 106.36 6.23 5.86 
100 2 99.37 6.43 6.47 
 




Day Mean measured 
concentration 
(µg/ml) 
SD RSD (%) 
100 1 98.41 3.21 3.26 
100 1 99.37 6.43 6.47 
 
 




Accuracy was assessed by evaluating the concentration values obtained from the analysis of 
samples of three different known concentrations. TC solutions of 80, 60 and 40 µg/ml were 
prepared and analysed. Accuracy (Table 2.4) was then determined and expressed as the 
mean percentage recovery of the known concentrations. A mean recovery of 96.09% ± 0.48% 
for the three concentrations was found. These results suggest good accuracy of the method 
(116). 
 
Table 2.4: Accuracy of the HPLC method in analysis of TC. 
Standard solution (µg/ml) Recovery (%) RSD (%) 
80 96.53 1.97 
60 96.16 5.39 




Solubility of TC was investigated in different concentrations of both acidic and basic amino 
acids as counterions. This provided data identifying suitable counterions for TC while 
quantifying the extent of solubility enhancement with such amino acids. 
 
2.1.3.2.1 Acidic amino acids 
 
Initially solubility of TC was investigated in aqueous solutions of acidic amino acids (L-aspartic 
acid and L-glutamic acid) of increasing concentrations up to 1000 µg/ml. The concentrations 
used were 62.5, 125, 250, 500 and 1000 µg/ml. This identified both L-aspartic acid, L-glutamic 
acid as suitable counterions. Solubility of TC in higher concentrations (1500, 2500, 3500 and 
4500µg/ml) of these amino acids was investigated subsequently. 
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Figure 2.6: Apparent TC solubility increased with increasing concentrations of both L-aspartic acid and L-
glutamic acid. Significant rise in solubility was observed with 1000µg/ml (p 0.0004, n = 3) aspartic acid and 
at 250µg/ml (p 0.0138, n = 3), 500µg/ml (p 0.0004, n = 3) and 1000µg/ml (p 0.0001, n = 3) glutamic acid. 
 
Table 2.5: Fold change in solubility of TC with increasing concentration of L-aspartic acid and L-glutamic 










62.5 0.98 62.5 0.88 
125 1.10 125 1.17 
250 1.42 250 1.37 
500 1.43 500 1.54 
1000 2.10 1000 1.71 
 
Page 86 of 252 
 
 
Figure 2.7: Change in TC solubility with increasing concentration of L-aspartic acid and L-glutamic acid. 
At these higher concentrations (>1000µg/ml), L-aspartic was the better acidic amino acid in enhancing 
apparent solubility of TC. Compared to contro, a significant (p 0.0001, n = 3) enhancement in apparent 
solubility was observed at all concentrations above 1000µg/ml with both acidic amino acids. 
 
Table 2.6: Fold change in solubility of TC with different concentrations of L-aspartic acid and L-glutamic 










1500 2.53 1500 1.66 
2500 3.67 2500 1.98 
3500 4.37 3500 1.65 
4500 3.94 4500 2.21 
 
Solubility of TC increased with increasing concentration of both acidic amino acids; L-aspartic 
acid and L-glutamic acid (Figure 2.6). At L-aspartic acid and L-glutamic acid concentration of 
1000 µg/ml, the solubility of TC increased by 2.10 and 1.71 fold (Table 2.5) respectively, when 
compared to control. The highest solubility in the L-aspartic acid solution was observed at a 
concentration of 3500 µg/ml of the amino acid (Figure 2.7). At this concentration, the solubility 
of TC peaked to 895.15 µg/ml (p 0.0001, n = 3), representing a 4.37 fold increase compared 
to control (Table 2.6). On the other hand, the enhancement of solubility observed in L-glutamic 
acid peaked to only 2.21 fold greater than control at 4500 µg/ml. 
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The pH data gathered was used to obtain theoretical percentage ionisation of TC and the 
corresponding amino acid. This was done using the Henderson-Hasselbalch equation, and 
the results were plotted on graphs (Figure 2.8 and Figure 2.9). The purpose of this was to see 
how the ionisation of the drug and amino acid changed with a change in amino acid 
concentration, and how this linked with the changes in solubility observed. Diagrams enabling 
easy visualisation of the effect of change in pH on ionisable sights were also constructed for 
both the amino acids and TC, separately and are presented in the discussion later. 
 
With increasing concentration of both amino acids, percentage of TC in the ionised state also 
increased. It is worth highlighting that with L-aspartic acid, the percentage of TC in the ionised 
form reached up to 66.88 % at 4500 µg/ml. This was substantially higher than the 47.04 %of 
TC in the ionised form with 4500 µg/ml of L-glutamic acid. 
 
 
Figure 2.8: % Ionisation of TC and L-Aspartic acid. With increasing L-aspartic acid concentration and 
decreasing pH, the % ionisation of L-aspartic acid decreased whereas the % ionisation of TC increased; 
n=3. 
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Figure 2.9: % Ionisation of TC and L-glutamic acid. With increasing L-glutamic acid concentration and 
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2.1.3.2.2 Basic amino acids 
 
2.1.3.2.2.1 Solubility of tetracycline with basic amino acids over 24 hour 
 
 
Figure 2.10: In the initial study TC solubility only increased appreciably with increasing concentration of 
L-lysine. Significant rise in solubility was observed with 62.5µg/ml (p 0.0274, n = 3) and 1000µg/ml (p 0.0004, 
n = 3) of arginine and at 62.5µg/ml (p 0.0004, n = 3), 125µg/ml (p 0.0001, n = 3), 250µg/ml (p 0.0001, n = 3), 
500µg/ml (p 0.0001, n = 3) and 1000µg/ml (p 0.0001, n = 3) of lysine. No significant (p 0.1225, n = 3) rise in 
the apparent solubility of TC was observed with histidine. 
 
Table 2.7: Amino acid molarity (representing concentrations of 62.5, 125, 250, 500 and 1000 µg/ml) and the 













62.5 1.22 62.5 1.35 62.5 1.14 
125 1.12 125 1.66 125 1.17 
250 1.11 250 2.05 250 1.10 
500 1.10 500 2.32 500 1.10 
1000 1.39 1000 2.44 1000 1.17 
 
Solubility of TC was also investigated in aqueous solutions of basic amino acids (L-arginine, 
L-lysine and L-histidine) of increasing concentrations maxed at 1000 µg/ml (Figure 2.10). The 
concentrations used were 62.5, 125, 250, 500 and 1000 µg/ml. This identified L-lysine as a 
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suitable counterion. Solubility of TC in higher concentrations (1500, 2500, 3500 and 
4500µg/ml) of this amino acid was investigated subsequently. 
 
 
Figure 2.11: % Ionisation of TC and L-histidine. With increasing L-histidine concentration and therefore 
increasing pH, the % ionisation of L-histidine decreased whereas the % ionisation of TC increased; n=3. 
 
At amino acid concentration 1000 µg/ml and with a 2.44 fold enhancement of solubility (Table 
2.7) more than control, L-lysine seemed the best candidate as a counterion for TC out of all 
acidic and basic amino acids. Consequently, solubility with higher concentrations (up to 4500 
µg/ml) of L-lysine were investigated (Figure 2.12). Interestingly, although the solubility of TC 
continued to rise with increasing concentration of L-lysine, the solubility maxed a 2.98 fold 
increase (Table 2.8) compared to the 3.94 fold increase (Table 2.6) with L-aspartic acid 
solution. 
 
Even more surprisingly the pH of the L-lysine-TC solution was found to decrease instead of 
the expected rise in pH with increasing concentration of the basic amino acid above 1000 
µg/ml. This along with other observations made whilst working with L-lysine and L-arginine 
prompted further investigations. 
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Figure 2.12: A shalow rise in TC solubility between 1000 and 4500µg/ml of L-lysine. The apparent rise in 
solubility was significant (p 0.0001, n = 3) at all these concentrations compared to control. The pH 
decreased despite increasing concentration of basic amino acid. 
 
Table 2.8: Amino acid molarity (representing concentrations of 1500, 2500, 3500 and 4500 µg/ml) and the 









2.1.3.2.2.2 Additional observations with tetracycline using basic amino acids 
 
It was visually observed that much more TC seemed to dissolve in L-lysine and L-arginine 
solution than in any of the acidic amino acid solutions (Figure 2.13).  Secondly, over the 24 
hour stirring time, the colour of the L-lysine-TC solution and L-arginine-TC solution changed 
from the original yellow to a dark brown (Figure 2.14). And finally, the chromatogram revealed 
additional peaks (Figure 2.15) of TC degradation products in L-arginine and L-lysine solutions 
at higher concentrations of the amino acids. 
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Figure 2.13: Upon visual evaluation, much more TC dissolved in L-arginine and L-lysine solutions 
compared to L-histidine or any of the acidic amino acids. 
 
 




Figure 2.15: Additional peaks of degradation products observed with L-arginine and L-lysine. 
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2.1.3.2.2.3 Tetracycline degradation kinetics with basic amino acids and 
identification of degradation products 
 
The degradation of TC over time in the presence of basic amino acids L-arginine (Figure 2.16) 
and L-lysine (Figure 2.17) was studied and order of degradation reaction was determined. TC 
was left in basic amino acid solutions without stirring or shaking. By 192 hours more than 90% 
of TC had degraded with both of the basic amino acids. To determine the order of degradation 
reaction, concentration over time (Figure 2.16a and Figure 2.17a), log10 concentration over 
time (Figure 2.16b and Figure 2.17b) and 1/concentration over time scatter charts were plotted 
(Figure 2.16c and Figure 2.17c). Whilst plotting concentration over time tests for zero order 
reaction, log10 concentration over time tests for first order reaction and 1/concentration over 
time tests for second order reaction. Since log10 concentration over time plot gave the 
straightest line, indicated by higher r2 values compared to other two plots, the order of 
degradation reaction of TC was determined to be first order in both L-arginine and L-lysine 
solutions. Since the rate constant (k) is negative k (–k) in the equations of zero order and first 
order reactions, the gradient was multiplied by -1 to determine the rate constant. This gave k 
of 0.0062 h-1 and 0.0064 h-1 for L-lysine and L-arginine respectively. Half-life (t1/2) of TC in 





= 0.693 𝑘⁄  
 
This gave a half-life of 111.77 h for TC in L-arginine solution of 4500 µg/ml and 108.28 h for 
TC in L-lysine solution of 4500 µg/ml. 
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Figure 2.16: Degradation of TC over 192 hours in L-arginine solution of 4500 µg/ml. A) Concentration over 
time B) log concentration over time C) 1/concentration over time. 
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Figure 2.17: Degradation of TC over 192 hours in L-lysine solution of 4500 µg/ml. A) Concentration over 
time B) log concentration over time C) 1/concentration over time. 
 
Page 96 of 252 
 
To confirm the formation of degradation products, MS of TC solution stirred in 4500 µg/ml of 
L-lysine overnight was conducted. Fractions were obtained as described in the methods 
section corresponding to each peak visible in the chromatogram. Fraction A corresponded to 
Peak 1 or the solvent front, fraction B for peak 2, fraction C for peak 3, fraction D for peak 4, 
fraction E for peak 5 and fraction F for peak 6 (Figure 2.15). Figure 2.18 to Figure 2.24 present 
MS spectra for blank (mobile phase) and fraction A to F. 
 
 
Figure 2.18: MS spectra for mobile phase. 
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Figure 2.19: MS spectra for fraction A. 
 
 
Figure 2.20: MS spectra for fraction B. 
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Figure 2.21: MS spectra for fraction C. 
 
 
Figure 2.22: MS spectra for fraction D. 
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Figure 2.23: MS spectra for fraction E. 
 
 
Figure 2.24: MS spectra for fraction F. 
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For simplicity, when considering peaks which were also present in the mobile phase sample, 
m/z peaks around or above 20% of relative intensity were taken into account. Peaks that were 
present in the mobile phase were used to blank the spectra from all the fractions in a bid to 
obtain the peaks of interest which were not present in the blank. All the major peaks are 
summarised in Table 2.9, whilst the peaks not present in the blank were taken to represent L-
lysine (m/z 148), TC (m/z 445) or the degradation products of TC (m/z 410, 417, 441, 447, 
460 and 477). 
 
Table 2.9: Summary of MS of chromatograph fractions. 
Fraction no. Major m/z peaks present in 
blank 
m/z not present in 
blank 
A 215, 278, 391 148, 441, 477 
B 215, 278, 287, 391 445 
C 215, 252,  278, 287, 391 417, 445 
D 215, 252, 278, 300, 315, 371, 391 417 
E 215, 252, 278, 287, 315, 391 447, 460 
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2.1.3.2.2.4 Instant solubility of tetracycline with basic amino acids 
 
In light of the above observations, it was decided to investigate the instant solubility of TC in 
the presence of the basic amino acids L-arginine and L-lysine. Instant solubility refers to 
solubility studies where TC was exposed to the basic amino acids solution for a minimal time 
before quantifying the amount of TC which had dissolved and excludes the overnight stirring 
of TC within the solution. 
 
In line with visual observation, the results revealed that the instant solubility of TC in L-arginine 
and L-lysine solution much greater than its solubility in acidic amino acid solutions. The 
increase in TC solubility was dependent on the concentration of the amino acid, with higher 
concentration of either L-arginine or L-lysine generally resulting a higher amount of TC 
dissolved (Figure 2.25 and Figure 2.26). Highest solubility of TC was reached at 4500 µg/ml 
of L-arginine and L-lysine and was found to be 5891.05 and 6534.96 µg/ml (Figure 2.25 and 
Figure 2.26), representing a 16.30 and 25.70 (Table 2.10) fold increase in solubility from 
control, respectively. The increase in amino acid concentration is calculated to result in 
increasing amounts of TC being in the ionised (Figure 2.27 and Figure 2.28) form despite 
lowering the percentage ionisation of the amino acid. This presents another correlation that 
TC solubility increases in basic amino acid solutions with increasing amounts of TC present 
in the ionised form. The percentage of TC in the ionised form reached a maximum of 119.08 
% and 121.71 % for L-arginine (Figure 2.27) and L-lysine (Figure 2.28) respectively. Note that 
a value above 100% represents two charges on TC. This is around double of the TC 
percentage ionisation achieved with same concentrations of L-aspartic acid and L-glutamic 
acid (Figure 2.8 and Figure 2.9). It is worth highlighting though that although the percentage 
of TC in the ionised form was barely 2 fold greater in basic amino acids as compared to acidic 
amino acids, the solubility of TC was around 7-8 fold greater in basic amino acids than L-
aspartic acid and 11-13 fold greater than L-glutamic acid. 
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Figure 2.25: Apparent TC solubility increased with increasing concentrations of L-arginine. Solubility of 
TC in L-arginine solution was much greater when analysed instantly after mixing with the amino acid 
solution as compared to when analysed after overnight stirring. Significant rise in solubility was observed 
at L-arginine concentrations of 500 µg/ml (p=0.00056), 1000 µg/ml (p<0.0001) 1500 µg/ml (p<0.0001), 2500 
µg/ml (p<0.0001), 3500 µg/ml (p<0.0001) and 4500 µg/ml (p<0.0001); n=3. 
 
 
Figure 2.26: Apparent TC solubility increased with increasing concentrations of L-lysine. Solubility of TC 
in L-arginine solution was much greater when analysed instantly after mixing with the amino acid solution 
as compared to when analysed after overnight stirring. Significant rise in solubility was observed at L-
arginine concentrations of 500 µg/ml, 1000 µg/ml, 1500 µg/ml, 2500 µg/ml, 3500 µg/ml and 4500 µg/ml; 
p<0.0001, n=3. 
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Table 2.10: Fold change in solubility of TC with increasing concentration of L-arginine and L-lysine (62.5, 
125, 250, 500, 1000, 1500, 2500, 3500 and 4500 µg/ml) compared to control. Solubility increased with 









62.5 0.77 62.5 1.45 
125 1.32 125 2.14 
250 1.72 250 3.22 
500 3.22 500 5.59 
1000 5.44 1000 8.81 
1500 7.38 1500 12.38 
2500 10.29 2500 16.11 
3500 13.60 3500 22.47 
4500 16.30 4500 25.70 
 
 
Figure 2.27: % Ionisation of TC and L-arginine. With increasing L-arginine concentration and decreasing 
pH, the % ionisation of L-arginine decreased whereas the % ionisation of TC increased; n=3. 
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Figure 2.28: % Ionisation of TC and L-lysine. With increasing L-lysine concentration and decreasing pH, 
the % ionisation of L-lysine decreased whereas the % ionisation of TC increased; n=3. 
 
2.1.3.2.3 Formation of tetracycline epimer 
 
 
Figure 2.29: Proportion of peak 1 (ETC) as compared to the sum of peak 1 and peak 2 (TC) in different 
solutions; n=3. 
 
Although an increase in solubility has been observed with both sets of amino acids, the ratio 
of the two peaks in the chromatogram changed significantly (Figure 2.29), in solubility 
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experiments conducted with acidic amino acids. With basic amino acids, such a substantial 
change was not observed in the ratios. When TC was analysed for obtaining calibration curves 
the peak area of peak 1 (ETC) was on average 5.77% (Figure 2.29; in methanol) of the total 
peak area; sum of peak 1 and peak 2 (TC). However this significantly increased to an average 
of 11.25% (p=0.000000024) and 12.78% (p=0.0000055) when analysed in L-aspartic acid and 
L-glutamic acid solutions respectively. The proportion of peak 1 was even greater at higher 
concentrations of the amino acids (results not presented). 
 
2.1.3.3 Octanol-water partitioning 
 
Before moving onto experimentation in bacteria, it was important to see how the partitioning 
of TC from water to octanol was effected by amino acids. For this purpose L-aspartic acid was 
used since it gave the highest enhancement in TC solubility without leading to its degradation. 
The concentrations used were molar ratios of 1, 2, 4, 8 and 16 of L-aspartic acid for every TC. 
As seen in Figure 2.30, increasing the concentration of L-aspartic acid resulted in less TC 
partitioning into the octanol phase and more into the water phase. This translates to a 
reduction in LogP of TC with increasing concentration of L-aspartic acid. 
 
 
Figure 2.30: TC concentration and its logP values in different concentrations of L-aspartic acid. With 









2.1.4.1 Acidic amino acids 
 
Although both L-aspartic acid and L-glutamic acid were able to enhance the solubility of TC, 
there was a considerable difference in their respective abilities to do so. Nevertheless, these 
results suggest that TC acted mainly as a base in the solution of both of the acidic amino 
acids. The results also suggest that the drug may have formed ion pairs with both L-aspartic 
acid and L-glutamic acid. 
 
 
Figure 2.31: Diagram depicting the predominant charges at a given pH as well as the three ionisable sites 
(pKa 1.88, 3.65 and 9.60) and the isoelectric point (2.77) of L-aspartic acid. At the pH range of 2.99-3.94, 




Figure 2.32: Diagram depicting the predominant charges at a given pH as well as the three ionisable sites 
(pKa 3.30, 7.70 and 9.70) and the isoelectric point (5.00) of TC. At the pH range of 2.99-3.94, in L-aspartic 
acid-TC solution, majority of TC was in the cationic or the zwitterionic form. 
 
Increasing L-aspartic acid concentration from 62.5µg/ml resulted in a decrease in pH from 
3.94 to 2.99. In this pH range TC exists as a cation and a zwitterion in an equilibrium where 
the ratio of the two species depends on the pH of the solution. The reason for this is clear 
upon analysis of the pKa values of TC and considering that generally an acidic group will ionise 
in a basic solution and a basic group will ionise in an acidic solution. With this general rule, in 
this pH range the basic group of TC with the pKa of 9.70 will be greater than 99.99% ionised, 
since the difference between this pKa value and the closest pH value of the solution is greater 
than 4 (7). With the basic group ionised, TC attains positive charge. Although the solution is 
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too acidic for the second acidic group of pKa 7.7 to be ionised, the first acidic group of pKa 3.30 
is ionised in this pH range, and this gives TC a second but negative charge. However as the 
pH of the solution decreases with increasing concentration of L-aspartic acid, the conditions 
become too acidic and less favourable for even the first acidic group to be ionised. At a pH 
2.99, only around 33.11% of the acidic group is ionised, and it also means that 33.11% of TC 
is present as the zwitterionic form. Therefore, around 66.88% of TC is present as a cation at 
pH 2.99. And since the amount of TC present as a cationic species increased with a 
decreasing pH, an increase in the apparent solubility of TC in water is observed. 
 
The solubility of TC increases with an increasing concentration of its cationic form because 
there are more polar molecules which are able to interact with polar water molecules and 
become solubilised. Likewise, since zwitterions have zero net charge, they are unable to 
interact with polar water molecules. Thus it is also observed that the solubility is higher when 
the zwitterionic concentration is lowest, and vice versa. 
 
 
Figure 2.33: Diagram depicting the predominant charges at a given pH as well as the three ionisable sites 
(pKa 2.19, 4.25 and 9.67) and the isoelectric point (3.22) of L-glutamic acid. At the pH range of 3.35-4.49, 




Figure 2.34: Diagram depicting the predominant charges at a given pH as well as the three ionisable sites 
(pKa 3.30, 7.70 and 9.70) and the isoelectric point (5.00) of TC. At the pH range of 3.35-4.49, in L-glutamic 
acid-TC solution, majority of TC was in the cationic or the zwitterionic form. 
 
As the concentration of L-glutamic acid increased from 62.5 to 4500µg/ml, the pH of L-glutamic 
acid-TC solution decreased from 4.49 to 3.35 respectively. Both the cationic and the 
zwitterionic form of TC exists in this pH range. The amount of each species is dependent upon 
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the pH of the solution. Analysis of the pKa values of TC, aid in the understanding of this 
relationship between pH and the ionic state of TC. As mentioned earlier, an acidic group will 
mainly ionise in a more basic solution, and vice versa. In L-glutamic acid-TC solution, the basic 
group of TC (pKa of 9.70) is more than 99.99% ionised, leaving TC with a positive charge. 
This is because the difference between the pKa of this group and highest pH value (4.49) of 
the solution is greater than 4 (7). Furthermore, the second acidic group of pKa 7.7 will only be 
0.2% ionised at the highest pH of the pH range of this solution. The first acidic group (pKa 
3.30) on the other hand will be 93.97 to 52.95% ionised, representing the increasing L-glutamic 
acid concentration and therefore the decreasing pH from 4.49 to 3.35 respectively. As the 
ionisation of the acidic group gives TC a negative charge, TC in L-glutamic acid-TC solution 
exists as both a zwitterion and a cation. The proportion of zwitterion is highest at the higher 
pH values since TC has both a positive charge and a negative charge from the ionisation of 
the basic and the acidic groups respectively. However, as the pH decreases, and the acidic 
group is less able to ionise at lower pH values, the proportion of TC in the cationic form 
increases and the zwitterionic form decreases. Thus increase in the cationic form of TC 
correlates with the enhancement of apparent solubility observed with L-glutamic acid as the 
counterion. 
 
This apparent enhancement in solubility observed with increasing concentration of ionic form 
of TC can be attributed to the higher hydrophilicity that polar molecules have as compared to 
non-polar molecules. On the other hand, with higher concentrations of zwitterions, the 
solubility is lower. This can be attributed to the net zero charge which is exposed to the 
surroundings of a zwitterion; due to the positive and negative charge of the zwitterion 
cancelling each other out. 
 
Although both L-aspartic acid and L-glutamic acid are acidic amino acids, there is a difference 
to the extent of which each one enhances the solubility of TC whilst serving as the counterion. 
Since polar molecules dissolve in water, the higher quantity of polar molecules that exist, the 
more of that molecule will dissolve. At amino acid concentration of 4500µg/ml, 66.88% of TC 
is ionised in the L-aspartic acid-TC solution, whilst in L-glutamic acid-TC solution 47.04% of 
TC is ionised. Thus herein lies the reason for the difference in solubility enhancement 
observed between the two amino acids; L-aspartic acid causes a higher percentage of TC to 
become ionised as compared to L-glutamic acid and therefore more TC dissolves in L-aspartic 
acid-TC solution compared to L-glutamic acid-TC solution. 
 
Unlike TC the percentage ionisation of both acidic amino acids decreased with the increase 
of their concentration. Nevertheless, the total amount of ionic amino acids did increase 
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although their percentage ionisation decreased; due to substantial increase in the 
concentration of the amino acids relative to the decrease in percentage ionisation. 
Furthermore, although they acted as counterions for TC in terms of causing ionisation of TC, 
whether they acted as counterions in terms of ion pair formation with TC is not clear from these 
results. It is likely that ion pairs did not form. However it is also likely that ion pairing was 
involved in the apparent enhancement of TC solubility which was observed. For the latter 
case, one hypothesis may be that ion pair formation between the zwitterionic drug and ionic 
amino acid, or vice versa, enabled one of the zwitterionic charges to be buried whereas the 
second remained exposed. Thus the newly formed polar species between a zwitterion and an 
ion would dissolve, just like the TC which is already in ionic form. For a second hypothesis, 
the cationic TC forms ion pairs with anionic amino acid. Here solvation may occur like the first 
case (Figure 1.4A) described by Higuchi (74). TC is larger and cationic. The amino acid is 
anionic and since it is also smaller, it may have a greater charge per unit area compared to 
TC. In other words, not all of the negative charge becomes buried. Thus solvation may occur 
through interactions between water and this relatively negative half of the ion pair. 
Nevertheless, these are theories which need to be investigated through ion pair 
characterisation studies. 
 
As seen in Figure 2.29, proportion of the epimer ETC significantly increased (p<0.00001) in 
both L-aspartic acid and L-glutamic acid solutions up to a concentration of 1000 µg/ml. Since 
the pH of these amino acid solutions ranged from 3.09 to 4.13, these findings find support in 
the literature which highlights that epimerisation occurs most rapidly between the pH of 2 and 
6 (105). Although inactive, ETC is a non-toxic isomer of TC and the process of epimerisation 
is reversible, making the increase in solubility a sensible trade-off (105). 
 
2.1.4.2 Basic amino acids 
 
2.1.4.2.1 Solubility of tetracycline with basic amino acids over 24 hour 
 
L-lysine was the only basic amino acid found to raise TC solubility by an appreciable amount. 
Surprisingly, L-arginine was not able to raise the apparent solubility of TC by a comparable 
amount to L-lysine, despite similar pKa values. 
 
The pH of L-histidine-TC solution ranged from 6.47 to 7.18, representing an amino acid 
concentration of 62.5 to 1000 µg/ml. Majority of TC was present in the zwitterionic form in this 
pH range. The largest percent (23.47%) of anionic TC was present at the pH of 7.18. In another 
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words since L-histidine did not greatly ionise TC, a significant rise in its solubility was not 
observed (p 0.1225, n = 3). 
 
2.1.4.2.2 Evidence for tetracycline degradation with basic amino acids 
 
Unlike the other amino acids, the change in pH with increasing concentration of L-lysine was 
bidirectional. Therefore the pH range of 7.04 (at 62.5 µg/ml) to 7.94 (at 1000 µg/ml) does not 
accurately represent an increasing amino acid concentration since at higher L-lysine 
concentrations the pH was below 7.94. Nevertheless throughout this concentration range, 
majority of L-lysine existed in the cationic form whilst some was also present in the zwitterionic 
form. Zwitterions exist due to both the carboxyl (pKa 2.18) and amino (pKa 10.53) group being 
ionised, giving L-lysine a negative and a positive charge respectively. However, since the pH 
range is greater than one less than the pKa of the second basic centre (amino group; pKa 
8.95), >90% of this group will also be charged, giving L-lysine an additional positive charge. 
This leaves L-lysine with an overall positive charge whilst TC was present mainly in the anionic 
form in this pH range. Since in this pH range, the percentage of TC which is in the ionised 
form (>90%) is greater than the percentage of TC in the ionised form with L-aspartic acid 
(66.88%) at 4500 µg/ml, it was surprising that TC did not reach as high a solubility 
enhancement with L-lysine (2.98 fold increase) as compared to L-aspartic acid (3.94 fold 
increase). 
 
This lack of TC solubility enhancement in L-arginine solution despite similar pKa values to L-
lysine, as well as the relatively shallow rise in solubility above concentrations of 1000 µg/ml 
can be explained by additional observations made during the study. Previous studies suggest 
that colour change indicates the formation of degradation products such as ATC and EATC 
(103). This together with additional peaks observed in chromatograms after overnight stirring 
indicates that TC gradually degrades, resulting in colour change of the solution, with the 
degradation products showing as additional peaks. This gives reason to the deceptively low 
solubility of TC observed in the initial study of L-arginine and L-lysine solutions as well as the 
bidirectional change in pH with increase in the concentration of the amino acid. 
 
Degradation of TC and oxytetracycline leading to red, red-brown or brown colouration in basic 
pH has been reported in the past (117, 118). Although photolysis and high temperature (50 
°C) were suggested to be contributing to this degradation, this study found degradation to 
occur in the absence of light and at room temperature. In addition, both studies suggested 
oxidation to play a role in colour change. Observations made during this study support this 
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mechanism; browning of TC in basic amino acid solutions was concentrated in the air water 
interface, from which the degraded TC would diffuse down, allowing non-degraded TC to take 
its place for the cycle to begin again (Figure 2.35). 
 
 
Figure 2.35: Browning of TC in L-arginine and L-lysine solutions was concentrated in the air/water 
interphase. 
 
Half-life of TC has been determined in the past by Sah H to be 329.2 h (119). Although the 
reported half-life by Sah H is specifically for tetracycline hydrochloride, it is almost three times 
greater than the t1/2 of TC in basic amino acid solutions determined in this study. Considering 
that the t1/2 would be even less (data not presented), possibly under 12 h, if the rate of 
degradation experiment was done whilst stirring the solution, it was decided to continue the 
microbiology work with acidic amino acids instead. However, out of interest and to add 
scientific knowledge it was decided to do instant solubility experiments of TC in basic amino 
acid solutions. It may be that further research may lead to techniques whereby solubility 
enhancement ability of basic amino acids can be maintained whilst also preventing TC 
degradation (117). 
 
To confirm degredation of TC, MS was carried out to analyse TC exposed to L-lysine solution 
at 4500 µg/ml. Majority of the peaks present in the blank sample can be either attributed to 
plasticisers or other background ions from the mobile phase. From those the peaks not present 
in the blank, peak with m/z of 148 can be attributed to L-lysine which has a molecular weight 
of 146.19. Peaks at m/z in fraction B and C correspond to ETC and TC. Due to their size, 
peaks at m/z 410, 417, 441, 447, 460 and 477 not present in the blank are likely to be 
degradation products of TC. Considering its relative abundance greater than other peaks, the 
major degradation peak seems to be of m/z 417. 
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For the major fragment at m/z 417, the change in mass from 445 is 28. This can be explained 
by the loss of two methyl groups from nitrogen on carbon 4 of TC. This would result in a m/z 
of 415. However, the 2 valance electrons on nitrogen may quickly allow bonding to hydrogen 
resulting in the observed m/z of 417. 
 
Liang Y et al have shown using standards that the m/z of 4-epi-anhydrotetracycline 
hydrochloride and anhydrotetracycline hydrochloride to be 427 (103). Subtracting 36 from this, 
which is the predominant m/z for HCl, gives a m/z of 391. Narukawa M et al have shown that 
oxalic acid can be detected in the positive-ion spectrum predominantly as ions with m/z of 40, 
24 and 12 (120). Cluster formation between C2+ (m/z of 24) and the fragment with m/z of 391 
may be contributing to the peak at 417. 
 
These are of course proposals. TC degradation can follow complex pathways, many of which 
have been proposed by Liang Y et al (103). To confirm what structures these peaks represent, 
NMR and IR would be needed. Nevertheless, MS results spectra do confirm the presence of 
degradation products whilst also validating that peak 1 and peak 2 do correspond to ETC and 
TC. 
 
2.1.4.2.3 Instant solubility of tetracycline with basic amino acids 
 
Both L-arginine and L-lysine were able to enhance the instant solubility of TC considerably. 
These results suggest that TC acted mainly as an acid in the solution of both of the basic 
amino acids and suggests that ion pair formation may have occurred between TC and both L-
arginine and L-lysine. 
 
 
Figure 2.36: Diagram depicting the predominant charges at a given pH as well as the three ionisable sites 
(pKa 2.17, 9,04 and 12.48) and the isoelectric point (10.76) of L-arginine. At the pH range of 7.40-9.16, 
majority of L-arginine was either in the zwitterionic form or the cationic form; proportion of zwitterion 
increases at higher values of this pH range. 
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Figure 2.37: Diagram depicting the predominant charges at a given pH as well as the three ionisable sites 
(pKa 3.30, 7.70 and 9.70) and the isoelectric point (5.00) of TC. At the pH range of 7.40-9.16, in L-arginine 
solution, majority of TC was in the cationic or the zwitterionic form; proportion of the anionic form 
increases as the pH in this range increases. 
 
Increasing L-arginine concentration from 62.5µg/ml resulted in an increase in pH from 7.40 to 
9.16. In this pH range TC exists as an anion and a zwitterion in an equilibrium where the ratio 
of the two species depends on the pH of the solution. The reason for this is clear upon analysis 
of the pKa values of TC. Generally an acidic group will ionise in a basic solution and a basic 
group will ionise in an acidic solution. With this general rule in mind, in this pH range the acidic 
group of TC with the pKa of 3.3 will be greater than 99.99% ionised, since the difference 
between this pKa value and the closest pH value of the solution is greater than 4 (7). With this 
acidic group ionised, TC attains a negative charge. The second negative charge on TC in this 
pH range is dependent on the pH and is due to the second acidic group of pKa 7.7. As the pH 
rises from 7.40 to 9.16, ionisation of this group rises from 33.31% to 96.65%. In other words, 
some TC molecules have one acidic group ionised whilst some have both ionised giving them 
two negative charges. Ionisation of the basic group of TC (pKa 9.7) is also dependent on the 
pH in this pH range; with increasing pH from 7.40 to 9.16 inoisation of TC basic group 
decreases from 99.50% to 77.58%. This means in the pH range of L-arginine solution, some 
TC molecules have single negative charge and some have two negative charges whilst some 
also have a positive charge which acts to neutralise one of the negative charges. This 
computes to an overall rise in TC ionisation from 33.81% to 119.08% representing a rise in 
pH from 7.40 to 9.16. Note that since this percentage is a sum of percentage ionisation of both 
acidic groups subtracted by percentage ionisation of the basic group, the value for example 
of 33.81% representing TC ionisation at a pH of 7.40 does not mean that 33.81% of all TC is 
ionised. In actuality, the value can be higher, since the basic group can be ionised in either 
the TC molecule with a single charge or the TC molecule with two charges; in the latter, TC 
will still have an overall negative charge. The calculation therefore predicts the lowest amount 
of TC likely to be in the ionised form. On the other hand, TC ionisation above 100% of course 
does not mean that more than 100% of TC in ionised. It means that some TC molecules have 
two charges, and we can quite confidently assume that near to 100% if not 100% TC would 
be ionised in these cases. Ultimately, since the amount of TC present as an ionic (anionic) 
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species increased with an increase in pH, an increase in the apparent solubility of TC in water 
is observed. 
 
The solubility of TC increases with an increasing concentration of its anionic form because 
there are more polar molecules which are able to interact with polar water molecules and 
become solubilised. Likewise, since zwitterions have zero net charge, they are unable to 
interact with polar water molecules. Thus it is also observed that the solubility is higher when 
the zwitterionic concentration is lowest, and vice versa. 
 
 
Figure 2.38: Diagram depicting the predominant charges at a given pH as well as the three ionisable sites 
(pKa 2.18, 8.95 and 10.53) and the isoelectric point (9.75) of L-lysine. At the pH range of 7.42-9.22, majority 
of L-lysine was either in the zwitterionic form or the cationic form; proportion of zwitterion increases at 
higher values of this pH range. 
 
 
Figure 2.39: Diagram depicting the predominant charges at a given pH as well as the three ionisable sites 
(pKa 3.30, 7.70 and 9.70) and the isoelectric point (5.00) of TC. At the pH range of 7.42-9.22, in L-lysine 
solution, majority of TC was in the cationic or the zwitterionic form; proportion of the anionic form 
increases as the pH in this range increases. 
 
As the concentration of L-lysine increased from 62.5 to 4500µg/ml, the pH of L-lysine-TC 
solution increased from 7.42 to 9.22 respectively. Both the anionic and the zwitterionic form of 
TC exists in this pH range. The amount of each species is dependent upon the pH of the 
solution. Analysis of the pKa values of TC, aid in the understanding of this relationship 
between pH and the ionic state of TC. As mentioned earlier, an acidic group will mainly ionise 
in a more basic solution, and vice versa. In L-lysine-TC solution, the first acidic group of TC 
(pKa of 3.30) is more than 99.99% ionised, leaving TC with a negative charge. This is because 
the difference between the pKa of this group and lowest pH value (7.42) of the solution is 
greater than 4 (7). Furthermore, the ionisation of the second acidic group of pKa 7.7 will 
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change from 34.18% to 97.04% ionised as the pH of the solution increases from 7.42 to 9.22. 
This will leave some TC molecules with 2 negative charges. Some of these charges will be 
buried at this pH range by the ionisation of the basic group (pKa 9.70). The percentage 
ionisation of this basic group decreases from 99.48% to 75.32% as the concentration of L-
lysine, and hence the pH increases from 7.42 to 9.22. As the ionisation of the basic group 
gives TC a positive charge, TC in L-lysine solution exists as both a zwitterion and an anion. 
The proportion of anionic form is highest at the higher pH values since at higher pH values, 
the acidic groups remain or become more ionised whereas the percentage ionisation of the 
basic group decreases. For the opposite reason, prevalence of the zwitterionic form is higher 
at lower pH values. Thus increase in the anionic form of TC correlates with the observed 
enhancement of apparent solubility of TC with L-lysine as the counterion. 
 
With L-arginine and L-lysine, the apparent enhancement in TC solubility observed with 
increasing concentration of its ionic form can be attributed to the higher hydrophilicity that 
polar molecules have as compared to non-polar molecules. Polar TC molecules are able to 
interact with polar water molecules and become solubilised. On the other hand, with higher 
concentrations of zwitterions, the solubility is lower. This can be attributed to the net zero 
charge which is exposed to the surroundings of a zwitterion; due to the positive and negative 
charge of the zwitterion cancelling each other out. Hence, they are unable to interact with polar 
water molecules and become solubilised. Thus it is also observed that the solubility is higher 
when the zwitterionic concentration is lowest, and vice versa. 
 
Unlike TC the percentage ionisation of both basic amino acids decreased with the increase of 
their concentration. Furthermore, although they acted as counterions for TC in terms of 
causing ionisation of TC, whether they acted as counterions in terms of ion pair formation with 
TC cannot be confirmed without experimentation. It is likely that ion pairs did not form. 
However it is also likely that ion pairing was involved in the apparent enhancement of TC 
solubility which was observed. For the latter case, one hypothesis may be that ion pair 
formation between the zwitterionic drug and ionic amino acid, or vice versa, enabled one of 
the zwitterionic charges to be buried whereas the second remained exposed. Thus the newly 
formed polar species between a zwitterion and an ion would dissolve as well as the TC which 
is already in ionic form. For a second hypothesis, the anionic TC forms ion pairs with the 
cationic amino acid. Here solvation may occur like the first case (Figure 1.4 A) described by 
Higuchi (74). TC is larger and anionic. The amino acid is cationic and since it is also smaller, 
it can be proposed to possess a greater charge per unit area compared to TC. In other words, 
not all of the positive charge becomes buried. Thus solvation may occur through interactions 
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between water and this relatively positive half of the ion pair. Nevertheless, these are theories 
which need to be investigated through ion pair characterisation studies. 
 
2.1.4.3 Octanol-water partitioning 
 
Octanol is widely used as a model for the membrane to determine oil-water partitioning of any 
given drug. A drug is more water soluble if the octanol-water partition coefficient is less than 
0, whereas LogP greater than 0 indicates that the drug is more lipid soluble. LogP is a good 
indication for not only how freely a drug can move into a lipid membrane, but also how freely 
it can move out of the lipid membrane to the other side (11, 12). If LogP is greater than 6, the 
drug will readily partition into the lipid membrane, but will also find it difficult to partition out of 
the membrane to the other side. On the other hand if LogP is less than 3, its partitioning into 
the membrane will be very slow. Thus drugs with LogP values between 3 and 6 are best 
absorbed through the lipid membrane by passive diffusion (11, 12). 
 
Since the solubility studies indicated L-aspartic acid to be the most appropriate counterion, 
partitioning of TC between the octanol and water phase was studied in L-aspartic acid solution. 
The results (Figure 2.30) give the LogP of TC as 0.0017, whereas the LogP of TC in L-aspartic 
acid solution was dependent on the concentration of the amino acid. With increasing 
concentration of L-aspartic acid, more TC dissolved in water and the LogP of TC decreased. 
This means that TC naturally distributes more or less equally between the aqueous and 
octanol phase. But in L-aspartic acid solution, TC exists in a more hydrophilic state. These 
results suggest and support the suggestion that TC is being ionised in L-aspartic acid solution, 
with the resulting polarisation increasing the drugs solubility in water, and decreasing its 
solubility in octanol. Further ion pair characterisation studies need to be carried out to see if 




The apparent solubility of TC was found to improve with both acidic and basic amino acids. 
The preliminary results show that basic amino acids, L-arginine and L-lysine, are most 
effective in enhancing the solubility of TC. However, considering the degradation of TC which 
has been observed with the basic amino acids, L-aspartic acid was chosen as the optimal 
counterion for TC, even though the octanol-water partitioning results show that the 
combination of L-aspartic acid and TC results in the drug becoming more hydrophilic and 
therefore less able to partition into the lipid membrane. 
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2.2 An investigation into the synergy between tetracycline and the acidic 
amino acids, aspartic acid and glutamic acid, on planktonic 




The next phase of work was to investigate whether using amino acids as counterions leads to 
synergy with tetracycline on bacteria. As shown in the previous section, both basic and acidic 
amino acids were able to enhance the solubility of TC. Basic amino acids are greater solubility 
enhancers of tetracycline as compared to acidic amino acids. However, basic amino acids 
lead to degradation of TC over time; majority of TC degraded into toxic products within 24 
hours. Considering TC is much more stable in the presence of acidic amino acids, and they 
act as moderate solubility enhancers of TC, these amino acids were selected whilst 
investigating the synergistic effect between TC and amino acids in bacteria. 
 
For the purpose of investigating the effect of acidic amino acids on planktonic bacteria, two 
species, namely S. aureus (NCTC 8325) and P. aeruginosa (PA01) were chosen. The rational 
for this relates to the existence of intrinsic resistance in bacteria to certain antibiotics. Since 
resistance can be intrinsic or acquired, choosing these species allows us to investigate the 
effect of amino acids (AA) on the resistance to TC of intrinsically resistant P. aeruginosa, whilst 
also (see if NCTC 8325 has resistance) on a S. aureus, which has the ability to acquire 
resistance. This also allowed the investigation of AA and TC synergy in both Gram-positive 
(S. aureus) and Gram-negative (P. aeruginosa) bacteria. 
 
Resistance incurred to tetracycline by bacteria can be divided into three broad categories; 
restriction in the access of the drug to ribosomes, binding sight alteration and TC inactivation 
(121, 122). Since acidic AA have been shown to increase TC solubility with the aim to enhance 
drug delivery, the mechanism of resistance which limits TC from accessing ribosomes 
captures particular interest. The access to ribosomes can be restricted by either restricting the 
amount of TC which permeates into the bacteria and or by utilising efflux pumps to throw back 
out the TC which is able to permeate (121, 122). To investigate whether AA are able to 
enhance drug delivery, TC accumulation was studied, which also provides insights into both 
drug uptake and drug efflux. 
 
In normal circumstances the mechanism of TC uptake into the cytoplasm depends on the 
class to which bacteria belong; Gram-positive and Gram-negative. Since in Gram-positive 
Page 118 of 252 
 
bacteria, TC only has to pass through one membrane, it can permeate via passive diffusion 
(123). On the other hand, in Gram-negative bacteria, TC needs to pass through two 
membranes, the outer and the inner to reach its target site of action. To accomplish this, TC 
transit occurs through two stages. The cationic stage, in chelation with magnesium, allows its 
passage through cation preferring porins into the periplasm. Although passive diffusion 
accounts for some TC being absorbed into the periplasm from the environment, the rigidity of 
the outer membrane restricts its extent. Once in the periplasm, the comparatively acidic state 
shifts equilibrium towards the neutral form of TC, allowing its diffusion into the cytoplasm 
through the inner membrane. 
 
TC which does manage to reach the cytoplasm can act on ribosomes if other resistance 
mechanisms, mentioned above, are absent. One of these mechanism utilised by bacteria is 
the pumping of the drug back out and resistance is incurred when the rate of this is equal or 
greater than the rate of uptake (121). Tetracycline efflux pumps generally belong to the major 
facilitator superfamily (MFS) and span the lipid bilayer of the inner cell membrane (124). 
According to a 2016 review by Grossman. TH, 30 different efflux pumps specific to TC have 
been identified and have been split into 7 groups in accordance with their amino acid sequence 
and the number of transmembrane segments they possess (122). TC efflux pumps of group 
1 and group 2 show the most clinical relevance. Whilst group 1 includes most common pumps 
found in Gram-negative bacteria such as Tet(A) and Tet(B), group 2 includes Tet(K) and 
Tet(L), which are the most common TC efflux pumps expressed Gram-positive bacteria (122, 
124). In either case, they function as TC-H+ antiporters to pump out TC in exchange of H+ 
(122, 124).  
 
Thus the aim of this chapter was to see if acidic amino acids act as anti-microbial agents 
against planktonic bacteria and whether they can be used to optimise existing antibiotics. For 
this we investigated the use of acidic amino acids as counterions to tetracycline, on the 
accumulation of the drug in planktonic S. aureus and P. aeruginosa cells. We further 
determined whether this translates to an effect in growth of the bacteria, whilst elucidating any 
other synergy between the drug and the amino acids. 
 
Interestingly, whilst investigating the effect of amino acids on the growth of P. aeruginosa, 
pigment production was observed. Since the extent of pigment production was observed to 
be influenced by the concentration of amino acid used, it was decided to quantify the pigments. 
Pyocyanin and pyoverdine were the pigments chosen to quantify since these are the most 
common pigments produced by P. aeruginosa 
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Tetracycline ≥98% (NT), L-Aspartic acid 98+% (T), L-glutamic acid 99% (N), D-(+)-glucose 
99.5% GC and phosphate buffered saline tablets were from Sigma Aldrich. Ethidium bromide 
10 mg/ml and tryptone soya broth was obtained from fisher scientific.  KCl (sigma Aldrich), 
MgCl2 and chloroform (fisher scientific) were gifted by technical staff. S. aureus strain NCTC 
8325 and P. aeruginosa strain PAO1 was gifted by Professor Peter A. Lambert. 
 
2.2.2.2 Determining the minimum inhibitory concentration (MIC) and minimum 
lethal concentration (MLC) of the amino acids and tetracycline 
 
MIC and MLC of L-Asp, L-Glu and TC was on S. aureus and P. aeruginosa was determined. 
To do this, overnight cultures of S. aureus and P. aeruginosa were grown. 0.1 O.D. of each 
bacteria was then incubated with two-fold serial dilutions of L-Asp, L-Glu or TC. The 
concentrations of amino acids used ranged from 30 mM to 0.23 mM whilst the concentration 
of TC used ranged from 112.50 µM to 0.014 µM. TC concentration tested was capped at 
112.50 µM with the solubility limitation of the antibiotic in water. Following this, the plates were 
incubated in a 37 °C incubator overnight. MIC was taken to be the lowest concentration with 
no visible growth (turbidity); generally two fold lower concentration than the MLC. To determine 
MLC, concentrations which showed no visible growth (turbidity) were plated on TSA agar 
plates and incubated at 37 °C overnight. MLC was taken to be the lowest concentration which 
resulted in no colony formation. 
 
2.2.2.3 Tetracycline accumulation assay 
 
To grow to logarithmic phase, 10 ml of overnight culture was added to 20ml of fresh TSB and 
incubated for one hour at 37 °C in an orbital shaking incubator. The culture was then 
centrifuged at 2860 g for 20 minutes and supernatant was discarded. The cell pellet was 
resuspended in 30 ml of 1 mM MgCl2 in 0.01 M PBS. Centrifugation step was repeated 
following which the pellet was resuspended in 11.95 ml of same buffer. The cell suspension 
was split into 4 equal volumes (2.5 ml each) and to each quarter 2.5 ml of double the working 
concentration of the drug (made up in same buffer) along with 250µl of 1 mg/ml Ethidium 
Bromide (EtBr) was added. For example, if working concentration is 1mM TC, add 2.5ml of 
2mM TC along with 250µl of EtBr. Aliquote 100 µl per well in 96 well plate. Observe 
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fluorescence every 5 minutes for 60 minutes (room temperature) at an excitation wavelength 
of 510 nm and an emission wavelength of 595 nm. 
 
To check for further accumulation using amino acids, 100 µl of amino acid concentrations 
ranging from 30 mM to 0.23 mM made up in 1 mM MgCl2, 0.01 M PBS and 100 mM glucose 
(to provide energy) was added to wells as required. Next 20µl of 1M KCl.was added to each 
well. Fluorescence was again observed as above. Controls included no drug (max AA conc), 
No glucose with No AA (max drug concentration used), no AA, no glucose (no drug or AA) 
and glucose (no drug or AA). 
 
2.2.2.4 Growth curve susceptibility assay 
 
Growth curves of L-Asp, L-Glu and TC were evaluated for S. aureus and P. aeruginosa in the 
presence of the combinations used in TC accumulation assays. To do this, overnight cultures 
of S. aureus and P. aeruginosa were grown. Solutions with double the working concentrations 
were prepared for the amino acids, TC and their combinations. 100 µL of these were then 
incubated with 100 µL of the culture in wells of 96 well plates. This gave working 
concentrations of the compounds and 0.1 O.D. of bacteria. The plates were than analysed in 
an incubated (37 °C) plate reader, set to read O.D. of each well every half an hour at 600 nm. 
 
2.2.2.5 Pyocyanin Quantification 
 
After susceptibility assay, 96 well plates were incubated in the fridge until Pyocyanin was 
quantified. Briefly, cell free supernatant was obtained by centrifugation at 3220 g for 10 
minutes. 100 µl of chloroform was added to 150 µl of the supernatant and vigorously vortexed. 
The samples were then centrifuged at 2996 g for 5 minutes and the supernatant was 
discarded. To the remaining bottom (chloroform) layer, 60 µl of 0.2 M HCl was added, followed 
by vigorous vortexing. The samples were again centrifuged at 2996 g for 5 minutes and the 
top layer was transferred to a 96 well plate. After all the samples were processed in this 
manner, the 96 well plate was read for absorbance using a plate reader at 520 nm. 
 
2.2.2.6 Pyoverdine Quantification 
 
After susceptibility testing as described above, the 96 well plates were kept in fridge until 
pyoverdine was quantified. Briefly, the plates were centrifuged at 3220 g for 10 min. Cell free 
supernatant was transferred to Greiner black bottom plates and the concentration of 
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pyoverdine was quantified using a fluorescence spectrophotometer at an excitation 
wavelength of 395 nm and an emission wavelength of 470 nm. The results were plotted 
relative to control. 
 
2.2.2.7 Statistical analysis 
 
Statistical analysis was conducted using GraphPad Prism. Initially one way ANOVA was 
carried out to look for overall significance within the data. This was followed by the uncorrected 
Fisher’s LSD test, to see where the significant difference lies. P values below 0.05 for the 






























2.2.3.1 MIC and MLC of S. aureus and P. aeruginosa 
 
Concentrations of amino acids screened for MIC for each bacteria were 30, 15, 7.5, 3.75, 1.88, 
0.94, 0.47, 0.23 mM whilst the concentrations of TC screened were 112.50, 56.25, 28.13, 
14.06, 7.03, 3.52, 1.76, 0.88, 0.44, 0.22, 0.11, 0.055, 0.027 and 0.014 µM. Amino acid and 
TC concentrations were capped at 30 mM and 112.50 mM respectively, due to their solubility 
limitations in water. All of the amino acid concentrations that were tested for MIC and MLC 
were below the MIC of both S. aureus and P. aeruginosa. Working concentrations of the drug 
used for accumulation studies were all below the MIC determined, as presented below. 
 
Table 2.11: TC MIC and MLC. * indicates that all concentrations tested were below MIC. 
 MIC MLC 
S. aureus 7.03 µM 14.06 µM 
PAO1 * * 
 
2.2.3.2 S. aureus 
 
To assess efflux, a slightly modified accumulation assay was used which provides indirect 
evidence of efflux behaviour. The experiment was split into two parts, depicted on the graphs 
by a dashed line; first part was for 60 min and the second part was for 120 min. Whilst in the 
first part bacteria were loaded with EtBr by depriving them of energy needed for efflux, the 
second part showed whether the test substances used were able to aid in its further 
accumulation. Efflux of TC in S. aureus was investigated at the TC concentrations of 3.52, 
1.76, 0.88 and 0.44 µM. To determine efflux behaviour of TC in synergism with amino acids, 
both L-Asp and L-Glu were used and each TC concentration was studied with amino acid 
concentrations ranging from 30 mM to 0.23 mM. Various controls were used to help better 
understand the observed patterns of efflux. The ‘no drug’ control which contained 30 mM of 
the respective amino acid, was used to evaluate the effect of amino acid on EtBr efflux in the 
absence of any competition from the drug for the efflux pump. The ‘0 mM’ AA was used to 
help gain insight into the effect of TC (at the concentrations used) on the efflux of EtBr in the 
absence of an AA, whilst ‘No Glucose and no AA’ (maximum concentration of drug only) 
showed this in the absence of energy. To see how efflux of EtBr is affected without any drug 
or AA in energised and energy deprived cells, ‘no glu’ and ‘glu’ controls were used. 
 





Figure 2.40: Efflux of TC in S. aureus using different concentrations of L-Asp (30 mM to 0.23 mM). a) 3.52 
µM TC b) 1.76 µM TC c) 0.88 µM TC d) 0.44 µM TC. In the legend, numbers 0 to 30 represent amino acid 
concentrations in combination with respective TC concentration; n=4. 
 
Figure 2.40 presents the efflux of TC with different concentrations of L-Asp in S. aureus. The 
pattern of efflux observed is similar (Figure 2.40a-d) irrespective of the concentration of the 
drug. Generally, in the second phase of the assessment, starting from the dashed line, there 
is a rise in intercellular EtBr, indicated by a rise in fluorescence intensity. This rise is similar to 
the rise in EtBr with ‘no glu’ used. Presence of ‘glu’ is the only variable which differs from this 
pattern; there is no substantial rise in the fluorescence intensity with ‘glu’ as the variable which 
lacks in both L-Asp and TC. The rise in fluorescence intensity is followed by a fall which varies 
in intensity. 15 mM L-Asp show the steepest reduction in intercellular EtBr followed by 7.5 mM 
L-Asp. Continuation of this pattern is observed where generally as the concentration of L-Asp 
is lowered, the rate of efflux of EtBr also decreases. 30 mM L-Asp is the only concentration 
which does not follow this pattern and has the slowest rate of reduction in fluorescence 
intensity. Interestingly, ‘no drug’ and ‘30 mM’ amino acid follow a similar pattern. 15 mM and 
7.5 mM L-Asp, once combined with TC, are the only treatments for which the fluorescence 
intensity decreases below the fluorescence intensity of ‘glu’. 
 
Page 124 of 252 
 
 
Figure 2.41: Efflux of TC in S. aureus using different concentrations of L-Glu (30 mM to 0.23 mM). a) 3.52 
µM TC b) 1.76 µM TC c) 0.88 µM TC d) 0.44 µM TC. In the legend, numbers 0 to 30 represent amino acid 
concentrations in combination with respective TC concentration; n=4. 
 
Efflux of TC by S. aureus in the presence of different concentrations of L-Glu is presented in 
Figure 2.41. The concentration of drug used (Figure 2.41a-d) does not affect the pattern of 
efflux observed. Like L-Asp, L-Glu causes a rise in intercellular EtBr levels with most 
treatments which is similar to the pattern obtained by ‘no glu’; the only exception being the 
control ‘glu’ which lacks both the amino acid and the drug. A concentration dependent fall in 
fluorescence intensity is observed after the initial rise in the second phase of the experiment. 
15 mM and 7.5 mM L-Glu show the steepest reduction in intercellular EtBr. This is followed by 
a pattern where generally as the concentration of L-Glu is lowered, the rate of efflux of EtBr 
also decreases. 0 mM L-Glu, which contains TC, shows the slowest rate of decrease in 
intercellular EtBr. 30 mM L-Glu is the only concentration which does not followed this patter 
and falls between 7.5 mM and 3.75 mM L-Glu. Interestingly, ‘no drug’, which contains 30 mM 
L-Glu and ‘30 mM’ L-Glu follow a similar pattern. It can also be observed that the fluorescence 
intensity for 30 mM, 15 mM, 7.5 mM and 3.75 L-Glu and ‘no drug’ decreases below the 
fluorescence intensity of ‘glu’. Also of note is that the patter observed with L-Glu is similar to 
the patter observed with L-Asp, except the pattern followed by ‘No Drug’ and ‘30 mM’ amino 
acids. 
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2.2.3.2.2 Growth curves 
 
To investigate how combining amino acid and TC translates to phenotypic change in S. 
aureus, growth curves were done to look for synergy between the amino acid and the drug. 
 
 
Figure 2.42: S. aureus growth curves with a) 30, 15 and 7.5 mM L-Asp amino acid on its own, b) with 14.06, 
7.03, 3.52, 1.76, 0.88 and 0.44 µM TC on its own, c) 30 mM L-Asp combined with 3.52, 1.76, 0.88 and 0.44 µM 
TC, d) 15 mM L-Asp combined with 3.52, 1.76, 0.88 and 0.44 µM TC and e) 7.5 mM L-Asp combined with 
3.52, 1.76, 0.88 and 0.44 µM TC; n=3. 
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Figure 2.42 presents the growth curves of S. aureus and includes curves for L-Asp on its own 
(Figure 2.42a), TC on its own (Figure 2.42b) and different concentrations of L-Asp combined 
with TC (Figure 2.42c-e) concentrations investigated in efflux experiments. L-Asp on its own 
(Figure 2.42a) was able to effect the growth of S. aureus in a concentration dependent manner 
where 30 mM L-Asp has the greatest effect and 7.5 mM has the lowest. TC on its own (Figure 
2.42b) was also able to effect the growth of S. aureus. To see whether there is a synergistic 
effect between the amino acid and the drug, growth curves obtained by exposure to 
combinations (Figure 2.42c-e) were compared with growth curves obtained by amino acid 
(Figure 2.42a) and drug (Figure 2.42b) in isolation. Where combination showed greater 
reduction in growth of the bacteria compared to both the drug and the amino acid in isolation, 
synergy was concluded. Greatest synergy between TC and L-Asp was observed with 30 mM 
of the amino acid. Whilst there was a noticeable effect on the growth of S. aureus with 0.44 
µM TC when combined with 15 mM or 7.5 mM L-Asp, a substantial effect was observed in 
combination with 30 mM L-Asp. With this combination (30 mM L-Asp and 0.44 µM TC), where 
the synergy is most prominent, the slower growth of S. aureus, represented by a shallower 
exponential phase, is followed by an early onset death phase. Combining 30 mM L-Asp with 
other TC concentrations also resulted in a noticeable synergistic effect. 
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Figure 2.43: S. aureus growth curves with a) 30, 15 and 7.5 mM L-Glu amino acid on its own, b) with 14.06, 
7.03, 3.52, 1.76, 0.88 and 0.44 µM TC on its own, c) 30 mM L-Glu combined with 3.52, 1.76, 0.88 and 0.44 µM 
TC, d) 15 mM L-Glu combined with 3.52, 1.76, 0.88 and 0.44 µM TC and e) 7.5 mM L-Glu combined with 3.52, 
1.76, 0.88 and 0.44 µM TC; n=3. 
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Figure 2.43 presents the growth curves of S. aureus when exposed to L-Glu, (Figure 2.43a), 
TC (Figure 2.43b), and L-Glu and TC combinations (Figure 2.43c-e). Like L-Asp, L-Glu is also 
able to effect the growth of S. aureus in a concentration dependent manner. TC on its own 
(Figure 2.43b) is also able to effect the growth of S. aureus. Synergy was determined as 
before. Greatest synergy between TC and L-Glu is observed with 30 mM of the amino acid. 
Whilst there is noticeable effect on the growth of S. aureus with 0.44 µM TC when it is 
combined with 15 mM L-Glu, a greater effect is observed in combination with 30 mM L-Glu. 
With this combination (30 mM L-Asp and 0.44 µM TC), where the synergy is most striking, the 
slower growth of S. aureus, represented by a shallower exponential phase is followed by an 
early onset death phase. Combining 30 mM L-Glu with other 0.88, 1.75 and 3.52 µM TC also 

























Page 129 of 252 
 
2.2.3.3 Pseudomonas aeruginosa 
 





Figure 2.44: Efflux of TC in P. aeruginosa using different concentrations of L-Asp (30 mM to 0.23 mM). a) 
112.50 µM TC b) 56.25 µM TC c) 28.13 µM TC d) 14.06 µM TC. In the legend, numbers 0 to 30 represent amino 
acid concentrations in combination with respective TC concentration; n=4. 
 
Figure 2.44 presents the efflux of TC with different concentrations of L-Asp in P. aeruginosa. 
The pattern of efflux observed is similar (Figure 2.44a-d) irrespective of what concentration of 
drug was used, with no striking difference between TC concentrations used. Generally, in the 
second phase of the assessment, there is a rise in intercellular EtBr, indicated by a rise in 
fluorescence intensity. The steepest rise is observed for 30 mM L- Asp, which is combined 
with TC and ‘No Drug’, which contains 30 mM L-Asp on its own. Interestingly, although not 
substantially different, ‘No Drug’ reached and maintained higher fluorescence intensity 
compared to 30 mM L-Asp. This is followed by 15 mM L-Asp, whose fluorescence intensity 
continued to rise until the end of the experiment. The rise in fluorescence intensity is greatest 
in these three variables and is significantly greater than the rise observed with other variables, 
including all other L-Asp concentrations, and ‘no glu’ (no L-Asp and no TC). The lowest rise in 
fluorescence intensity was observed with the presence of ‘glu’ (no L-Asp and no TC) which 
sustained a fluorescence intensity significantly lower than all other variables. 




Figure 2.45: Efflux of TC in P. aeruginosa using different concentrations of L-Glu (30 mM to 0.23 mM). a) 
112.50 µM TC b) 56.25 µM TC c) 28.13 µM TC d) 14.06 µM TC. In the legend, numbers 0 to 30 represent amino 
acid concentrations in combination with respective TC concentration; n=4. 
 
Efflux experiments of TC with P. aeruginosa were also carried out in the presence of L-Glu 
and the results are presented in Figure 2.45. Again, the concentration of TC used did not affect 
the efflux patter observed (Figure 2.45a-d). Like with L-Asp, and following similar pattern, the 
steepest rise in fluorescence intensity is observed for 30 mM L-Glu and ‘No Drug’ which 
contains 30 mM L-Glu. This is followed by 15 mM L-Glu. The rise in fluorescence intensity is 
greatest in these three variables and pattern is strikingly different from that observed with other 
variables. As expected the lowest rise in fluorescence intensity was observed with the 
presence of ‘glu’ (no L-Glu and no TC) which sustained a fluorescence intensity significantly 
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2.2.3.3.2 Growth curves 
 
 
Figure 2.46: P. aeruginosa growth curves with a) 30, 15 and 7.5 mM L-Asp amino acid on its own, b) with 
225.00, 112.50, 56.25, 28.13 and 14.06 µM TC on its own, c) 30 mM L-Asp combined with 112.50, 56.25, 28.13 
and 14.06 µM TC, d) 15 mM L-Asp combined with 112.50, 56.25, 28.13 and 14.06 µM TC and e) 7.5 mM L-Asp 
combined with 112.50, 56.25, 28.13 and 14.06 µM TC; n=3. 
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Figure 2.46 presents the growth curves of P. aeruginosa and includes curves for L-Asp on its 
own (Figure 2.46a), TC on its own (Figure 2.46b) and different concentrations of L-Asp 
combined with TC (Figure 2.46c-e) concentrations investigated in efflux experiments. L-Asp 
on its own (Figure 2.46a) is unable to effect the growth of P. aeruginosa. On the other hand, 
TC on its own (Figure 2.46b) is able to effect the growth of P. aeruginosa in a concentration 
dependent manner where 112.50 µM TC has the greatest growth hindering effect and 14.06 
µM has the lowest. To see whether there is a synergistic effect between the amino acid and 
the drug, growth curves obtained by exposure to combinations (Figure 2.46c-e) were 
compared with growth curves obtained by amino acid (Figure 2.46a) and drug (Figure 2.46b) 
in isolation. Where combination showed greater reduction in growth of the bacteria compared 
to both the drug and the amino acid in isolation, synergy was concluded. Greatest synergy 
between TC and L-Asp is observed with 30 mM of the amino acid. With 30 mM L-Asp, there 
was a substantial increase in the effectiveness of 56.25, 28.13 and 14.06 µM TC, represented 
by a concentration dependent strikingly shallower exponential phase. Other than this, a 
noticeable effect in growth of P. aeruginosa is also observed with 15 mM L-Asp combined with 
56.25 µM TC and 7.5 mM L-Asp combined with 56.25, 28.13 and 14.06 µM TC. 
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Figure 2.47: P. aeruginosa growth curves with a) 30, 15 and 7.5 mM L-Glu amino acid on its own, b) with 
225.00, 112.50, 56.25, 28.13 and 14.06 µM TC on its own, c) 30 mM L-Glu combined with 112.50, 56.25, 28.13 
and 14.06 µM TC, d) 15 mM L-Glu combined with 112.50, 56.25, 28.13 and 14.06 µM TC and e) 7.5 mM L-Glu 
combined with 112.50, 56.25, 28.13 and 14.06 µM TC; n=3. 
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Growth curves of P. aeruginosa are presented in Figure 2.47. The curves compare untreated 
growth of P. aeruginosa with growth in the presence of L-Glu (Figure 2.47a), TC (Figure 2.47b) 
and combinations of L-Glu and TC (Figure 2.47c-e). Whilst L-Glu on its own (Figure 2.47a) 
exhibits no effect the growth of P. aeruginosa, a concentration dependent inhibition is 
observed with TC on its own (Figure 2.47b). Synergy was again determined using the criteria 
described earlier. Greatest synergy between TC and L-Glu is observed with 30 mM of the 
amino acid. With 30 mM L-Glu, there was a significant increase in the effectiveness 56.25, 
28.13 and 14.06 µM TC, represented by a substantially flatter exponential phase. There is no 
synergistic effect in growth of P. aeruginosa with 15 or 7.5 mM L-Glu. 
 
2.2.3.3.3 Pigment production 
 
Figure 2.48a and Figure 2.49a presents visually observed pigment production whereas Figure 
2.48b and Figure 2.49b presents pyocyanin which was quantified using the chloroform and 
0.2 M HCl extraction method outlined in methods section. There is a general consistency in 
the visually observed pigment production and the pyocyanin quantified; a more intense green 
colour (Figure 2.48a and Figure 2.49a) correlates with higher pyocyanin production (Figure 
2.48b and Figure 2.49b). To look for statistical significance in the results, initially one way 
ANOVA was carried out to look for overall significance within the data. Following this 
uncorrected Fisher’s LSD test was carried out to see where the significant difference lies. 
Fisher’s LSD test was chosen over a test which corrects for multiple comparisons because in 
answering the hypothesis each comparison stood alone, such that when checking how a 
specific combination of amino acid and the drug compared to both its parts in isolation, its 
relation to other concentrations (of the amino acid, drug or any of their combinations) was not 
part of the hypothesis and irrelevant in answering the question posed. 
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Figure 2.48: Effect of L-Asp, TC and L-Asp and TC combinations on the production of pyocyanin; n=3. 
 
Pyocyanin production by P. aeruginosa in the presence of L-Asp, TC and their combinations 
is presented in Figure 2.48. Maximum pyocyanin production was observed with untreated P. 
aeruginosa. L-Asp and TC both used in isolation, resulted in a concentration dependent 
significant (p<0.0001) reduction in pigment production, where higher concentration of the 
amino acid or drug resulted in less pyocyanin production. The only concentration of L-Asp 
which did not show a significant reduction in pyocyanin production was 7.5 mM. To determine 
synergy between amino acid and drug combinations, results for L-Asp with TC were compared 
with the values obtained with the amino acid and the drug in isolation. Combinations which 
resulted in significant reduction in pigment production compared to both the amino acid on its 
own and the drug on its own were accepted as exhibiting positive synergy. Although synergy 
is observable with many L-Asp and TC combinations, statistically significant synergy was 
observed for 14.06 µM TC combined with 15 (p=0.00011) and 7.5 mM L-Asp (p<0.0001). 
Despite the combination of 15 mM and 7.5 mM L-Asp with all TC concentrations resulting in 
significantly lower pyocyanin production compared to the corresponding amino acid 
concentration in isolation, this reduction was not significant compared to the corresponding 
TC concentrations and hence no synergy was concluded. 
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Figure 2.49: Effect of L-Glu, TC and L-Glu and TC combinations on the production of pyocyanin; n=3. 
 
Figure 2.49 presents pyocyanin production by P. aeruginosa and compared the pyocyanin 
produced by untreated controls with that produced by L-Glu, TC and their combinations. 
Compared to the control, which produced most amount of pyocyanin, L-Glu on its own was 
able to reduce the amount of pyocyanin produced; noticeably at 30 mM and significantly at 15 
mM (p=0.034). TC used in isolation also resulted in a significant (p=0.000000031, 
p=0.000000047, p=0000015, p=0.00025 for 112.50, 56.25, 28.13 and 14.06 µM TC 
respectively) reduction in pyocyanin production which was concentration dependent. Higher 
concentration of the drug resulted in less pyocyanin production. Synergy between L-Glu and 
TC was determined as with L-Asp. Although synergy is observable with many L-Glu and TC 
combinations, statistically significant synergy was observed for 30 mM and 15 mM L-Glu 
combined with a TC concentration of 112.50 µM (p=0.048 for 30 mM L-Glu only), 28.13 µM 
(p=0.000011 and p=0.00043 with 30 mM and 15 mM L-Glu respectively) and 14.06 µM 
(p=0.000000042 and p=0000034 with 30 mM and 15 mM L-Glu respectively). 
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Figure 2.50: Effect of L-Asp, TC and L-Asp and TC combinations on the production of pyoverdine; n=3. 
 
Pyoverdine production by P. aeruginosa in the presence of L-Asp, TC and their combinations 
is presented in Figure 2.50. Maximum pyoverdine production was observed with untreated P. 
aeruginosa. TC used in isolation, resulted in a concentration dependent significant 
(p<0.00001) reduction in pigment production, where higher concentration of the drug resulted 
in less pyoverdine production. The only concentration of L-Asp which exhibited a significant 
(p=0.000012) reduction in pyoverdine production was 30 mM. To determine synergy between 
amino acid and drug combinations, results for L-Asp combined with TC were compared with 
the values obtained with the amino acid and the drug in isolation. Combinations which resulted 
in significant reduction in pigment production compared to both the amino acid on its own and 
the drug on its own were accepted as exhibiting positive synergy. Although synergy is 
observable with many L-Asp and TC combinations, statistically significant synergy was 
observed for 14.06 µM TC combined with 30 (p<0.00000000001) and 7.5 mM L-Asp 
(p<0.00000000001) and 28.13 µM TC combined with 30 mM (p=0.011) L-Asp. Despite the 
combination of 15 and 7.5 mM L-Asp with all TC concentrations resulting in significantly lower 
pyoverdine production compared to the corresponding concentration of the amino acid on its 
own, the reduction was not significant compared to the corresponding TC concentrations and 
hence no synergy was concluded. 
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Figure 2.51: Effect of L-Glu, TC and L-Glu and TC combinations on the production of pyoverdine; n=3. 
 
Reduced pyoverdine production was also observed with L-Glu and the results obtained with 
the amino acids on its own, TC on its own and their combinations is presented in Figure 2.51. 
Unlike the outlier 28.13 µM TC, the drug’s use in isolation, generally resulted in a concentration 
dependent significant (p<0.01) reduction in pyoverdine production, where higher 
concentration of TC resulted in less pyoverdine production. 30 mM was the only L-Glu 
concentration, which when used in isolation resulted in a significant (p=0.00070) reduction in 
pyoverdine production. Synergy was determined as described above. Statistically significant 
synergistic reduction in pyoverdine production was seen in the middle of the four TC 
concentrations investigated. TC concentrations of 56.25 µM showed significant reduction in 
pyoverdine production in combination with 30 mM (p=0.00035) and 15 mM (p=0.0004) L-Glu 
when compared to the two corresponding constituents in isolation. A similar pattern was 
observed when 28.13 µM TC was combined with 30 mM and 15 Mm L-Glu, giving a p value 













EtBr is a substrate of many efflux pumps including TC efflux pumps such as tetA (125, 126). 
This property allowed the indirect measurement of TC accumulation within bacteria by 
quantifying the amount of intracellular EtBr. Since EtBr is expected to compete with TC for 
being effluxed out of the cell, one can assume that higher levels of intracellular EtBr correlates 
with proportionally higher levels of TC within the cell. 
 
Generally, accumulation results indicate that use of amino acids is able to raise intracellular 
levels of TC. This is further supported by a synergistic effect of amino acids and TC on the 
growth of bacteria. 
 
Both amino acids show a similar species dependent pattern in TC accumulation hinting 
towards a similar underlying mechanism. The interspecies difference in the pattern observed 
can probably be attributed to the presence of a single membrane in S. aureus as compared 
to an outer and an inner membrane in P. aeruginosa. Whilst with S. aureus an accumulation 
pattern which is concentration dependent is observed, only 30 mM and 15 mM amino acids 
seem to effect TC accumulation in P. aeruginosa. This along with the fact that 30 mM amino 
acids enable faster accumulation of TC as compared to 15 mM, indicates that although 
accumulation of TC is also concentration dependent in P. aeruginosa, a particular amino acid 
threshold concentration needs to be reached. 
 
Interestingly, with S. aureus, amino acid, drug or combined treatments show similar pattern to 
the control with no glucose, which also does not have any drug or amino acid. This shows that 
whatever the concentration of amino acid used, even in the presence of glucose, amino acids 
have a similar effect in TC accumulation as energy deplete bacteria. To add to this, increasing 
the concentration of amino acid seems to lead to faster efflux. Considering the bacterial growth 
results however, where higher amino acid concentration leads to significant reduction in 
bacterial growth, it is likely that this is efflux in disguise, but is in actuality cell death due to 
increase TC accumulation accompanied by a lowered cytoplasmic pH. Pattern observed for 
amino acid with P. aeruginosa is similar such that 0 mM to 7.5 mM show identical accumulation 
as the control lacking glucose. At 15 mM and 30 mM of amino acids however, EtBr 
accumulation is much greater. The observation that in S. aureus TC accumulation drops after 
peaking whereas in P. aeruginosa it does not, can be explained with the ability of Gram-
negative bacteria to return cytoplasmic pH back to baseline faster than Gram-positive bacteria 
(127, 128). Since P. aeruginosa also produces detectable pigments, their production was 
affected synergistically with the use of amino acid and TC. The two most common pigments 
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of P. aeruginosa were quantified; pyocyanin and pyoverdine (129). The decrease in pigment 
production observed coincides with disruption in growth of bacteria and can be explained with 
fewer cells present to produce the pigments. 
 
With 30 mM amino acid, intracellular levels of EtBr reach a higher level without the presence 
of TC as compared to in its presence. This is surprising since presence of TC is expected to 
compete with the efflux of EtBr, raising its intracellular levels. Nevertheless, this hints towards 
a mechanism which is efflux independent and instead involves increase rate of TC and EtBr 
uptake due to amino acids through mutual transporter. In such a case, presence of TC 
probably competes with EtBr for uptake, potentially through amino acid channels as discussed 
later, decreasing the amount of EtBr within the cell. 
 
It is worth highlighting that even though the accumulation assays carried out do indicate 
whether amount of TC is increasing or decreasing within the cell, the assay although hints, 
does not conclusively distinguish between the mechanisms of this change. Elevated 
intracellular levels can be due both an increase in TC uptake or decrease in TC efflux. 
Whichever the case, raised TC levels within the cell would be detected as increased levels of 
intracellular EtBr. Following subsections will propose a few mechanism by which use of acidic 
amino acids L-Asp and L-Glu may have led to an increased uptake or a decreased efflux of 
TC. The likelihood that the results observed are due to a combination of both an increase in 
TC uptake and a decrease in its efflux cannot be ruled out. 
 
2.2.4.1 Increase in tetracycline uptake through porins 
 
To understand how the amino acids may be aiding in TC uptake it is important to understand 
the general mechanism TC uptake. P. aeruginosa is a Gram-negative bacteria which has two 
membranes; an outer membrane and an inner membrane. These membranes differ in their 
selectivity as barriers (130). Furthermore, the outer membrane is asymmetric, such that its 
inner leaflet is composed of phospholipids whereas its outer leaflet is composed of 
lipopolysaccharides (41). The inner membrane on the other hand is a bilayer of phospholipids. 
This makes the outer membrane more rigid as compared to the inner membrane and confers 
it comparatively more resistance to passive diffusion of hydrophobic compounds (130). This 
means that although an uncharged molecule may pass through the inner membrane, its ability 
to reach the inner membrane is somewhat hindered by the outer membrane. The outer 
membrane contains porins and interestingly, Mortimer and Piddock showed that porins OmpF, 
OmpC and PhoE are involved in the uptake of TC (130, 131). Loss of both OmpF and OmpC 
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reduced TC accumulation whilst in their absence, presence of PhoE enhanced TC 
accumulation within the cells. Interestingly, OmpF and OmpC show preference for cation 
uptake over anion uptake for Escherichia coli (E. coli), whilst the porin OprF of P. aeruginosa 
shows a similar preference for cations (132). Protein F plays a role in antibiotic uptake from 
the outer membrane and has also been suggested as a major route for the uptake of 
hydrophilic substances (132, 133). Furthermore, the loss of the porin OprF, also referred to in 
literature as protein F, has been suggested to be significant in reducing the outer membrane 
permeability (134). Also aiding in the influx of cationic species through the outer membrane is 
the presence of a high level of anions within the periplasm (135). This confers the outer 
membrane an interior-negative Donnan potential, which has been suggested to drive the 
movement of cationic species such as positively charged magnesium chelates of TC from 
outside of the cell into the periplasm (136, 137). It is worth noting that Mortimer and Piddock 
also suggest that the accumulation of a significant amounts of TC, albite a fraction of the 
wildtype, within cells in the absence of all major porins suggests that other mechanisms in TC 
uptake through the outer membrane are also involved (131). Once inside the periplasm, the 
drug can now work its way through the inner membrane into the cytoplasm. The concentration 
of the drug within the cytoplasm is in equilibrium with the periplasm (136). Whilst the 
mechanism of uptake through the inner membrane has been attributed to the proton motive 
force (PMF), this PMF seems create a pH difference which serves to keep magnesium 
chelated TC within the cytoplasm as opposed to aiding movement of TC through the inner 
membrane; lower pH in the periplasm created by the PMF shifts the equilibrium such that TC 
preferentially exists in the uncharged and lipophilic form which after passively diffusing through 
the inner membrane, forms positively charged magnesium chelates that are unable to diffuse 
back out (122, 137-139). In other words, it seems that PMF does not directly provide energy 
for the transport of TC, instead it indirectly leads to TC accumulation by preventing its diffusion 
back out. Argast and Beck support that the uptake of TC within bacteria is via passive diffusion 
which is energy independent (140). They also suggest that part of this uptake can be attributed 
to TC binding to phospholipids. 
 
In view of this, a mechanism through which acidic amino acids may be enhancing TC uptake 
in P. aeruginosa is presented here. TC has three ionisable sights consisting of two acidic 
groups (pKa 3.3 and 7.7) and one basic (pKa 9.7). In the concentrations where substantial 
increase in accumulation (Figure 2.44 and Figure 2.45) was witnessed, the pH of the external 
solution was around 3. At this pH in accordance to the Henderson Hasselbalch equation, one 
acidic group (pKa 3.3) would be 33.39% ionised whilst the other (pKa 7.7) would be 0.002% 
ionised. The basic group on the other hand would be 100% protonated, resulting in an overall 
66.61% of TC to be present in the cationic form. This cationic TC moves through porins such 
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as OprF through the outer membrane of P. aeruginosa aided by the Donnan potential 
attracting positively charged species into the periplasm. Once in the periplasm, the 
comparatively higher pH shifts the equilibrium of TC towards the unionised form which is able 
to passively diffuse through the phospholipid bilayer of the inner membrane. 
 
However, Wilks and Slonczewski have shown that in E. Coli the pH of the cytoplasm and 
periplasm drops to a similar pH of the environment it is exposed to (128). Although the pH of 
cytoplasm shoots back to near baseline under a minute, followed by a more gradual reversion 
of the pH towards the baseline, the pH of the periplasm stays low for up to 5 minutes. Thus 
influx of hydrogen ions in the presence of cationic amino acids may negate the Donnan 
potential needed for TC to penetrate into the periplasm. Nevertheless, other mechanisms of 
cationic transport through porins are possible. Modelling shows that cations are attracted to 
negative charges in the pores, suggesting that cations don’t just simply diffuse (141, 142). It 
is likely that under normal conditions, both mechanism would be involved in the movement of 
TC to the periplasm. Furthermore, if the pH of the periplasm in P. aeruginosa also drops with 
exposure to the acidic amino acids, equilibrium would not be expected to shift towards the 
unionised form of TC. In this case the 33.39% of TC which has zero net charge would be 
expected to diffuse through and may be what gives rise to the TC accumulation observed 
(Figure 2.44 and Figure 2.45). The actual percentage of TC  with zero net charge would be 
slightly higher than this since periplasmic pH does not actually reach as low at the 
environmental pH (128). 
 
Also, acidic pH has been linked to porin closure. However many of these studies are regarding 
the porin OmpF (142). To add to this, no effect on OmpT at low pH values suggests that the 
effect of pH on the porin varies from porin to porin (143). With this in mind and the observed 
increase in intracellular TC accumulation with exposure to acidic amino acids, makes it likely 
that OprF in P. aeruginosa may not close in response to lowered pH. Interestingly, porins like 
OmpF and OmpC can also close in response to voltage, whereas OprF has been shown to 
not be voltage gated (132, 142). 
 
2.2.4.2 Amino acid and tetracycline ion pairing 
 
Another mechanism leading to elevated intracellular TC levels may be uptake via amino acid 
channels. Uptake of prodrugs through amino acids channels such as ATB(0,+) has been 
reviewed in depth by Ganapathy et al. ATB(0,+) are amino acid channels with a broad 
substrate specificity (denoted by B) recognising both neutral (denoted by 0) and cationic amino 
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acids (denoted by +). Although anionic aspartic acid and glutamic acid is unlikely to be 
recognised by this transporter, Hatanaka et al. have shown that once these amino acids are 
neutralised by esterification, they are able to interact with ATB(0,+) (144, 145). This was 
concluded by inhibition of the transport of another ATB(0,+) substrate, glycine, in the presence 
of aspartate and glutamate derivatives (144). Furthermore, bacteria have many amino acid 
transporters belonging to both MFS and ATP-binding cassette superfamilies which are able to 
transport both amino acids and their derivatives (146, 147). With this in mind, a mechanism 
allowing uptake of TC through amino acid transporters can be proposed. Considering that at 
L-Asp and L-Glu concentrations of 30 mM and 15 mM, a substantial percentage of these 
amino acids exist in the anionic form whilst many TC molecules exist in the cationic form, a 
neutral ion pair is able to form between these two oppositely charged species. It is likely that 
such an ion pair may be recognised by amino acid transporters and taken up resulting in the 
enhanced accumulation of TC observed. 
 
Of further interest is the observation that glutamic acid and ciprofloxacin exposure are able to 
upregulate the expression of PEPT2 which is a peptide transporter with broad substrate 
specificity (145, 148). PEPT2 has been linked to the transport of valacyclovir, which is a 
prodrug formed by esterification of the poorly bioavailable Acyclovir with the neutral amino 
acid valine (145). Lack of a peptide bond in this prodrugs suggests that a peptide bond is not 
a prerequisite for substrate to be recognised and transported through PEPT2 (149). 
Valacyclovir is also recognised by ATB(0,+), indicating that drugs can be coupled with neutral 
amino acids as esters through esterification at the α-carboxyl group of the amino acid, allowing 
the uptake of resulting prodrug through amino acid channels (145). If neutral amino acids are 
also able to increase the uptake of TC in the same way as the presented acidic amino acids, 
such a finding would be highly significant. Not only would this overcome the problem with 
antimicrobial resistance, it will also negate the pH related toxicity, which otherwise would make 
application of acidic amino acids at such concentrations impossible within the body. 
 
2.2.4.3 Prevention of efflux by acidic amino acids 
 
Earlier it was discussed that TC efflux pumps generally belong to the MFS of efflux pumps 
(122). Bazzone et al. showed that sugar/H+ symporters, specifically those belonging to MFS, 
are inactivated by both alkaline and acidic pH (150). They suggested that whilst in a basic pH, 
the inactivation may be due to the lack of protons, an acidic environment would prevent 
deprotonation and inhibit further H+ binding to the pump. They also highlighted that protonation 
or deprotonation is only affected by the pH of the compartment in which it is happening. For 
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example, if proton release is in the cytoplasm, acidic pH of the cytoplasm would restrict 
deprotonation whereas the external pH would have no effect (150). Keeping this in mind, it is 
likely that the use of acidic amino acids inhibits TC efflux pumps by creating a comparatively 
acidic environment which in turn prevents deprotonation both inside and outside the cell. 
Although, pH homeostasis keeps cytoplasmic pH of bacteria as close to neutral as possible 
once exposed to acidic environments, truly physiological pH is not reached for some time in 
both Gram-negative and Gram-positive bacteria (128, 151, 152). Reaching the original pH 
may even require the environment pH to be neutralised (152). This along with the finding by 
Bazzone et al that even slight decrease in pH decreases pump functionality supports the 
above hypothesis (150). 
 
Another possible mechanism of anti-efflux activity of acidic amino acids may relate to the 
anionic form of the amino acid forming ion pairs with the metal Mg2+. The TC efflux pump TetA 
is expressed by both S. aureus and P. aeruginosa (153, 154). Yamaguchi et al found that in 
inverted membrane vesicles bearing TetA, no uptake of 60Co2+ occurred in the absence of 
TC, concluding that the uptake of 60Co2+ required tetracycline efflux pumps (123, 155). If this 
means that TC requires chelation with metal cations for it to be effluxed, lack of Mg2+ as a 
result of scooping up by L-Asp- and L-Glu- may be hindering TC efflux and resulting in the 
elevated intracellular TC levels observed in the efflux experiments as well as the 




Whilst amino acids are able to enhance the solubility of TC, in this subchapter the results 
present that they also act synergistically with TC to enhance its effectiveness against S. 
aureus and P. aeruginosa. It seems that the inhibition of growth of both bacteria and the 
reduction in pigment production by P. aeruginosa may be as a result of enhanced TC 
accumulation caused by L-Asp and L-Glu. It seems the underlying mechanism differs between 
Gram-positive and Gram-negative bacteria, and may include increased uptake of TC through 
outer membrane porins, increased uptake of TC as amino acid ion-pairs through amino acid 
transporters and inhibition of TC efflux through efflux transporters. However, what still remains 
to be seen is whether the synergy observed with amino acids is limited to TC or whether it is 






















Chapter 3: Effect of acidic amino acids as counterions 
on the accumulation and efflux of ciprofloxacin in 
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3.1 Introduction 
In the previous chapter, it was demonstrated that amino acids are able to increase intracellular 
accumulation of TC. Along with this an increase in the antimicrobial effectiveness of TC, as 
evident through a decrease in growth of both S. aureus and P. aeruginosa when combinations 
of amino acids and TC were used as compared to TC or amino acids on their own, was 
observed. Was the synergistic effect of amino acids limited to TC? Or can the synergy be used 
with other antimicrobial agents, potentially opening doors to broader applications. To 
investigate this, Ciprofloxacin (Cip) was chosen as it has been demonstrated in the past that 
its solubility and permeability can be enhanced using various amino acids (156). 
Being active against both gram-negative and gram-positive bacteria, Cip (Figure 3.1) is often 
a widely used antibiotic for post-procedural prophylaxis (157, 158). It is also often a choice for 
many infections ranging from eye and ear infections to respiratory tract and urinary tract 
infections, as indicated by the British National Formulary (158, 159). Cip is one of the 
antibiotics of the fluoroquinolone class of antibiotics and is a bactericidal in effect. Its 
mechanism of action acts to stop DNA replication by inhibiting DNA-gyrase and DNA 
topoisomerase activity (160). 
Figure 3.1: Chemical structure of Cip. Image taken from British Pharmacopeia (102). 
However, like many other antibiotics, its future use is under threat. Resistance to Cip is on an 
ever increasing global rise (161, 162). Three main routes of resistance to Cip are discussed 
in literature. Firstly, mutations in the enzymes, DNA-gyrase and DNA topoisomerase renders 
the drug unable to act on these targets, allowing DNA replication to function normally (163, 
164). The second mechanism involves restriction of Cip accumulation within the bacterial. This 
is either through restricting the amount of Cip that can penetrate into the bacteria and/or 
pumping back out the Cip which manages to get in (163, 164). Finally, bacteria can acquire 
resistance to Cip through plasmid-located genes (163, 164). Considering the role of amino 
acids in enhancing permeability of various drugs in caco-2 monolayers as well as buccal cell 
layers, the second mechanism is of most interest here (156, 165). 
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The route of uptake of Cip is certainly different between gram-positive and gram-negative 
bacteria, and can be attributed to the presence of an outer membrane in gram-negative 
bacteria. Whilst Cip most probably penetrates the membrane of gram-positive bacteria 
through passive diffusion, the mechanism needed for penetration into gram-negative is a little 
more complicated and has been discussed in detail in the previous chapter. Briefly, the 
asymmetric nature of the outer membrane in gram-negative bacteria makes it rigid and thus 
more resistant to passive diffusion of hydrophobic compounds (130). Due to this, drugs like 
Cip pass through the outer membrane using porins(164). Thus gram-negative bacteria can 
confer resistance by altering expression of these membrane proteins, limiting uptake of the 
drug (163). 
 
Various efflux pumps have been identified to extrude fluoroquinolones in a number of bacteria. 
In P. aeruginosa, majority belong to the RND superfamily and include MexAB-OprM, MexCD-
OprJ, MexEF-OprN and MexXY (163). Whereas, the MFS superfamily makes up most of the 
efflux identified currently in S. aureus and includes NorA, NorB, NorC and SdrM (163).  
 
Thus, this highlights a mechanism which can be used to combat AMR, i.e. enhancing drug 
accumulation by increasing penetration of the drug through the membrane/s and/or hindering 
the efflux of the drug. These mechanisms are of particular interest here because as mentioned 
earlier, amino acids have been shown to enhance drug permeation into cells. This chapter 
thus studies whether amino acids can combat AMR through an accumulation enhancing 
mechanism and proposes the potential ways this could be occurring. 
 
To investigate this, the effect of acidic amino acids on the efflux of Cip on planktonic bacteria 
was conducted. It was decided to use the same bacteria as were used for efflux experiments 
with tetracycline (TC); S. aureus (NCTC 8325) and P. aeruginosa (PA01). This holds the 
benefit that these pathogens are among the priority pathogens which the WHO listed in a bid 
to help focus research and development (47). To add to this, using these bacteria also allowed 
the investigation of L-Asp and L-Glu synergy with Cip in both gram-positive (S. aureus) and 
gram-negative (P. aeruginosa) bacteria. Furthermore it provides evidence as to whether 
mechanisms of TC and potentially Cip permeability enhancement are similar or different. 
 
The aim of the study presented in this chapter was to evaluate whether the accumulation 
enhancing effect of the amino acids, as witnessed with tetracycline, was achievable with other 
antibiotics or whether the synergy was limited to optimising tetracycline only. For this we 
investigated the use of acidic amino acids as counterions to Cip and determined its effect on 
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the accumulation of the drug in planktonic S. aureus and P. aeruginosa cells. Along with the 
effect on efflux, we further evaluated any other synergistic effect, including the effect on 
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Ciprofloxacin 98%, ethidium bromide 10 mg/ml and tryptone soya broth was obtained from 
fisher scientific. L-Aspartic acid 98+% (T), L-glutamic acid 99% (N), D-(+)-glucose 99.5% GC 
and phosphate buffered saline tablets were from Sigma Aldrich. KCl (sigma Aldrich), MgCl2 
and chloroform (fisher scientific) were gifted by technical staff. S. aureus strain NCTC 8325 
and P. aeruginosa strain PAO1 was gifted by Professor Peter A. Lambert. 
 
3.2.2 Determining the minimum inhibitory concentration and minimum lethal 
concentration of amino acids and ciprofloxacin 
 
Minimum inhibitory concentration (MIC) and minimum lethal concentration (MLC) of L-Asp, L-
Glu and Cip on S. aureus and P. aeruginosa was determined. To do this, overnight cultures 
of S. aureus and P. aeruginosa were grown. 0.1 O.D. of each bacteria was then incubated 
with two-fold serial dilutions of L-Asp, L-Glu or Cip. The concentrations of amino acids used 
ranged from 30 mM to 0.23 mM whilst the concentration of Cip used ranged from 135.81 µM 
to 2.12 µM. Following this, the plates were incubated in a 37 °C incubator overnight. MIC was 
taken to be the lowest concentration with no visible growth (turbidity); generally one two-fold 
dilution below MLC. To determine MLC, concentrations which showed no visible growth 
(turbidity) were plated on TSA agar plates and incubated at 37 °C overnight. MLC was taken 
to be the lowest concentration which resulted in no colony formation. 
 
3.2.3 Ciprofloxacin accumulation assay 
 
To bring to logarithmic phase, 10 ml of overnight culture was added to 20ml of fresh TSB and 
incubated for one hour at 37 °C in an orbital shaking incubator. The culture was then 
centrifuged at 2860 g for 20 minutes and supernatant was discarded. The cell pellet was 
resuspended in 30 ml 1 mM MgCl2 in 0.01 M PBS. Centrifugation step was repeated following 
which the pellet was resuspended in 11.95 ml of same buffer. The cell suspension was split 
into 4 equal volumes (2.5 ml each) and to each quarter 2.5 ml of double the working 
concentration of the drug (made up in same buffer) along with 250 µl of 1 mg/ml Ethidium 
Bromide (EtBr). For example if working concentration is 1 mM Cip, add 2.5 ml of 2 mM Cip 
along with 250 µl of EtBr. Aliquot 100 µl per well in 96 well plate. Observe fluorescence every 
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5 minutes for 60 minutes (room temperature) at an excitation wavelength of 510 nm and an 
emission wavelength of 595 nm. 
 
To check for further accumulation using amino acids, 100 µl of amino acid concentrations 
ranging from 30 mM to 0.23 mM made up in 1 mM MgCl2, 0.01 M PBS and 100 mM glucose 
(to provide energy) was added to wells as required. Next 20 µl of 1M KCl was added to each 
well. Controls included no drug (max AA conc), No glucose with No AA (max drug 
concentration used), no AA, no glucose (with no drug or AA) and glucose (with no drug or AA). 
 
3.2.4 Growth curve susceptibility assay 
 
Growth curves of L-Asp, L-Glu and Cip were evaluated for S. aureus and P. aeruginosa in the 
presence of the combinations used in Cip accumulation assays. To do this, overnight cultures 
of S. aureus and P. aeruginosa were grown. Solutions with double the working concentrations 
were prepared for the amino acids, Cip and their combinations. 100 µL of these were then 
incubated with 100 µL of the culture in wells of 96 well plates, in such a way that the resulting 
cell suspension consisted of the desired working concentrations of the test substances along 
with 0.1 O.D. of bacteria. The plates were than analysed in an incubated (37 °C) plate reader 
set to read O.D. of each well every half an hour at 600 nM. 
 
3.2.5 Pyocyanin quantification 
 
After susceptibility assay, 96 well plates were incubated in the fridge until Pyocyanin was 
quantified. Briefly, cell free supernatant was obtained by centrifugation at 3220 g for 10 
minutes. 100 µl of chloroform was added to 150 µl of the supernatant and vigorously vortexed. 
The samples were then centrifuged at 2996 g for 5 minutes and the supernatant was 
discarded. To the remaining bottom (chloroform) layer, 60 µl of 0.2 M HCl was added, followed 
by vigorous vortexing. The samples were again centrifuged at 2996 g for 5 minutes and the 
top layer was transferred to a 96 well plate. After all the samples were processed in this 
manner, the 96 well plate was read using a plate reader at 520 nm. 
 
3.2.6 Pyoverdin quantification 
 
After susceptibility testing as described above, the 96 well plates were kept in fridge until 
pyoverdin was quantified. Briefly, the plates were centrifuged at 3220 g for 10 min. Cell free 
supernatant was transferred to Greiner black bottom plates and the concentration of pyoverdin 
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was quantified using a fluorescence spectrophotometer at an excitation wavelength of 395 nm 
and an emission wavelength of 470 nm. The results were plotted relative to control. 
 
3.2.7 Statistical analysis 
 
Statistical analysis was conducted using GraphPad Prism. Initially one way ANOVA was 
carried out to look for overall significance within the data. This was followed by the uncorrected 
Fisher’s LSD test, to see where the significant difference lies. P values below 0.05 for the 































3.3.1 MIC and MLC 
 
Before conducting accumulation experiments, MIC and MLC of the amino acids and Cip was 
conducted on the S. aureus strain NCTC 8325 and P. aeruginosa strain PAO1. Concentrations 
of amino acids screened for MIC for each bacteria were 30, 15, 7.5, 3.75, 1.88, 0.94, 0.47, 
0.23 mM whilst the concentrations of Cip screened were 0.14, 0.068, 0.034, 0.017, 0.0085, 
0.0042 and 0.0021 mM. All amino acid concentrations tested were below MIC. 
 
Table 3.1: Cip MIC and MLC. 
 MIC MLC 
S. aureus 16.98µM 33.95 µM 
PAO1 2.12µM 4.24 µM 
 
3.3.2 S. aureus 
 
Like in the TC chapter, a slightly modified accumulation assay was used for efflux assessment 
of Cip which allows indirect assessment of the efflux behaviour of the drug. Again the 
experiment was conducted in two parts. The first part was for 60 min for which bacteria were 
loaded with maximum EtBr by depriving them from the energy needed for efflux. The second 
part of the experiment was conducted for 120 min and was the main part used to assess 
whether the test substances used were able to effect accumulation of EtBr. The concentrations 
of Cip used in the assessment of efflux of Cip in S. aureus were 8.49 µM, 4.24 µM, 2.12 µM 
and 1.06 µM. The amino acids investigated for potential modulation of Cip efflux were L-Asp 
and L-Glu. To do this, each of the above mentioned Cip concentration were studied individually 
with L-Asp and L-Glu concentrations of 30 Mm,15 mM, 7.5 mM, 3.75 mM, 1.88 mM, 0.94 mM, 
0.47 mM and 0.23 mM. 
 
Along with the test compounds above, various controls were also used in a bid to better 
understand the observed patterns of efflux. The ‘No Drug’ control consisted of 30 mM L-Asp 
or L-Glu on its own and was used to gain insight into the effect of the amino acid on efflux EtBr 
whilst EtBr had no competition for the efflux pump in the form of Cip. On the other hand, the 
control ‘0 mM L-Asp or 0 mM L-Glu’ which contained Cip on its own was essential in 
determining whether amino acids modulated Cip efflux or not compared to Cip on its own. It 
Page 153 of 252 
 
was also felt necessary to assess the efflux of EtBr in the presence (glu) and absence (no glu) 





Figure 3.2: Efflux of Cip in S. aureus using different concentrations of L-Asp (30 mM to 0.23 mM). a) 8.49 
µM TC b) 4.24 µM TC c) 2.12 µM TC d) 1.06 µM Cip. In the legend, numbers 0 to 30 represent amino acid 
concentrations in combination with respective Cip concentration; n=4. 
 
Figure 3.2 presents the accumulation of Cip on its own along with its combinations with 
different concentrations of L-Asp in S. aureus. A striking observation is that the pattern of 
accumulation for each concentration of Cip used is similar. In other words no difference in the 
pattern of accumulation was observed between Cip concentration of 8.49 µM, 4.24 µM, 2.12 
µM and 1.06 µM. After 60 minutes, which represents the second phase of accumulation 
assessment in the accumulation experiment, a general rise fluorescence intensity is observed. 
This indicates a rise in intracellular EtBr. After this rise, a fall in fluorescence intensity is 
observed, potentially indicating EtBr efflux. A concentration dependent pattern in the rise and 
fall of fluorescence intensity is observed between 7.5 mM L-Asp and 0 mM L-Asp; as the 
concentration increases the rise as well as the fall in fluorescence intensity is steeper, or it 
can be said that the rate of influx and efflux of EtBr decreases with a decrease in concentration 
of L-Asp. For some reason L-Asp concentrations of 15 mM and more so 30 mM do not follow 
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this pattern. It is worth noting that 0 mM L-Asp, which is basically Cip on its own shows the 
slowest increase and decrease in fluorescence intensity. 
 
 
Figure 3.3: Efflux of Cip in S. aureus using different concentrations of L-Glu (30 mM to 0.23 mM). a) 8.49 
µM TC b) 4.24 µM TC c) 2.12 µM TC d) 1.06 µM TC. In the legend, numbers 0 to 30 represent amino acid 
concentrations in combination with respective Cip concentration; n=4. 
 
Efflux of Cip in S. aureus was also investigated in combination with different concentrations of 
L-Glu and is presented in Figure 3.3. Like with L-Asp, the concentration of Cip does not effect 
the pattern of efflux observed, only the concentration of L-Glu seems to modulate this pattern. 
As mentioned earlier, the second phase of the assessment (after 60 min) represents the 
pattern of efflux in the presence of the drug and the amino acid. In this phase, a general rise 
in fluorescence intensity is observed, possibly suggesting a rise in intracellular EtBr levels. 
Whilst lack of glucose (no glu) follows a similar pattern, least increase in fluorescence intensity 
is observed with the presence of glucose (glu); both of these controls lack both Cip and L-Glu, 
the only difference being the absence or presence of glucose, respectively. Ultimately, the rise 
in fluorescence intensity is followed by a gradual fall. Interestingly, 15 mM and 7.5 mM do not 
follow the pattern of slow reduction in fluorescence intensity and instead both show a steep 
reduction in fluorescence intensity which plateaus to a lower level then ever observed in part 
one or two of the experiment. It is also noted that 30 mM L-Glu follows a somewhat similar 
pattern to the no drug control. A general pattern observable in the results is that the rate of 
reduction in fluorescence intensity lowers with a decrease in L-Glu concentration. The main 
outlier in this regard is Cip in combination with 30 mM L-Glu. In other words whilst the L-Glu 
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concentration of 15 mM and 7.5 Mm result in fastest efflux of EtBr from within the cells, the 
concentrations of 0 mM, 0.23 mM and 0.47 mM show slowest efflux, only surpassed by the 
control (No glu) lacking energy required for efflux. The pattern of efflux observed for 15 mM 
and 7.5 mM L-Glu is similar to the pattern observed with L-Asp of the same concentrations, in 
the sense that these concentrations lead to the greatest rate of reduction in fluoresce intensity 
after the initial rise. 
 
3.3.2.2 Growth curves 
 
Although a synergy in efflux of Cip is observed between both L-Asp and L-Glu when they are 
combined with the drug, it raised questions with regards to whether or not this synergy 
translates into synergy in the effectiveness of Cip against S. aureus. To study this, growth 
curves were done to look at the effect of combining L-Asp or L-glu with the drug on the growth 
of S. aureus over a period of 16 hours. 
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Figure 3.4: S. aureus growth curves with a) 30, 15 and 7.5 mM L-Asp amino acid on its own, b) with 16.98 
8.49, 4.24, 2.12 and 1.06 µM Cip on its own, c) 30 mM L-Asp combined with 8.49, 4.24, 2.12 and 1.06 µM Cip, 
d) 15 mM L-Asp combined with 8.49, 4.24, 2.12 and 1.06 µM Cip and e) 7.5 mM L-Asp combined with 8.49, 
4.24, 2.12 and 1.06 µM Cip; n=3. 
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Growth curves of S. aureus in the study with L-Asp are presented in Figure 3.4. The curves 
include those of L-Asp (Figure 3.4a) and Cip (Figure 3.4b) both on their own and Cip 
concentrations of 8.49 µM, 4.24 µM, 2.12 µM and 1.06 µM in combination with L-Asp 
concentrations of 30 mM (Figure 3.4c), 15 mM (Figure 3.4d) and 7.5 mM (Figure 3.4e). The 
curves are presented alongside each other with the same axis, enabling easy comparison 
between curves. A concentration dependent effect of L-Asp was observed on the growth of S. 
aureus; as the concentration of L-Asp is increased from 30 mM to 7.5 mM, a higher inhibitory 
effect on S. aureus growth is observed. On the other hand, although a concentration 
dependent effect is also observed with Cip alone, surprisingly, a lower concentration of Cip 
presents greater hindrance in the growth of S. aureus. Nevertheless, this shows that Cip on 
its own also effects the growth of S. aureus. Having these controls, the effect of L-Asp on its 
own and Cip on its own allows the comparison to their combinations when evaluating for 
synergistic effect. To see whether there is a synergistic effect in S. aureus growth when 
combining L-Asp and Cip, growth curves obtained by exposure to combinations (Figure 3.4c-
e) were compared with growth curves obtained by the amino acid (Figure 3.4a) and the drug 
(Figure 3.4b) in isolation. In cases where combination showed greater reduction in growth of 
the bacteria compared to both the drug and the amino acid in isolation, synergy was 
concluded. With this rule in mind, the concentration of L-Asp which seems to present the best 
synergy with Cip is 15 mM, since apart from its combination with 1.06 µM Cip, the 
combinations noticeably hinder the growth of S. aureus in comparison to the corresponding 
Cip concentrations on their own as well as 15 mM L-Asp on its own. Combinations between 
7.5 mM L-Asp and Cip, again excluding 1.06 µM Cip, also show some synergy. No synergy 
was observed when Cip was combined with 30 mM L-Asp. 
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Figure 3.5: S. aureus growth curves with a) 30, 15 and 7.5 mM L-Glu amino acid on its own, b) with 16.98 
8.49, 4.24, 2.12 and 1.06 µM Cip on its own, c) 30 mM L-Glu combined with 8.49, 4.24, 2.12 and 1.06 µM Cip, 
d) 15 mM L-Glu combined with 8.49, 4.24, 2.12 and 1.06 µM Cip and e) 7.5 mM L-Glu combined with 8.49, 
4.24, 2.12 and 1.06 µM Cip; n=3. 
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When investigating the growth of S. aureus in the presence of L-Glu, Cip, and L-Glu and Cip 
combinations, similar results to those obtained with L-Asp were obtained. Figure 3.5 above 
presents the growth curves obtained and include those for L-Glu (Figure 3.5a) and Cip (Figure 
3.5b) both on their own. To evaluate synergy, Cip concentrations of 8.49 µM, 4.24 µM, 2.12 
µM and 1.06 µM in combination with L-Glu concentrations of 30 mM (Figure 3.5c), 15 mM 
(Figure 3.5d) and 7.5 mM (Figure 3.5e) are also presented here. Again to ease comparison 
between the curves, they are presented alongside each other with the same axis. Both L-Glu 
and Cip on its own effected the growth of S. aureus. However no difference was observed in 
the extent of growth inhibition between the different concentrations of Cip used. On the other 
hand, a concentration dependent inhibition in S. aureus growth was observed with L-Glu 
where apart from 7.5 mM, substantial inhibition was observed and increasing the 
concentration of the amino acid resulted in greater modulation of S. aureus growth. These 
curves (Figure 3.5a,b) were compared to curves obtained by combining Cip with L-Glu (Figure 
3.5c-e) to look for synergy. Like before, to synergy growth curves obtained by exposure to 
combinations (Figure 3.5c-e) were compared with growth curves obtained by the amino acid 
(Figure 3.5a) and the drug (Figure 3.5b) in isolation. Combinations which showed greater 
reduction in growth of the S. aureus in comparison to both Cip and L-Glu in isolation, were 
concluded to exhibit positive synergy. Considering this, like with L-Asp, combining Cip with15 
mM and 7.5 mM L-Glu showed best synergy where apart from combining with 1.06 µM L-Glu, 
all other combinations reduced S. aureus growth greater than their corresponding Cip and L-
Glu concentrations. Cip combination with 7.5 mM L-Glu specially stands out because not only 
it modulates S. aureus growth to a similar level as 15 mM combinations does, the reduction is 
much greater for 7.5 mM combination than for 15 mM combination when compared to their 
corresponding amino acid concentration on its own; 7.5 mM L-Glu did not affect S. aureus 
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3.3.3 Pseudomonas aeruginosa 
 
Like with S. aureus, the possibility of synergy between the amino acids and Cip was also 
investigated for P. aeruginosa. The concentrations of Cip used were 1.06 µM, 0.53 µM, 0.27 
µM and 0.13 µM. The amino acids used for to investigate this synergy were again L-Asp and 
L-Glu. Each Cip concentration mentioned above was studied individually as well as in 
combination with L-Asp and L-Glu concentrations of 30 Mm,15 mM, 7.5 mM, 3.75 mM, 1.88 





Figure 3.6: Efflux of Cip in P. aeruginosa using different concentrations of L-Asp (30 mM to 0.23 mM). a) 
1.06 µM Cip b) 0.53 µM Cip c) 0.27 µM Cip d) 0.13 µM Cip. In the legend, numbers 0 to 30 represent amino 
acid concentrations in combination with respective Cip concentration; n=4. 
 
Figure 3.6 presents the accumulation of Cip and L-Asp in P. aeruginosa. Results for the drug 
and the amino acid accumulation separately and in combinations are presented here. Figure 
3.6a, Figure 3.6b, Figure 3.6c, and Figure 3.6d present Cip concentrations of 1.06, 0.53, 0.27 
and 0.13 µM respectively. As with S. aureus, the pattern of efflux obtained from all of the Cip 
concentrations used is similar with no observable difference. In the second part of the 
accumulation experiment, a general rise in fluorescence intensity is observed, indicating a rise 
in intracellular accumulation of EtBr. A very distinct pattern of efflux is observed with P. 
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aeruginosa, where ‘glu’ causes a minimal rise and Cip combination with 30 mM and 15 mM L-
Asp as well as ‘no drug’ which also contains 30 mM L-Asp, causes biggest increase in 
fluorescence intensity. The rest of the combinations, along with the energy deprived ‘no glu’ 
control present a moderate rise in fluorescence above ‘glu’. It is also worth noting that whilst 
the accumulation curve for Cip combinations with 15 mM L-Asp ends with a plateau by the 
end of the experiment, the curve for 30 mM L-Asp whether with Cip or without (no drug) shows 
a decelerating decrease in fluorescence intensity following the initial rise. 
 
 
Figure 3.7: Efflux of Cip in P. aeruginosa using different concentrations of L-Glu (30 mM to 0.23 mM). a) 
1.06 µM Cip b) 0.53 µM Cip c) 0.27 µM Cip d) 0.13 µM Cip. In the legend, numbers 0 to 30 represent amino 
acid concentrations in combination with respective Cip concentration; n=4. 
 
Efflux of Cip in P. aeruginosa was also investigated in combination with different 
concentrations of L-Glu and is presented in Figure 3.7. Along with this efflux experiments were 
also conducted for Cip and 30 mM L-Glu on their own and these serve as controls. The 
concentrations of Cip used are 1.06 (Figure 3.7a), 0.53 (Figure 3.7b), 0.27 (Figure 3.7c) and 
0.13 µM (Figure 3.7d). A very consistent pattern is again evident, i.e. the concentration of Cip 
does not affect the pattern of efflux observed, only the concentration of L-Glu seems to 
modulate this pattern. The second phase of the assessment (after 60 min) represents the 
pattern of accumulation of EtBr in the presence of the drug and the amino acid. In this a 
general rise in intracellular EtBr is hinted by a rise in fluorescence intensity. A very clean 
pattern of accumulation is observed again, like with L-Asp, where all L-Glu and Cip 
combinations follow the same pattern as that of Cip on its own (0 mM L-Glu). The only 
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deviation observed from this pattern are clearly substantial and are with Cip combinations with 
30 mM and 15 mM L-Glu and 30 mM L-Glu on its own (no drug). The 30 mM combination 
presents with fastest rate of EtBr uptake followed by 30 mM on its own. Even though with the 
15 mM combination, EtBr seems to accumulate within cells slower than with the 30 mM 
combination, the fluorescence intensity is equal for both by the end of the experiment, 
indicating that combinations allow accumulation of same amount of EtBr within the cells. 
Although the energised and the energy deprived controls ‘glu’ and ‘no glu’ were not included 
in the experiment with the amino acid L-Glu, it would be fair to assume that they follow a similar 
pattern as when efflux experiments on P. aeruginosa with L-Asp were conducted. 
 
3.3.3.2 Growth curves 
 
To investigate how the synergy between Cip and the amino acids observed with efflux 
experiments translates into the efficacy of Cip on the bacteria, growth curves were conducted 
for P. aeruginosa that was no treated and that which was treated with Cip, amino acids and 
Cip and amino acid combinations. 
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Figure 3.8: P. aeruginosa growth curves with a) 30, 15 and 7.5 mM L-Asp amino acid on its own, b) with 
4.24, 2.12, 1.06, 0.53, 0.27 and 0.13 µM Cip on its own, c) 30 mM L-Asp combined with 1.06, 0.53, 0.27 and 
0.13 µM Cip, d) 15 mM L-Asp combined with 1.06, 0.53, 0.27 and 0.13 µM Cip and e) 7.5 mM L-Asp combined 
with 1.06, 0.53, 0.27 and 0.13 µM Cip; n=3. 
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To make comparison between growth curves of L-Asp (Figure 3.8a), Cip (Figure 3.8b) and 
their combinations (Figure 3.8c-e) easier, the growth curves are presented alongside each 
other in Figure 3.8. Whilst Cip has a concentration dependent effect on the growth of P. 
aeruginosa, where a higher concentration hinders more greatly the growth of the bacteria, L-
Asp on its own was generally unable to effect the growth of P. aeruginosa; only a delay in the 
onset of the exponential phase was observed with 30 mM L-Asp. In the process of evaluating 
the presence of synergy between L-Asp and Cip, the growth curves obtained by exposure to 
combinations (Figure 3.8c-e) were compared with growth curves obtained by individual parts 
(Figure 3.8a,b). Although, combining Cip with L-Asp leads to an early onset death phase, a 
very interesting pattern is observed. It seems that when L-Asp is combined with higher 
concentration of Cip, it reduces the effectiveness of Cip and enhances P. aeruginosa growth, 
whereas if L-Asp is combined with lower concentrations of Cip, it results in a synergistic 
inhibition of the growth of P. aeruginosa. More specifically, combining 30, 15 or 7.5 mM of L-
Asp with Cip concentrations 1.06 and 0.53 µM seems to aid the growth of P. aeruginosa, whilst 
combining with 0.27 and 0.13 µM does seem to present some positive synergy resulting in the 
early onset of death phase mentioned earlier. Also combining the amino acids with 0.27 and 
0.13 µM Cip leads to less overall P. aeruginosa growth, hinted lower normalised O.D. at the 
peaks. 
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Figure 3.9: P. aeruginosa growth curves with a) 30, 15 and 7.5 mM L-Glu amino acid on its own, b) with 
4.24, 2.12, 1.06, 0.53, 0.27 and 0.13 µM Cip on its own, c) 30 mM L-Glu combined with 1.06, 0.53, 0.27 and 
0.13 µM Cip, d) 15 mM L-Glu combined with 1.06, 0.53, 0.27 and 0.13 µM Cip and e) 7.5 mM L-Glu combined 
with 1.06, 0.53, 0.27 and 0.13 µM Cip; n=3. 
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Growth curves of P. aeruginosa with L-Glu and L-Glu combinations with Cip (Figure 3.9) 
showed very similar results as to those obtained with L-Asp. Figure 3.9a presents the growth 
curves of P. aeruginosa when exposed to L-Glu concentrations of 30, 15 and 7.5 mM, whilst 
Figure 3.9b presents the growth curves obtained for different Cip concentrations. Alongside 
these are presented growth curves for Cip and L-Glu combinations (Figure 3.9c-e). Again, Cip 
effects the growth of P. aeruginosa, in a concentration dependent manner, where a higher 
concentration hinders more greatly the growth of the bacteria whilst a lower concentration of 
Cip has less of an affect. The only concentration of L-Glu which somewhat inhibits P. 
aeruginosa growth is 30 mM L-Glu. When comparing growth curves obtained with 
combinations with the growth curves obtained by Cip and L-Glu individually, the combinations 
which modulated the growth of P. aeruginosa more than both of the individual parts were taken 
to exhibit synergy. Like when using L-Asp, it seems that when L-Glu is combined with higher 
concentration of Cip (1.06 and 0.53 µM), it reduces the effectiveness of Cip and enhances P. 
aeruginosa growth, whereas if L-Asp is combined with lower concentrations of Cip (0.27 and 
0.13 µM), it results in a synergistic inhibition of the growth of P. aeruginosa. Only with 
combinations using 30 mM L-Glu was there no synergy observed, since 30 mM L-Glu on its 
own inhibited P. aeruginosa growth to a similar level. Two main effects of synergy are 
observed. Firstly combining the drug with L-Glu results in an earlier onset of the death phase. 
And secondly, combining 15 and 7.5 mM L-Glu with 0.27 and 0.13 µM Cip leads to less overall 
P. aeruginosa growth. 
 
3.3.3.3 Pigment production 
 
Like with TC, pigment production during the growth curve experiments varied depending on 
the combinations of Cip and amino acids P. aeruginosa was exposed to. Due to this, it was 
appropriate to quantify the pigments produced. Visual production of the pigments can be seen 
in Figure 3.10a and Figure 3.11a. Figure 3.10b and Figure 3.11b on the other hand present 
pyocyanin production and was quantified using the chloroform/HCl extraction method. A 
relation between the pigment intensity is observed where a more intense green pigmentation 
(Figure 3.10a and Figure 3.11a) corresponds to higher amounts of pyocyanin (Figure 3.10b 
and Figure 3.11b) present. For statistical analysis, initially one way ANOVA was conducted to 
whether there was significant difference within the data or not. This was followed by the 
uncorrected Fisher’s LSD test to see where this significant difference lies. Fisher’s LSD test 
was chosen over tests which correct for multiple comparisons because in answering the 
hypothesis each comparison stood alone, such that when checking how a specific 
combination of amino acid and the drug compared to both its parts in isolation, its relation to 
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other concentrations (of the amino acid, drug or any of their combinations) was not part of the 
hypothesis and irrelevant in answering the question posed. 
 
 
Figure 3.10: Effect of L-Asp, Cip and L-Asp with Cip combinations on the production of pyocyanin by P. 
aeruginosa; n=3. 
 
Figure 3.10b presents pyocyanin production by P. aeruginosa when incubated with L-Asp, Cip 
and various L-Asp and Cip combinations. Cip showed a statistically significant (p<0.0001) 
concentration dependent reduction in pyocyanin production where a higher concentration of 
the drug led to less pigment production. The only L-Asp concentration which resulted in 
significant pigment reduction was 30 mM (p<0.0001). Synergy between Cip and L-Asp was 
confirmed if a particular combination resulted in less pigment production compared to both of 
its corresponding parts. If combination only resulted in less pigment production compared to 
one of the corresponding part, no synergistic effect was confirmed. Although all combinations 
significantly (p<0.0001) reduced the amount of pyocyanin produced by P. aeruginosa, none 
seem to show statistically significant synergy. Granting 0.27 and 0.13 µM Cip combined with 
30 mM L-Asp did show significant reduction compared to the corresponding Cip 
concentrations, this was not significantly lower than 30 mM L-Asp on its own. It may be worth 
pointing out that although not statistically significant combinations, some synergy is witnessed 
with the combinations 15 mM + 0.27 µM, 15 Mm + 0.13 µM and 7.5 Mm + 0.27 µM. 
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Figure 3.11: Effect of L-Glu, Cip and L-Glu with Cip combinations on the production of pyocyanin by P. 
aeruginosa; n=3. 
 
Pyocyanin production by P. aeruginosa once treated with Cip, L-Glu and their combinations 
at various concentrations is presented in Figure 3.11. Interestingly, 15 and 7.5 mM L-Glu led 
to increased pyocyanin production whilst 30 mM significantly (p=0.011) reduced its production. 
Cip concentrations of 1.06 (p<0.001), 0.53 (p=0.0078) and 0.27 µM reduced pyocyanin 
production in a concentration dependent manner, with 1.06 µM reducing the most and 0.27 
µM reducing the least. 0.13 µM Cip had no significant change on pyocyanin production. As 
before, synergy was established if combinations led to greater reduction in pyocyanin 
production compared to both Cip and L-Glu of the same concentration as that used in the 
combination. With this rule in mind, the only combination which showed substantial synergy 
(p=0.031) was 0.13 µM Cip combined with 15 mM L-Glu. Though Cip concentrations of 0.27 
and 0.13 µM led to reduced pyocyanin production compared to the corresponding Cip 
concentrations, the amount of pyocyanin was not less than that produced by 30 mM L-Glu on 
its own. Hence these combinations did not show any synergistic effect in pyocyanin 
production. 
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Figure 3.12: Effect of L-Asp, Cip and L-Asp and Cip combinations on the production of pyoverdine by P. 
aeruginosa; AA (mM), Cip (µM); n=3. 
 
Pyoverdine production by P. aeruginosa was also quantified. Its production when exposed to 
Cip, L-Asp and their combinations is presented in Figure 3.12. When used in isolation only 30 
mM L-Asp (p<0.0001) and 1.06 µM Cip (p<0.0001) resulted in a significant reduction in 
pyoverdine production. Once Cip and L-Asp were combined, synergistic decrease in 
pyoverdine production was observed using 15 mM (p<0.01) and 7.5 mM L-Asp (p<0.01) in 
combination with 0.53, 0.27 and 0.13 µM Cip. Although combining these Cip concentrations 
with 30 mM L-Asp hindered pigment production compared to the corresponding Cip 
concentrations, the amount produced was not lower than that produced with exposure to the 
amino acid on its own.  Likewise, even though combining 1.06 µM Cip with 15 and 7.5 mM L-
Asp resulted in lower pyoverdine compared to when these amino acid concentrations were 
used in isolation, the values obtained were not lower than that those obtained with 1.06 µM 
Cip. Hence no synergy is attributed to any combinations with 30 mM L-Asp or 1.06 µM Cip. 
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Figure 3.13: Effect of L-Glu, Cip and L-Glu and Cip combinations on the production of pyoverdine by P. 
aeruginosa; n=3. 
 
Results for pyoverdine production when L-Glu was used as an accumulation enhancer for Cip 
are presented in Figure 3.13. Both L-Glu (p<0.001) and Cip (p<0.05) showed a concentration 
dependent reduction in pyoverdine production where a higher concentration of the amino acid 
and the drug resulted in less production of the pigment. Like with L-Asp, Cip combinations 
with 30 mM L-Glu did not result in any positive synergy, since the combinations did not 
decrease pyoverdine production lower than the amount produced by 30 mM L-Glu on its own. 
The combinations which showed significant synergy, due to being more inhibitive in pigment 
production than both of the corresponding parts, were 15 mM L-Glu combined with 1.06 
(p<0.0001) and 0.27 µM (p<0.0001) Cip and 7.5 mM L-Glu combined with 1.06 (p=0.022), 
















In a bid to overcome the ever growing resistance to the antibiotics in clinical use, adjuvants 
are in use and also form part of a research area in the field of AMR. Generally, adjuvants aim 
to inhibit the resistance mechanism to particular drugs. For example, if an enzyme inactivates 
a drug, the adjuvant would act to increase the activity of the drug by inhibiting the enzyme. 
Likewise, if a drug is extruded out of efflux pumps, the adjuvant would act to inhibit this efflux 
(67, 69, 70, 166, 167). 
 
Unfortunately, being classified as an adjuvant, whether it has intrinsic antibiotic activity or not, 
does not make a substance immune from bacteria acquiring resistance against it. A good 
example for this is the β-lactamase inhibitor sulbactam which functions by inhibiting the β-
lactamase enzyme that would otherwise inhibit the β-lactam class of antibiotics such as 
ampicillin (168). Although sulbactam was approved for clinical use in 1986, persistence 
despite sulbactam-penicillin co-administration was reported as early as 1988 (169, 170). In 
united states, rate of resistance to sulbactam-ampicillin was reported to be 35.2% in the period 
of 2003 to 2005 and rose to 44.9% and 41.2% by the period of 2006 to 2008 and the period 
of 2009 to 2012 respectively (168, 171). Although substances which are able to restore 
sulbactam activity have been identified, this approach does not seem ideal; inhibiting the 
resistance to adjuvants which are meant to be inhibiting the resistance to antibiotics seems 
inefficient (71). Furthermore, this many only be a temporary solution and resistance to such 
mechanisms will probably immerge. 
 
Although sulbactam can confer intrinsic antibiotic activity, resistance is also likely to arise 
against adjuvants which do not (169). This is because even with the lack of intrinsic activity, 
the indirect antibacterial activity exhibited by combinations of the adjuvants with an antibiotic, 
is likely to select for phenotypes resistant to the adjuvant. 
 
Other forms of adjuvants are those which act by the inhibition of efflux pumps and modulation 
of membrane permeability. To enhance the accumulation of drugs in resistant bacteria, these 
are the two main strategies employed (166). To the author’s knowledge, naturally occurring 
acidic amino acids L-Asp and L-Glu have not been studied for their potential role as adjuvants 
to increase intracellular accumulation of drugs. Thus in this study, the amino acids which have 
already been proven to enhance the permeability of Cip as well as other drugs in caco-2 mono 
layers, were investigated as potential adjuvants to Cip in enhancing the drugs permeability in 
bacteria (40, 156). 
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The results in this chapter present that the accumulation of Cip can be enhanced within 
bacteria with the use of acidic amino acids as counterions. With S. aureus the effect is amino 
acid concentration dependent. On the other hand, though with P. aeruginosa, enhancement 
in accumulation only occurs with the two highest amino acid concentrations used, the efflux 
pattern when 15 and 30 mM L-Asp or L-Glu is used, stands out. This in turn presents as 
synergistic reduction in S. aureus and P. aeruginosa growth as well as reduced toxic pigment 
production in the latter. 
 
The findings in this chapter are similar to those in the previous chapter which shows that L-
Asp and L-Glu are able to enhance TC accumulation within both S. aureus and P. aeruginosa. 
Again, this was accompanied with a synergistic inhibition on the growth of both bacteria as 
well as reduced pigment production by P. aeruginosa. This shows that L-Asp and L-Glu 
enhance drug permeation in a manner which is independent to the drug used and thus can 
potentially be used to enhance accumulation of many antibiotics within a broad range of 
bacteria. 
 
In this regards, it is useful to consider here that TC acts on the 30S ribosomal subunit to inhibit 
protein synthesis whilst Cip has its inhibitory affect by acting on DNA-gyrase and DNA 
topoisomerase IV, inhibiting cell replication. Meaning, the two mechanisms of action are 
completely different and not related. Due to this it is likely that the amino acids work in a 
manner which is independent to interfering with these mechanisms. Substantiating the 
possibility that amino acids act by a mechanism which interferes with a mutually shared 
process subjected to both antibiotics. Some of these mechanisms are discussed in detail in 
the previous chapter and will be briefly outlined later on along with another possible 
mechanism which will be explored in this chapter. 
 
Interestingly, the growth curves for S. aureus give an indication as to why 30 mM L-Asp or L-
L-Glu combined with Cip did not follow the concentration dependent efflux pattern observed 
with other amino acid concentrations whilst also giving insight into the steep reduction in 
fluorescence intensity observed with 15 mM and 7.5 mM these amino acids during efflux 
experiments. Growth curve data clearly shows that when 15 mM and 7.5 mM L-Asp or L-Glu 
are combined with Cip, S. aureus, growth is hindered synergistically. Keeping in mind that 
these combinations also cause an initial surge of EtBr and therefore Cip within the bacteria, it 
is possible that bactericidal activity of the increased Cip within the cells causes cell death 
(172). The resulting cell death would subsequently enable EtBr to leak out of cells, and since 
EtBr has differential intracellular and extracellular fluorescence, a great reduction in 
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fluorescence intensity is observed (126). This is also likely to be the reason for the efflux 
pattern obtained when 15 mM and 7.5 mM of the amino acids were combined with TC. In other 
words, the reduction in fluorescence intensity observed with Cip or TC combined with 15 mM 
or 7.5 mM of either amino acid is unlikely due to EtBr efflux, but rather through reduction in 
intracellular EtBr secondary to cell death. Since when Cip is combined with 30 mM L-Asp or 
L-Glu, there is no reduction in S. aureus growth, EtBr does not leak out and hence no drastic 
reduction in fluorescence is observed, explaining why the efflux pattern observed with these 
combinations (Cip with 30 mM L-Asp or L-Glu) present as outlier to the concentration 
dependent pattern observed with other concentrations. 
 
Another interesting observation was that the pattern of efflux, though different in the two 
bacteria used, was similar irrespective of what concentration of Cip was used. This was the 
case with different Cip concentrations studied in both S. aureus and P. aeruginosa. The 
observation indicates that the concentration of Cip used did not affect the efflux of EtBr. Yet it 
is also clear that the presence of Cip does indeed effect the efflux of EtBr, as evident from the 
clear difference in efflux pattern between 0 mM of any amino acid used as compared to the 
‘glu’ control; only difference between the two being the presence or absence of Cip, 
respectively. A potential explanation for this apparent discrepancy may be that the 
concentration of EtBr (~114 µM) is far greater than the concentrations of Cip used, potentially 
rendering negligible the difference between the Cip concentrations used. All this also holds 
true for TC, again reiterating that amino acids potentially use a drug independent mechanism 
of enhancing accumulation. 
 
It is possible that the differences in the efflux patterns observed with S. aureus and P. 
aeruginosa are due to the differences in their membranes. Being gram-positive S. aureus has 
only one membrane whilst the gram-negative P. aeruginosa has an outer and inner 
membrane. As mentioned earlier the outer membrane of gram-negative bacteria confers 
substantial resistance to the uptake of antibiotics. Thus, 30 mM and 15 mM L-Asp and L-Glu, 
probably act to enhance Cip uptake by modulating the outer membranes permeability, whilst 
15 mM and 7.5 mM are more effective in modulating the membrane permeability of gram-
positive bacteria. 
 
A striking observation is that despite amino acids substantially effecting the growth of S. 
aureus in a concentration dependent manner, they seem to exert no or minimal effect on the 
growth of P. aeruginosa on their own. What makes this even more interesting is that despite 
their lack of inhibitory effect on the growth pattern of P. aeruginosa, when they are combined 
with the drug, a substantial synergistic effect is observed. This is observed with both TC and 
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Cip but is more apparent with TC. Either way, this makes it more likely that the role played by 
amino acids in this synergism is to increase the effect of the drug, rather than exhibit intrinsic 
antibiotic activity, most likely through a mechanism resulting in its increased uptake or reduced 
efflux. However, the presence of synergy on the growth of P. aeruginosa between the drugs 
and 7.5 mM of either L-Asp or L-Glu, hints towards other mechanisms of enhancing drug 
effectiveness, independent of those effecting intracellular drug concentrations, to be also 
involved. This is because despite the synergy, Cip or TC combined with 7.5 mM of the amino 
acids did not show any evidence of enhanced drug uptake or a decrease in drug efflux. 
Nevertheless, due to the reasons discussed above, an accumulative effect of antimicrobial 
activity of the amino acids and Cip or TC on their own is highly unlikely to be the cause of the 
synergistic effect observed on P. aeruginosa growth. 
 
As mentioned earlier, some of the adjuvants used and even those under research are probably 
liable to resistance. It seems the potential mechanisms leading to enhanced drug 
accumulation by the acidic amino acids used here are very non-specific. These mechanisms 
were discussed in detail in the earlier chapter with reference to TC and include increase in TC 
uptake, amino acid and TC ion pairing and prevention of efflux by acidic amino acids. It is 
likely that similar mechanisms also lead to enhancement of Cip accumulation and are briefly 
discussed later in context of Cip. Nevertheless, it is hoped that the non-specificity of the 
mechanisms would make it highly unlikely for resistance mechanisms to evolve against these 
amino acids. Utilisation of such non-specific mechanisms however will need exploration and 
appropriate development and control in order to avoid potential toxicity issues. 
 
3.4.1 Enhanced ciprofloxacin accumulation through increased uptake, ion-
pairing with acidic amino acids and efflux prevention 
 
Mechanisms which may be resulting in the enhanced Cip accumulation within S. aureus and 
P. aeruginosa may involve increase uptake, ion-pairing between Cip and the amino acids or 
inhibition of efflux by the amino acids. These were discussed in the chapter presenting efflux 
of tetracycline and the reader is referred to it for an in-depth exploration of these mechanisms. 
As will be briefly discussed here the same mechanisms can leading to enhanced Cip uptake. 
 
3.4.1.1 Increased uptake through porins 
 
Due to the highly selective nature of the outer membrane of gram-negative bacteria, antibiotics 
usually utilise porins found in this membrane to penetrate within the cell (130).  OprF is a major 
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outer membrane protein of P. aeruginosa (173). It has been suggested to allow antibiotic 
penetration, whilst showing preference to cations (132, 133, 174). Along with this, Cip is known 
to utilise porins too (175). Since in the presence of acidic/anionic amino acids, like TC a major 
proportion of Cip is likely to have been present in the cationic form, thus it may be that this 
charge eases the passage of Cip through porins like OprF, penetrating through the selective 
outer membrane and reaching the periplasm. Here the comparatively higher pH shifts the 
equilibrium towards more neutral molecules of Cip which are than able to passively diffuse 
through the inner membrane and reach the cytoplasm to carry out their function. Along with 
this ion-pairing between acidic amino acids and Cip may be resulting in Cip uptake too. 
 
3.4.1.2 Ion-pairing between acidic amino acid and ciprofloxacin 
 
As discussed in the previous chapter, amino acid channels such as ATB(0,+) which are able 
to transport not only amino acids, but also prodrugs formed by reactions such as esterification 
of a drug with the amino acids (144, 145). Interestingly bacteria also express transporters that 
are able to carry out a similar function. Transporters belonging to the MFS and ABC-binding 
cassette superfamilies have been suggested to transport amino acids and their derivatives 
(146, 147). Thus, since in the given Cip and amino acid concentrations, both exist not only as 
neutral species but also as oppositely charged species, ion-pairs are likely to form between 
the cationic Cip and the anionic acidic amino acids, conferring the newly formed species the 
ability to be recognised and taken up through these amino acid channels. 
 
3.4.1.3 Amino acids inhibit ciprofloxacin efflux in S. aureus 
 
Majority of the efflux pumps present in S. aureus belong to the MFS superfamily (163). 
Interestingly, it has been shown that transporters such as those which belong to the MFS 
superfamily, which function by substance/H+ symport, can be inhibited by acidic pH (150). This 
is because the acidic pH probably prevents deprotonation of the symporter thus preventing 
any further transport (150). This gives reason as to why the pattern of TC and Cip 
accumulation caused by amino acids is similar, and highlights again that mechanisms not 
specific to drugs are probably at play. It may be that the acidic pH of the surrounding 
environment caused by the L-Asp and L-Glu prevents deprotonation of the symporter, 
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3.4.2 Amino acids based Mg2+ and Ca2+ chelation 
Another possible mechanism, not explored earlier, relates to the ability of amino acids to act 
as chelating agents. Ethylenediaminetetraacetic acid (EDTA), an anionic substance has been 
well studied for its ability to chelate cations like Ca2+ and Mg2+, leading to outer membrane 
disorganisation, consequently resulting in enhanced permeability of otherwise hard to 
permeate drugs. These cations play a crucial role in outer membrane integrity by binding to 
adjacent lipopolysaccharide molecules. Without this, the negative charges present on 
lipopolysaccharide molecules found on the outer leaflet would cause repulsion between them, 
resulting in loss of integrity for the outer membrane (176). Thus Ca2+ and Mg2+ act by 
neutralising the negatively charged lipopolysaccharides, maintaining outer leaflet and thus 
outer membrane stability (176). Hence like EDTA, here it is proposed that acidic amino acids, 
a substantial proportion of which would be present as anions, act as Ca2+ and Mg2+ chelators. 
This exposes the negative charges present on the lipopolysaccharide molecules, causing 
repulsion between them. With repulsion between its constituents, the outer membrane loses 
stability and becomes permeable to Cip and TC, presenting as the enhanced accumulation of 
these drugs observed in P. aeruginosa. Supporting this hypothesis is that amino acids, 
aspartic acid and glutamic acid, are known to act as chelators of metals including Ca2+ and 
Mg2+ (177). The above proposed mechanisms are depicted in Figure 3.14. 
Figure 3.14: Diagram depicting possible mechanisms utilised by acidic amino acids in enhancing TC and 
Cip accumulation within both Gram-positive S. aureus (single membrane) and Gram-negative P. 
aeruginosa (two membranes). These mechanisms include a) charge triggered permeation through porins, 
b) efflux pump inhibition, c) permeation as ion-pairs through amino acid transporters and d)
disorganisation of the outer membrane via chelation of otherwise stabilising cations such as Mg2+ and Ca2+
by acidic amino acids.




In conclusion, acidic amino acids have been shown in this chapter to act as adjuvants able to 
overcome resistance to Cip in both S. aureus and P. aeruginosa, synergistically inhibiting the 
growth of bacteria. Likewise synergistic reduction in pigment production by P. aeruginosa was 
also observed by combining the amino acids with the drug. This appears to result from the 
ability of L-Asp and L-Glu to enhance the accumulation of Cip within these bacteria. These 
findings may hold a key to strategies for overcoming the ever increasing AMR and it is hoped 
that the potential underlying mechanisms will make it substantially rarer for resistance to 
emerge. 
 
It seems that amino acids probably function through multiple mechanisms, allowing the uptake 
of antibiotics belonging to different classes. Whilst the results suggest that the mechanism 
utilised are not drug-dependent, they probably depend on whether the bacteria in question is 
gram-negative or gram-positive, requiring traversing through two or one membrane 
respectively. Thus the uptake of both TC and Cip in P. aeruginosa is probably due to one or a 
combination of factors such as the effect of L-Asp and L-Glu on porin permeability, permeation 
as ion-pairs through amino acid transporters, efflux pump inhibition and disorganisation of the 
outer membrane via chelation of otherwise stabilising cations by amino acids, catering for 
permeation through both membranes. On the other had permeation into S. aureus only 
requires crossing through one membrane and is probably due to permeation through amino 
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Biofilms are communities of sessile microorganisms (bacteria or fungi) living in a self-produced 
matrix (matrix of extracellular polymeric substances) which aids the survival of these 
microorganisms (58). The formation of biofilm can be divided into stages. Firstly planktonic 
bacteria attach to a surface reversibly (58). At this stage the bacteria are still susceptible to 
antibiotics. Hence prophylaxis in alloplastic surgery proves very useful as at this stage since 
the antibiotics are able to act on the planktonic forms which become reversibly attached (57). 
In the absence of a challenge during the next stage, the bacteria become irreversibly attached 
through self-adhesion structures such as pili, multiply and form colonies. Furthermore, 
extracellular polymeric substances, which form the matrix are secreted and deposited around 
the colonies (57). The matrix is a key structural component of the biofilm community and 
consists of water, polysaccharides, proteins, lipids and DNA (57). Hydrogen bonding between 
water molecules and hydrophilic polysaccharides holds water within the biofilms whilst 
polymers such as glycopeptides, lipids and lipopolysaccharides aid in scaffolding and holding 
the biofilm together (57). As the biofilm grows thicker, it becomes mature; a process which is 
coordinated through quorum sensing and other signalling pathways (57). Finally, the sessile 
bacteria in the biofilm are able to become free and spread to other surfaces to form new 
biofilms (57, 58). 
 
Biofilm forming bacteria are commonly associated with chronic infections, which are infections 
that persist despite antibiotic therapy and the body’s immune response (57). This is because 
the therapy and immune response are able to overcome planktonic bacteria, but are unable 
to penetrate the biofilm defences. After a while, when the individual seems to be cured, the 
sessile communities in biofilms give rise to planktonic forms, which in turn leads to a relapse 
of the disease state (58). Since the bacteria in biofilms have evolved complex survival 
strategies, biofilms act as a persistent base which poses constant pathogenicity to the body 
through continuous release of virulence factors and planktonic forms (57). Hence a chronic 
state of infection is maintained due to the inability of the immune system or drugs to eradicate 
the biofilm. 
 
Biofilm formation on abiotic surfaces can result in complications with implants as well as 
catheters. A good example which highlights the danger associated with biofilms is a biliary 
stent in which the growth of Escherichia coli (E.coli) biofilm lead to repeated incidents of 
sepsis(57). In this case, antibiotic therapy was of no avail and the second episode of sepsis 
proved fatal. DNA typing revealed that the same E.coli clonal type was present in the biofilm 
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as the one responsible for sepsis (57). On the other hand, biofilms are also implicated on biotic 
surfaces such as acute and chronic wounds. In such cases, along with the disease state of 
infection, biofilms also hinder wound healing (178). 
 
The problem is exacerbated by the fact that resistance to antibiotics can be up to 1000 times 
higher for bacteria in biofilms and the underlying mechanisms of resistance are likely to be a 
combination of conventional resistance mechanisms found in planktonic phenotypes as well 
as those specific to biofilm phenotypes (58). Such specific mechanisms include retardation of 
antibiotic diffusion by the biofilm matrix as well as slowed growth of bacteria due to decreased 
metabolic rate in biofilms (57). The latter leads to resistance because most antibiotics have 
their effect on rapidly dividing cells (58). 
 
There is an urgent need therefore for strategies which can successfully and safely prevent as 
well as those which can treat infections where biofilms are implicated. The strategies studied 
can be divided into four major categories; prevention of biofilm formation, weakening of the 
biofilm, disruption or dispersal of the biofilm and killing of bacteria particularly the 
subpopulation which persists (58). 
 
One strategy utilises D-amino acids to inhibit and disperse biofilms. Their role was seen after 
D-leucine, D-methionine, D-tryptophan and D-tyrosine, isolated prior to disassembly of 
Bacillus subtilis biofilms, were found to prevent new biofilm formation as well as cause its 
dispersal. It was found that D-amino acids caused cells in the biofilm to release amyloid fibres 
which are involved in linking cells in the biofilm together. YqxM is a protein required in the 
formation and anchoring of the Tas A amyloid fibres (amyloid fibres which in their composition 
contain Tas A protein) to the cell wall (64). These amyloid fibres give structural integrity to the 
biofilm. Strains with mutations in this protein were able to form biofilms in the presence of D-
amino acids, indicating that the anti-biofilm activity of these amino acids was dependent on 
the strain with the wild type YqxM protein (65). 
 
Since this finding, D-amino acids have also proved to be effective as strategies for the 
prevention and dispersal of Staphylococcus epidermidis, Staphylococcus aureus (S. aureus) 
and Pseudomonas aeruginosa (P. aeruginosa biofilms) (66, 179). Studies have demonstrated 
their effectiveness in combination with antimicrobials in a bid to overcome the antimicrobial 
resistance of biofilms (66). It is generally claimed that L-amino acids have no effect and 
literature attributing anti-biofilm activity to these isomers is limited (65, 180, 181). 
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S. aureus was used in this study as it is one of the most clinically prominent bacteria and is 
frequently the causative agent in both acute and chronic infections. Its infections can range 
from relatively mild skin infections to life-threatening infections such as endocarditis and 
pneumonia (182). Furthermore, other D-amino acids have been shown to prevent its biofilm 
formation as well as cause its dispersal. S. aureus NCTC 8325, a strain with a well-defined 
genotype, was used for this investigation. 
 
Amino acids are able to increase the solubility of Ciprofloxacin (Cip) (156). It was hypothesised 
that this solubility enhancing property of various amino acids, along with their potential anti-
biofilm activity, can be utilised as a dual approach to decrease antimicrobial resistance within 
bacterial biofilms, through amino acid-drug synergy. 
 
Thus the primary aim of the study presented in this chapter was to determine whether the 
amino acids exhibit anti-biofilm activity and whether this can be used with Cip to synergistically 
enhance the antibiotics activity on biofilms. To achieve this we investigated the effect of using 
D-isomers of acidic amino acids on S. aureus biofilm inhibition and dispersal, specifically on 
their effect on biofilm density, colony forming unites (CFU) and biofilm architecture. The 
presence of synergy when combining amino acids and Cip was investigated by determining 
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S. aureus strain NCTC 8325 was gifted by Professor Peter A. Lambert. Tryptone soya broth 
(TSB), tryptone soya agar (TSA), Ciprofloxacin 98%, D(-)-aspartic acid 99+%, D(-)-glutamic 
acid 99+% were all obtained from Fisher Scientific whereas L-aspartic acid 98+% and L-
glutamic acid 99% were obtained from Sigma Aldrich. Crystal violet (CV) was obtained from 
Sigma Aldrich. Phosphate buffered saline (PBS) tablets and LIVE/DEADTM BacLightTM 
Bacterial Viability Kit were obtained from Thermofisher Scientific. 
 
4.2.2 General methods 
 
The biofilm formation, quantification and dispersal assays were adapted from published 
protocols (66, 183, 184). For inoculum preparation, 10 ml TSB was inoculated with a colony 
of S. aureus and incubated overnight at 37°C in an aerobic orbital shaker at ~50 cycles/min. 
The optical density (OD) was measured using a spectrophotometer at a wavelength of 600 
nm, and the culture was diluted with TSB to adjust the O.D. to 0.1. Minimum lethal 
concentration (MLC) of Cip against planktonic forms of S. aureus was previously determined 
and found to be 3.75 x 10-6 g/ml. 
 
4.2.3 Biofilm dispersal assay 
 
The biofilms were grown for appropriate number of hours (6, 12, 24, 48 and 72 h) before 
addition of the amino acids. To do this, 500 µl of the diluted culture was added to each well of 
the 24 well plate. The plates were then incubated in a static incubator for 37 °C. 
 
To examine the dispersal effects of amino acids, 40 mM solutions of aspartic acid (Asp), 
glutamic acid (Glu) and aspartic acid combined with glutamic acid (AA) were prepared in the 
broth followed by filter sterilisation using 0.22 µm syringe filters. Broth was used for serial 
dilution to attain working concentrations of 40, 20, 10, 5, 2.5 mM for the amino acids from the 
stock solution. After 72 h of incubation, the wells were washed once with PBS. 500 µl of media 
with various concentrations of amino acids were added to the wells. Negative control was TSB 
without any amino acids. The plates were then incubate overnight at 37 °C, washed and 
quantified by crystal violet staining. Cip and Cip in combination with amino acids was assessed 
in a similar way. 
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4.2.4 Biofilm Inhibition assay 
 
To determine the inhibitory effects of amino acids, Cip and Cip combined with AA, the biofilms 
were allowed to grow whilst being exposed to these test substances from the start of the 
experiment. For this the culture was mixed with the D-amino acids before it was incubated for 
6, 12, 24, 48 and 72 h. Briefly, after achieving appropriate culture (0.1 OD) and test substance 
concentration within each well, the plates were left in a 37 °C incubator for the desired time 
before the biofilm density was quantified. Again for negative control biofilms, TSB lacking any 
test substance was used. 
 
4.2.5 Crystal violet staining 
 
The media was removed from the plates through gentle shaking into a beaker and followed 
by gentle dabbing of the plates on a bed of paper towels to remove excess media. Each well 
was then washed once with 500 µl PBS followed by staining with 500 µl of 0.1% CV (w/v) for 
30 min. The wells were then washed three times by submerging the plates in a tub of distilled 
water and by gently dabbing in a bed of paper towels to remove any excess stain. The plates 
were then left overnight or for a few hours (until dry) before proceeding. 
 
Once dry 625 µl of 30% (v/v) acetic acid was added to each well to dissolve the CV. Plates 
were left to incubate for 15 min after which the solubilised crystal violet was transferred into a 
new plate and the biofilm was quantified by determining the O.D. using a plate reader at the 
wavelength of 570 nm. 
 
4.2.6 Colony forming units 
 
To determine the colony forming units, excess media was removed from the wells and the 
wells were washed with PBS once as described earlier. Next 500µl of TSB was added to each 
well and the biofilm was resuspended in the media by scraping and re-pipetting. This detached 
the biofilm from the well surface whilst also breaking up any free floating aggregates of the 
biofilm in the media. After vortexing the suspension, the Miles and Misra method was used to 
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4.2.7 Rate of cell attachment 
 
Rate of cell attachment to a glass surface was determined through live imaging obtained using 
ZEISS Celldiscoverer 7. Images were obtained every 5 min over 2.5 h. Since the focus of lens 
was set at the surface of the glass, the clearly visible cells were taken to be those which had 
attached to the surface. ZEISS Celldiscoverer 7 software was used to quantify the number of 
cells which had attached.  
 
4.2.8 Fluorescence and Confocal Imaging of Biofilms 
 
Glass coverslips were sterilised with 70% (v/v) ethanol and placed in wells of 6 well plates. 
Biofilms were grown on coverslips as detailed under biofilm inhibition assay and washed with 
0.85% (v/v) sodium chloride whilst dabbing on a bed of paper towel to maximise drainage. 
Dyes SYTO 9 and propidium iodide (PI) from the LIVE/DEAD BacLight Bacterial Viability Kit 
were used to stain the cells. Staining solution was made in deionised water at a concentration 
of 3 µl/ml of each dye from a stock of 3.34 mM SYTO9 and 20 mM PI. The plates were then 
incubated for 90 min at 37 °C with 500 µl of the staining solution in each well. The wells were 
then rinsed with RNA free water, and the plates left upside down to drain for 10-15 min. The 
coverslip were then mounted onto slides using BacLight mounting oil. The biofilm samples 
were then analysed using confocal microscopy using CLSM TCS SP5 II system (Leica 
Microsystems GmbH, UK) using a x63 and a x100 oil immersion lens. An argon laser was 
used to excite SYTO 9 fluorophores and a helium-neon laser was used to excite PI 
fluorophores at a wavelength of 488 nm and 543 nm respectively. The emission analyser filters 
were set between the range of 493 nm to 530 nm for SYTO 9 and 625 nm to 676 nm for PI. 
For fluorescence imaging, biofilms were stained in a similar way within the wells of a 24 well 
plate and analysed on the same day using Leica Widefield Fluorescence Microscope (Leica 
Microsystems GmbH, UK). 
 
4.2.9 Statistical analysis 
 
One-way ANOVA was followed by a post-hoc t-test Bonferroni correction to determine where 








4.3.1 Biofilm inhibition and dispersal using D-Asp and D-Glu 
 
The concentration of amino acids used were 2.5 mM, 5 mM, 10 mM, 20 mM and 40 mM. 
Upper limit was capped at 40 mM considering the solubility limitations of these amino acids in 
water. Figure 4.1a and Figure 4.1b show the effect on biofilm density of D-Asp and D-Glu 
whilst they were used separately as inhibiting and dispersing agents. Concentration 
dependent anti-biofilm activity (Figure 4.1a-d) was observed with each time point (Figure 
4.1c,d) whether amino acids were used in isolation or in combination. However, greater anti-
biofilm activity (Figure 4.1c,d) was observed by combining D-Asp and D-Glu (D-AA). Figure 
4.1a-d also show that D-AA were effective in both preventing (inhibition) the formation of new 
biofilms, as well as the breakdown (dispersal) of already formed biofilms. Significant inhibition 
was achieved with the lowest concentration (2.5 mM) of D-AA used whereas minimum of 5 
mM D-AA concentration was required to obtain statistically significant dispersal. The maximum 
inhibition and dispersal effect was obtained with the higher concentrations of D-AAs used i.e. 
20 mM and 40 mM. The D-AA were better at inhibition than dispersal. Anti-biofilm activity was 
investigated on biofilms grown for 6, 12, 24, 48 and 72 h. The amino acids were similar in 
effectiveness at all the time points. Therefore, considering that bacteria are most resistant 
once the biofilm has matured, the 72 h time point was considered appropriate for conducting 
further work (186). For biofilms grown for 72 h, at 40 mM 37.55% of biofilm was dispersed 
whereas 96.89% was inhibited from forming (Figure 4.1c,d). 
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Figure 4.1: a) Inhibition and dispersal of S. aureus biofilm using 2.5, 5, 10, 20 and 40 mM D-Asp. b) Inhibition 
and dispersal of S. aureus biofilm using 2.5, 5, 10, 20 and 40 mM D-Glu. c) Inhibition of S. aureus biofilm 
using equimolar concentrations of D-AA. d) Dispersal of S. aureus biofilm using equimolar concentrations 
of D-AA. a-d) One-way ANOVA showed an overall significant difference within the data and was followed 
by a post-hoc t-test with Bonferroni correction to see which concentration significantly (p<0.0083 was 
taken as significant; indicated by * ) significantly inhibited or dispersed biofilms; n=3, ±S.D. e) Fluoresence 
imaging showing 72 h biofilm formation. i) Control ii) inhibited with 40 mM D-Asp iii) inhibited with 40 mM 
D-Glu iv) inhibited with equimolar concentrations of D-Asp and D-Glu (40 mM of each); D-Asp = D-Aspartic 
acid; D-Glu = D-Glutamic acid; D-AA = D-Asp and D-Glu. 
 
Fluorescence images in Figure 4.1e confirm that both D-Aspartic acid and D-Glutamic acid 
have anti-biofilm activities and that combining both amino acids is more efficacious. High 
levels of extracellular DNA (eDNA) was evident in the untreated biofilm (Figure 4.1e i) 
compared to those treated (Figure 4.1e ii,iii,iv). Use of amino acids leads to patchy (Figure 
4.1e ii,iii) and incomplete (Figure 4.1e iv) biofilm formation. Equimolar combination of both 
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amino acids was therefore chosen for further investigations. The work presented here was 
obtained using combination of both aspartic acid and glutamic acid such that if 40mM D-AA is 
stated, it means that 40mM of D-Asp and 40mM of D-Glu was used together. 
 
4.3.2 L-AA also inhibit and disperse biofilms 
 
It was important to investigate whether the anti-biofilm activity of D-AA is restricted to the 
isomeric form. For this, combination of L-Asp and L-Glu (L-AA) were investigated for their anti-
biofilm properties, whilst using the same concentrations as D-AA. L-AA showed a similar, 
concentration dependent dispersal and inhibition profile (Figure 4.2) to D-isomers whilst 
inhibiting and dispersing biofilms. 
 
 
Figure 4.2: Dispersal and Inhibition of S. aureus biofilm using L-AA (equimolar combination of L-Asp and 
L-Glu) was dependent on the concentration of amino acids used. One-way ANOVA showed an overall 
significant difference within the data and was followed by a post-hoc t-test with Bonferroni correction to 
see which concentration significantly (p<0.0083 was taken as significant; indicated by *) significantly 
inhibited and dispersed biofilms; n=3, ±S.D; L-Asp = L-Aspartic acid; L-Glu = L-Glutamic acid; L-AA = L-
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4.3.3 Synergistic effect of D-AA and Cip on biofilm inhibition and dispersal 
 
Although, Cip on its own also has anti-biofilm activity, potential synergistic effect of using Cip 
with amino acids was investigated. Anti-biofilm activity of Cip and D-AA alone was compared 
to combined D-AA (2.5 – 40 mM) + Cip (1 MLC, 4 MLC and 8 MLC; number represents x times 
MLC) at various concentration combinations (Figure 4.3a-e). 40 mM D-AA showed 
significantly greater biofilm inhibiting (p<0.001) and dispersing (p<0.0001) activity as 
compared to 8 MLC Cip. Whilst 40 mM D-AA + Cip (8 MLC, 4 MLC or 1 MLC) maintained the 
anti-biofilm activity of the amino acid, there was no synergistic effect observed of these 
combinations on biofilm density (Figure 4.3a). However, at specific combinations with lower 
concentrations of D-AA, significant synergistic effect was observed (Figure 4.3b-e); 10 mM D-
AA + 1 MLC Cip and 20 mM D-AA + 4 MLC Cip showed significant synergy in biofilm inhibition 
whilst 5 mM D-AA + 4 MLC Cip showed significant synergy in biofilm dispersal. 
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Figure 4.3: a) Efficacy of 8 MLC Cip, 40mM D-AA and 40mM D-AA combined with 1 MLC, 4 MLC and 8 MLC 
Cip on biofilm density whilst inhibiting and dispersing S. aureus biofilms. Two tailed T-test revealed that 
D-AA have a significantly (indicated by *) greater anti-biofilm activity (inhibition p<0.001, dispersal 
p<0.0001) as compared to 8x MLC of Cip. One-way ANOVA showed no significant synergistic effect (p>0.05) 
on biofilm density between D-AA and when D-AA and Cip are used in combination. a-e) Synergistic effect 
of using combination of 1 MLC (b, d) or 4 MLC (c, e) Cip with 2.5, 5, 10 and 20mM D-AA on biofilm inhibition 
(b, c) and dispersal (d, e). One-way ANOVA showed an overall significant difference for amino D-AA + Cip 
data (b-e). This was followed by a post-hoc t-test with Bonferroni correction to see which concentration of 
D-AA + Cip had significantly higher (p<0.01) anti-biofilm activity as compared Cip on its own. Next one-tail 
t test was done to see whether this combination of D-AA + Cip had significantly (p<0.05) improved anti-
biofilm activity as compared to the corresponding D-AA on its own. b) 10 mM D-AA + 1 MLC Cip was 
significantly (*) able to inhibit greater biofilm formation compared to both Cip and D-AA on their own 
(p<0.001 and p<0.00001 respectively). c) 20 mM D-AA + 4 MLC Cip was significantly (*) able to inhibit greater 
biofilm formation compared to both Cip and D-AA on their own (p=0.00014 and p=0.014 respectively). d) 
No combination was significantly able to disperse greater biofilm compared to both Cip and D-AA on their 
own e) 5 mM D-AA + 4 MLC Cip gave significant (*) rise in biofilm dispersal activity compared to both Cip 
and D-AA on their own (p=0.0045 and p=0.018 respectively). a-e) D-AA = 40 mM D-Aspartic acid and 40 mM 
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4.3.4 Effect on colony forming units 
 
Since biofilms are composed of bacterial cells and extracellular matrix, it was necessary to 
distinguish how the anti-biofilm activity of amino acids was distributed between these two 
components. Measuring biofilm density is a quantitative method that does not distinguish 
between matrix and cells. To determine the effect of amino acids and Cip on the viability of 
cells residing in S. aureus biofilms, viability assays were carried out by estimating the CFU/mL. 
Figure 4.4 compares the log10 CFU/ml of untreated biofilms with biofilms treated with 40mM 
D-AA, 40mM L-AA, and 40mM D-AA + 8 MLC Cip. Experiments for dispersal showed greater 
than 1 log reduction (≥91.89%) decrease in log10 CFU/ml for biofilms dispersed with 40mM D-
AA and 40mM L-AA, as compared to untreated biofilms. Whereas for inhibition using the same 
treatments, there was greater than 2 log reduction (≥99.85%) in the number of viable bacterial 
cells attached to the surface. 
 
 
Figure 4.4: Effect of 40 mM D-AA, 40 mM L-AA and 40 mM D-AA + 8 MLC on CFU after biofilm inhibition 
and dispersal. ≥99.85% (inhibition) and ≥91.89% (dispersal) reduction in CFU from control was observed 
for D-AA, L-AA and D-AA + 8 MLC; D-AA = 40 mM D-Aspartic acid and 40 mM D-Glutamic acid; x MLC = x 
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4.3.5 D-AA treatment prevents eDNA meshwork formation 
 
For confocal imaging, biofilms were grown on glass coverslips. After the treatment 
experiments, biofilms were stained with the dyes SYTO 9 and PI which stain nucleic acids in 
live and dead cells respectively. When both dyes are used in conjunction, the SYTO 9 channel 
generally represents the nucleic acid which is present within intact membranes and the PI 
channel enables the visualisation of nucleic acids outside cells (eDNA) or cells with a 
compromised cell membrane. The images taken through confocal microscopy are presented 
in Figure 4.5, Figure 4.6 and appendix Figure 1. Images of inhibited (Figure 4.5) and dispersed 
(Figure 4.6) biofilms from both, the SYTO 9 channel and the PI channel along with their overlay 
are presented. In this way the structure of eDNA can be more easily visualised whilst also 
being able to see how it spatially relates to both live and dead cells. 
 
Untreated S. aureus biofilm covers the whole field of view and it has the highest cell density. 
In comparison, cells within all inhibited and dispersed biofilms have a patchy or clustered 
distribution. S. aureus cells in the control biofilms are interconnected and held in position by 
an organised distribution of eDNA throughout (Figure 4.5.1 and Figure 4.6.1). This meshwork 
of eDNA is filamentous in nature and almost seems to represent a honeycomb like structure. 
Furthermore, there is a uniformity in the thickness of eDNA between cells within the biofilms, 
raising the question as to whether the intercellular distance within the biofilm is precisely 
controlled and not without purpose. 
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Figure 4.5: Confocal images of inhibited S. aureus biofilms. a) combined channel; b) SYTO 9 channel; c) 
Promidium Iodide channel; 1) control biofilm; 2) inhibited with 40mM D-AA (40mM D-Asp and 40mM D-Glu); 
3) treated with Cip; 4) treated with 40mM D-AA and 8 MLC Cip; blue arrow) presence of intercellular eDNA; 
yellow arrow) lack of intercellular eDNA; green arrow) eDNA presence is inconclusive. 1) Untreated S. 
aureus biofilms are reinforced by an organised honeycomb like meshwork made of interconnected 
intercellular eDNA. eDNA forms a filamentous mesh like structure within the biofilm and surrounds all 
cells. 2) Biofilms inhibited with D-AA show a complete lack of eDNA. 3) Biofilms inhibited by Cip express 
a lower population of S. aureus cells. A dense eDNA meshwork provides structure to these persisting cells. 
4) Biofilm treated with a combination of D-AA and 8 MLC Cip lack in eDNA meshwork structure; D-AA = 40 
mM D-Aspartic acid and 40 mM D-Glutamic acid; x MLC = x times minimum lethal concentration; Cip = 
ciprofloxacin. 
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From visual analysis of the confocal images it is clear that both inhibited and dispersed biofilms 
exposed to D-AA, whether in isolation (Figure 4.5.2 and Figure 4.6.2) or in combination with 
Cip (Figure 4.5.4 and Figure 4.6.4), not only lack this organised structure of eDNA, but lack 
eDNA altogether. Considering the clear lack of eDNA within inhibited biofilms, any eDNA 
present within biofilms dispersed by these agents is most probably a result of being entrapped 
within the complex matrix. Like cells within biofilms treated with D-AA and D-AA + Cip, S. 
aureus cells within biofilms treated with Cip on its own are also distributed in clusters. 
However, Cip-only treated biofilms do not lack eDNA (Figure 4.5.3 and Figure 4.6.3). 
Moreover, the eDNA which is present in these biofilms seems to be more densely structured 
as compared to that of untreated biofilms. Dispersing with Cip-only also reveals an interesting 
feature; the eDNA seems to be present as patches or in boundaries, with number of viable 
cells decreasing as we move away from these boundaries (Figure 4.6.3 and appendix Figure 
1). 
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Figure 4.6: Confocal images of dispersed S. aureus biofilms. a) combined channel; b) SYTO 9 channel; c) 
Promidium Iodide channel; 1) control biofilm; 2) dispersed with 40mM D-AA (40mM D-Asp and 40mM D-
Glu); 3) dispersed with Cip; 4) dispersed with 40mM D-AA and 8 MLC Cip; blue arrow) presence of 
intercellular eDNA; yellow arrow) lack of intercellular eDNA. 1) Untreated S. aureus biofilms are reinforced 
by an organised honeycomb like meshwork made of interconnected intercellular eDNA. eDNA forms a 
filamentous mesh like structure within the biofilm and surrounds all cells. 2) Biofilms dispersed with D-AA 
lack majority of the eDNA. The pan-biofilm eDNA network is lost, any remaining eDNA is likely to be that 
entrapped between other matrix substances. 3) Presence of eDNA networks provides structure to 
persisting cells in biofilms treated with Cip on its own. 4) Biofilm treated with a combination of D-AA and 
8 MLC Cip lack in eDNA meshwork structure and have minimal eDNA; eDNA = extracellular DNA; eDNA = 
extracellular DNA; D-AA = 40 mM D-Aspartic acid and 40 mM D-Glutamic acid; x MLC = x times minimum 
lethal concentration; Cip = ciprofloxacin. 
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4.3.6 D-AA reduce the rate of cell attachment 
 
Since attachment of cells to a surface is the key initial stage of biofilm formation, it was 
appropriate to investigate the effect of D-AA on cell attachment.  Figure 4.7 shows that 
exposing S. aureus cells to 40 mM D-AA reduces the rate of cell attachment compared to 
untreated cells. Throughout the attachment assay, a gradual increase in the percentage 




Figure 4.7: 40 mM D-AA considerably reduce the number of cells attached to the plate surface over 2.5 
hours of incubation. b) The rate of S. aureus attachment is also slower in cells treated with 40mM D-AA as 
compared to control; D-AA = 40 Mm D-Aspartic acid and D-Glutamic acid. FOV = field of view; n=2. 
 




Aspartic acid and glutamic acid are known to enhance the solubility of Cip (156). Considering 
that one of the mechanisms of antimicrobial resistance in biofilms is the hindrance of drug 
diffusion through their matrix, it was decided to utilise these solubility enhancers of Cip in order 
to overcome this mechanism of antimicrobial resistance in S. aureus biofilms. Along with this, 
since amino acids themselves are known to possess anti-biofilm activity, whether D-Asp and 
D-Glu confer anti-biofilm activity was also investigated, whilst also studying the nature of this 
activity. 
 
Although the effectiveness of D-isomers of amino acids as anti-biofilm agents is somewhat 
under debate (65, 180, 181), much attention has been given to them over the past decade 
and their role in inhibiting and dispersing biofilms. On the other hand, most publications agree 
on a lack of anti-biofilm activity of L-amino acids, and some even attribute pro-biofilm activity 
to them (187-189). Literature claiming that L-amino acids have anti-biofilm activity is rare (180, 
181). It was therefore appropriate to choose D-isomers as solubility enhancers for Cip. A 
hypothesis was drawn that any potential anti-biofilm activity specific to D-isomers would 
supplement the above proposed biofilm perfusion enhancing mechanism and may further 
enhance the efficacy of Cip. 
 
Due to age dependent variation in cells and matrix of a biofilm, Vidakovic et al. (2018), 
hypothesized that susceptibility to the antimicrobial agent (phage) may vary depending on age 
of the biofilm. They found that younger biofilms (<48 h) were more susceptible to phage activity 
than older (>60 h) ones (190). Similarly, Yang et al. (2015) found that younger biofilms (24 h) 
were more susceptible to inhibition by D-Asp than biofilms grown for 48 h and 72 h (181). Data 
presented here shows that whilst inhibiting, generally the anti-biofilm activity of D-AAs is 
independent of age, since in most concentrations, the percentage reduction in biofilm 
formation is similar regardless of how long the biofilm was incubated for (appendix Figure 2). 
On the other hand, dispersing already formed biofilm becomes less effective as the biofilm 
ages from 6h to 48h. At 72h, however the efficacy of amino acids again rises (appendix Figure 
3), probably due to endogenous dispersal mechanisms also being involved at this point. 
 
It seems Tong et al. (2014) were the first to attribute anti-biofilm activity to L-amino acids, 
shortly followed by Yang et al. (2015) (181). Whilst Yang et al. (2015) found that D and L-Asp 
were able to inhibit and disperse S. aureus biofilms, Tong et al. (2014) only reported inhibition 
of Streptococcus mutants biofilms (180, 181). However, the latter found inhibition with both D 
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and L-isomers of both of the acidic amino acids. In this chapter we show that either isomer of 
both Asp and Glu are able to inhibit and disperse S. aureus NCTC 8325 biofilms (Figure 4.1-
Figure 4.6). To our knowledge, this is a previously unreported biofilm forming strain to be 
tested with these amino acids. 
 
Contrary to our findings with S. aureus, L-Glu has been reported to enhance biofilm formation 
of Azotobacter chroococcum (A. chroococcum). The concentration (40mM) we present to be 
most potent in anti-biofilm activity, Velmourougane et al. (2017) show, possess the highest 
pro biofilm activity (189). However their results in another paper seem to suggest that eDNA 
may be low if at all present in A. chroococcum biofilms (191). Furthermore, it seems that the 
importance of eDNA in forming biofilms and their role in stability after biofilm formation varies 
from species to species (192). Absence of eDNA is probably unlikely, as even without any 
specific DNA releasing mechanisms, eDNA is a natural product of dead cells. It is more likely 
therefore, that eDNA does not play a pivotal role in the formation of A. chroococcum biofilms, 
rendering the anti-eDNA mechanism of L-Glu presented later on in this chapter unchallenged. 
Hence, with no disruption to biofilm structure, the pro-biofilm effects L-Glu, as observed by 
Velmourougane et al. become more pronounced. 
 
The ability of the dyes SYTO 9 and PI to distinguish between live and dead cells can be 
attributed firstly, to the inability of PI to enter live cells possessing intact membranes (except 
in exceptional cases), whereas SYTO 9 is able to enter both live and dead cells (193, 194). 
Secondly, PI has higher affinity for, and is able to, displace SYTO 9 from nucleic acids (194); 
despite the presence of SYTO 9 within dead cells or within extracellular matrix, SYTO 9 is 
unable to compete against PI for nucleic acids. Hence, DNA within both dead cells and the 
extracellular matrix (eDNA) is detected through the fluorescence of PI bounded to it. This is 
made feasible by the fact that the fluorescence of both dyes is substantially lower when 
unbound; fluorescence of both dyes is enhanced greatly when the dyes are attached to nucleic 
acids. As a result, despite the presence of SYTO 9, it is not detected in the presence of PI. 
This allowed confident localisation of eDNA through confocal imaging (Figure 4.5 and Figure 
4.6). It seems that under specific conditions PI may also enter live cells. Kirchhoff et al. (2017) 
showed that PI can enter live cells if there are changes to membrane potential, resulting in 
yellow/orange cells as opposed to the expected green or red (193). It is likely that the orange 
cells seen in Figure 4.5.2 and Figure 4.6.2 are due to some uptake of PI which binds to DNA 
within the cells (193). Since the rest of the DNA within the cells has SYTO 9 bounded to it, 
fluorescence of both red and green makes cells appear orange in the overlay. This uptake of 
PI through intact membranes may be due to a change of membrane potential or an increase 
in the permeability of PI through other mechanism caused by amino acids (40, 193). 
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With amino acid exposure, one cause for the reduction in biofilm CFU/ml and in the rate of cell 
attachment (Figure 4.4 and Figure 4.7) is likely due to reduction in planktonic cell viability 
(appendix Figure 4). However another important cause suggested by confocal findings is lack 
of eDNA (Figure 4.5 and Figure 4.6). Recently, Sugimoto et al. (2018) showed that eDNA is 
the most common component of S. aureus biofilms suggesting it to be a prime target for anti-
biofilm therapeutics (195). This chapter proposes that a way to target this vital structural matrix 
component is acidic amino acids; the biofilms inhibited and dispersed with D-AA at 40mM 
concentration were unable to form (Figure 4.5.2) or lost (Figure 4.6.2) their eDNA honeycomb 
meshwork, respectively. Since eDNA is important in initial bacterial attachment to a surface 
and also for further biofilm growth, including cell aggregation, the lack of eDNA or its inability 
to form a structural framework means that the biofilm is neither able to build a strong 
foundation nor is able to mature, ultimately stunting its growth (196, 197). Furthermore, with 
the continuous role of aggregating cells and providing stability to the already formed biofilms, 
lack of eDNA leads to the breakdown of already formed biofilms, at least partially. Thus the 
low number of viable cells in inhibited biofilms can be attributed to the inability of the cells to 
attach and aggregate. Whereas in dispersed biofilms, this would be due to destabilisation of 
the eDNA mediated intercellular bonding mechanism; the cells are released from the biofilm 
due to the lack of eDNA which would otherwise hold them together. 
 
Whilst the cells within a S. aureus biofilm are interconnected through cell wall structures, 
matrix components also play a major role in the stabilisation of the biofilm (198). The major 
components of the extracellular matrix in S. aureus biofilms are the polysaccharide 
intercellular adhesin (PIA) and as aforementioned, extracellular DNA (eDNA). The 
mechanisms involved in the release of eDNA from S. aureus cells is not yet clear. However it 
seems to be highly dependent on autolysis which has been attributed to many systems 
including those leading to a reduction in cell wall integrity (199, 200). As discussed later, 
findings reported in this chapter highlight that eDNA release may also be derived by externally 
influenced lysis. Nevertheless, this eDNA has been described as an electrostatic net that 
anchors cells together (197). However, for eDNA to serve its purpose in the matrix, S. aureus 
seems to employ certain moonlighting proteins i.e. enolase and GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) which are attached to the cell surface (201). Although these 
proteins are cytoplasmic in origin, they serve a second function in the matrix acting as a bridge 
between the cells and the eDNA. The removal of these proteins by increasing the pH causes 
the release of eDNA from the S. aureus biofilms; showing that the role of eDNA in the structural 
stability of the biofilm is dependent on these cell surface proteins (197). These proteins are 
proposed as an ideal bridge because they are thought to be positively charged, and hence 
Page 199 of 252 
 
are able to interact with and connect the negatively charged cells on one side with the 
negatively charged eDNA on the other (197). 
 
It seems that eDNA in a healthy biofilm surrounds all cells individually (Figure 4.5.1 and Figure 
4.6.1), helping them aggregate and provides structural stability and integrity to the biofilm. Das 
et al. (2011) suggest that bacterial aggregation mediated by eDNA is due to acid-base 
interactions (202). We propose that acidic amino acids prevent the formation of eDNA 
meshwork, and if already present, break it down by interfering with these acid-base 
interactions. The mechanism that may be employed by acidic amino acids is depicted in Figure 
4.8. Negatively charged eDNA helps aggregate cells by interacting with positively charged S. 
aureus surface proteins (enolase and GAPDH) on multiple cells; thus acting as an intercellular 
electrostatic bridge (Figure 4.8a). The importance of these proteins in intercellular bridging is 
highlighted by their presence, at varying concentrations, along the entire surface of bacteria 
(203-209). Since at the pH value of 4.01, the ionised acidic amino acids are negatively 
charged, they are able to interact with these positively charged proteins. Resulting ion-pair 
formation, neutralises the positive charge on enolase and GAPDH, rendering eDNA unable to 
interact with these proteins. Therefore, during inhibition intercellular bridges do not form, 
neither are cells able to aggregate (Figure 4.8c). Dispersal with amino acids utilises a similar 
mechanism. Anionic amino acids displace enolase and GAPDH associated eDNA. Release of 
eDNA causes a release of cells from the biofilm since they are now unable to aggregate with 
each other (Figure 4.8b). Greater effectiveness of D-AA in combination as compared to their 
use individually can be explained through the presence of a greater number of anions in 
combination. More anions present greater obstruction for eDNA-protein interaction, resulting 
in combined D-AA exhibiting greater anti-eDNA activity. Support for the role of charge in the 
underlying mechanism is provided by the observation that neutralising the acidic amino acids 
using NaOH halts anti-biofilm activity (appendix Figure 5) of the amino acids. 
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Figure 4.8: Mechanism of biofilm inhibition and dispersal using D-AA. D-AA exhibit anti-eDNA activity. a) 
Normal conditions: eDNA forms intercellular bridges by interacting with surface bound positively charged 
proteins (enolase and GAPDH) via acid-base interactions. b) Dispersal: addition of anionic D-AA displaces 
eDNA from the surface bound positively charged proteins. eDNA is released and the intercellular bridges 
are broken. c) Inhibition: the present D-AA interact with surface bound positively charged proteins 
preventing eDNA from associating with these proteins; intercellular bridges are unable to form; eDNA = 
extracellular DNA; D-AA = D-Aspartic acid and D-Glutamic acid; GAPDH = glyceraldehyde-3-phosphate 
dehydrogenase. 
In dispersed biofilms, it is likely that other matrix components are still present which would 
explain why there is a greater percentage reduction in viable cell number (Figure 4.4 and 
appendix Table 1) as compared to total biofilm density (Figure 4.1 and appendix Table 1). This 
is because with the release of eDNA, the cells are unable to stay aggregated and are released 
from the biofilm. However, other matrix components remain unaffected and constitute to the 
remaining biofilm density (Figure 4.1a,b,d,e and appendix Figure 3) observed after dispersal 
experiments. This also gives reason as to why D-AA seem to appear more efficacious at 
reducing biofilm density whilst inhibiting than whilst dispersing. Conversely, cell number and 
eDNA are not the only effected components in inhibited biofilms. Clearly, other matrix 
components are also unable to become established and form a consequential part of the 
percentage reduction observed in biofilm density (appendix Table 2). This further highlights 
the role of eDNA in not only the aggregation of cells but also the establishment of other matrix 
components. 
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Confocal images show that use of treatment with Cip on its own leads to biofilms with 
seemingly denser eDNA structures (Figure 4.5.3 and Figure 4.6.3). This is a visual reminder 
as to why biofilms are a major cause of chronic infections. Whilst an antibiotic may get rid of 
majority of the bacterial load from the body, persister cells remain unharmed within biofilms. 
Biofilms are then able to re-establish once treatment is stopped and ultimately, the infection 
recurs. Interestingly, treating already formed biofilms with Cip alone reveals eDNA localised 
in a seemingly well-fortified boundaries (Figure 4.6.3 and appendix Figure 1). Here we 
hypothesis two potential implications of these findings. Firstly, these boundaries suggest that 
within a biofilm eDNA structures have weak and strong points. Cells away from these 
boundaries are released upon treatment giving rise to voids within treated biofilms. Since 
these boundaries seem circular in morphology, they may be boundaries to microcolonies 
within the biofilm. Previous studies have shown eDNA to be highly concentrated around P. 
aeruginosa microcolonies (210, 211). A second possibility is that upon threat, cells which are 
to persist within the biofilm are able to further fortify and make dense the eDNA structures 
surrounding them. This is made feasible due to the excess of eDNA present as a result of 
antibiotic triggered cell death. In either case, it is appropriate to speculate that these strong 
points within eDNA meshwork are likely responsible for cell persistence and antimicrobial 
resistance. 
 
Despite the ability of acidic amino acids to enhance the solubility of Cip (156), no synergistic 
effect of combining 40Mm D-AA and Cip was found in biofilm density or on cell viability. The 
reasons may be different for inhibition and dispersal. When inhibiting biofilms, 40Mm amino 
acids are alone able to inhibit 96.89% of the biofilm from forming. This leaves minimal room 
for improvement for any amounts of Cip which may be added in biofilms in combinations with 
the amino acids. Similarly, with a reduction of 97.60% CFU in biofilms dispersed with D-AAs, 
there are not many viable cells within the biofilm left for Cip to act on. In either case, any effect 
of Cip has probably gone unnoticed. Therefore it seemed likely that a synergistic effect may 
be more pronounced at lower concentrations of D-AAs. Further experiments were carried out 
which confirmed that at lower but specific concentrations, a synergistic effect on biofilm density 









Acidic amino acids are able to disperse already formed biofilms and inhibit new S. aureus 
biofilm formation. This coincides with a lack of eDNA present in treated biofilms, suggesting 
that eDNA is a target for the observed D-AA anti-biofilm activity. Hence, an anti-eDNA 
mechanism is proposed; D-AA modulate the acid-base interactions which are essential for 
anchoring eDNA to cells. The findings further confirm that eDNA is critical to S. aureus 
biofilms, both in formation stages as well as once established. Targeting matrix components 
not only helps fight biofilms on its own, but may also be used to increase the efficacy of other 
antimicrobial agents. Furthermore, the role of antibiotics in increasing antimicrobial resistance 
is reiterated, whilst suggesting that the mechanisms of acquiring antimicrobial resistance is 
not limited to cells but may extend to the matrix. Therefore, to fight antimicrobial resistance 
drugs that target cells alone should be used in conjunction with ways to disrupt the matrix or 
inhibit its formation. The findings from this work can lead to applications where amino acids 








































Chapter 5: Investigating the effect of acidic and basic 
amino acids on the solubility, caco-2 monolayer 
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5.1 Introduction 
Being one of the oldest drugs used for cardiovascular care, digoxin (Figure 5.1) is frequently 
used to treat atrial fibrillation and for patients suffering with heart failure (212). Its mechanism 
of action relates to inhibition of sodium-potassium adenosine triphosphatase (ATPase) which 
ultimately results in lower heart rates and increased myocardial contractility due to lengthening 
of the cardiac action potential (212). 
Figure 5.1: Chemical structure of digoxin. Image taken from British Pharmacopeia (102). 
BCS classification is a system which puts drugs into four groups depending on their solubility 
and permeability profiles. Surprisingly, in literature, digoxin has been grouped into classes I, 
II, and IV (213-215). However according to Caldeira TG et al, digoxin was grouped into classes 
I and II only provisionally without taking into consideration the effect on permeability of efflux 
transporters(213). Valizadeh et al, through conducting permeability experiments on rat 
jejunum suggested that digoxin belongs to BCS class IV (216). In summary, digoxin is both 
poorly soluble and has poor permeability. 
Finding ways to overcome solubility and permeability limitations for digoxin can reduce toxicity 
to patients as well as costs for the pharmaceutical companies. Our group has previously 
shown that amino acids possess the ability to enhance drug permeation through both caco-2 
monolayers as well as buccal cell layers (165). Therefore in this study, we aim to investigate 
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the effect of acidic and or basic amino acids on the solubility profile of digoxin as well as their 
effect on the permeability of the drug through caco-2 monolayers. 
 
Digoxin is taken up into cells via passive diffusion but its uptake into the body is limited by 
efflux. It is a well-known substrate for P-glycoprotein (P-gp), so much so that it is also 
sometimes used to validate the integrity caco-2 monolayers (217, 218). Caco-2 cells serve as 
a well-established in vitro model of the enterocytes. Once cultured on permeable cell inserts 
(transwells), under appropriate conditions they form monolayers which are well differentiated. 
These differentiated cells are highly polarised, possess microvilli, exhibit tight junctions and 
express similar transporters to those present in intestinal epithelium, resulting in an 
appropriate selective barrier for the study of both passive and active drug transport. Like 
enterocytes they possess distinct apical and basolateral features allowing for the investigation 
of drug absorption and secretion through apical to basolateral and basolateral to apical studies 
respectively. 
 
The primary aim of the study in this chapter was to evaluate the role of charged amino acids 
on solubility and the in vitro permeability of digoxin. This was done by first setting up a HPLC 
method and determining the saturated solubility of digoxin in different concentrations of amino 
acids in aqueous medium. Finally permeability experiments using caco-2 monolayers were 
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Digoxin was purchased from Acros Organics whereas L-Aspartic acid (Asp), L-Glutamic acid 
(Glu), L-Arginine (Arg), L-Histidine (His), L-Lysine (Lys) were purchased from Sigma Aldrich. 
HPLC grade Acetonitrile was purchased from Fisher Scientific UK. Caco-2 cells were 
purchased from Public Health England (PHE). Minimum essential medium eagle (EMEM), 
Dimethyl sulfoxide (DMSO), Thiazoyl Blue Tetrazolium Bromide (MTT) and Corning® 
Transwell® polycarbonate membrane cell culture inserts were obtained from Sigma Aldrich. 
GibcoTM Fetal bovine serum and GibcoTM Hank’s balanced salt solution (HBSS; no calcium, 
no magnesium and no phenol red) and digoxin (95%; ACROS OrganicsTM) was obtained from 
Fisher Scientific. Eagle’s minimum essential medium (MEM) Non-essential amino acids 
solution (without L-glutamine), penicillin-streptomycin (pen-strep) and L-glutamine solution 
(200 mM) was obtained from as well as Sigma Aldrich. Trypsin used was 0.25% trypsin, 2.21 
mM EDTA in HBSS w/o calcium, magnesium and sodium bicarbonate (CorningTM). 0.4% 
Trypan Blue solution was purchased from Sigma Aldrich. 
 
5.2.2 HPLC analysis 
 
HPLC was used for obtaining a calibration curve and further sample quantification using the 
Agilent Technologies 1260 infinity. Eclipse Plus C18 3.5µm 150 x 4.6 mm column was used. 
The method was adapted from British Pharmacopoeia. Mobile phase consisted of Water and 
Acetonitrile (70:30 v/v). Analysis was carried out at ambient temperature with the flow rate of 
1 ml/min and an injection volume of 40 μL. λmax for digoxin was determined using Genesys 
10s UV-Vis Spectrophotometer to be 220 nm and hence the UV detector for HPLC analysis 
was set at 220 nm. 
 
To obtain the calibration curve, stock solution was prepared by dissolving digoxin in DMSO at 
a concentration of 20mM. This stock solution was used to make chromatographic standard 
solutions by diluting with appropriate volume of water. 
 
5.2.3 Digoxin solubility study 
 
Saturated solubility of digoxin in different concentrations of amino acids were determined. 
Stock solution of amino acids (arginine, lysine, histidine, glutamic acid and aspartic acid) with 
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a concentration of 4500 µg/ml was prepared. Dilutions were prepared from this stock solution 
ranging from 4500 µg/ml down to 62.5 µg/ml. Excess amounts of digoxin was added to each 
dilution of each amino acid solution. The mixture was stirred at ambient temperature for up to 
24 hours until excess drug had deposited. The pH of the solution was obtained (Xisherbrand 
Hydrus 500 pH meter) after which the supernatant was filtered through 0.45 µm syringe filter. 
The concentration of the filtrate was determined through HPLC using the method detailed 
above. 
 
5.2.4 Cell revival 
 
Caco-2 cells were obtained from Public Health England. The frozen vial was wrapped with 
tissue soaked in 70% ethanol which was followed by loosening of the lid to release excess 
liquid nitrogen. The lid was retightened and the frozen vial was thawed in a 37 °C water bath. 
The vial was again wiped with 70% ethanol soaked tissue before opening in a sterile biological 
safety cabinet/ tissue culture hood. The contents of the vial was then added to T25 flask 
containing 6ml of media. The media used for culturing caco-2 cells was EMEM supplemented 
with 10% FBS, 1% non-essential amino acids, 1% 200 mM L-glutamine and 0.5% pen-strep. 
After 24 hour incubation in 37 °C incubator with 5% CO2, the media was changed to remove 
unattached cells. 
 
5.2.5 Caco-2 cell culture, routine maintenance and cell splitting 
 
As above, Caco-2 cells were purchased from PHE and were received at passage 43 (P 43). 
The passages used throughout the study ranged from P 47 to a maximum of P 60. Cells were 
grown at 37 °C and 5% CO2 in T75 flasks and the media used was EMEM supplemented with 
10% FBS, 1% non-essential amino acids, 1% 200 mM L-glutamine and 0.5% pen-strep. The 
media was changed every 2-3 days which replenished nutrients for the cells and removed 
dead cells. 
 
To maintain caco-2 cells for experiments, the cells were split at around 80% confluence. To 
do this cells were washed with sterile HBSS which allowed removal of serum which would 
otherwise deactivate the trypsin. This was followed by incubation with 3 ml trypsin and 
subsequent incubation at 37 °C for a couple of minutes. The flasks were gently tapped to aid 
detachment of cells from the solid surface. Once sufficient cells were detached, as visualised 
by an inverted light microscope the cell culture media was quickly added to halt trypsin activity. 
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The resulting cell suspension was split into 4 new flasks and incubated at 37 °C with 5% CO2 
until needed for permeability experiments or further splitting. 
 
5.2.6 Cell counting 
 
To count cells, a clean a grease free haemocytometer was used. A coverslip was affixed onto 
the haemocytometer by applying slight moisture; newton’s rings observed once coverslip fixed 
onto haemocytometer appropriately. When ready, it was ensured that the cell suspension to 
be counted was thoroughly mixed. Next, a small volume of the suspension was diluted with 
0.4% trypan blue. 10 µL of this diluted suspension was then pipetted at the edge of the 
mounted coverslip and allowed to run under. The haemocytometer was then visualised under 
a light microscope and live cells were counted on multiple big squares. Average of the squares 
was then taken and cell concentration per ml calculated using the following formula. 
 
Average No. of cells per square ×  dilution factor × 1 × 104 
 
5.2.7 Determining Digoxin and amino acid concentrations for permeability 
experiments using the MTT assay 
 
5.2.7.1 Determining optimal concentration of Caco-2 cells for MTT assay 
 
For MTT assay to be carried out, the optimal cell density for seeding was first determined. 
This was done by seeding 100 µl of caco-2 cell suspension in cell culture media with serial 
dilutions ranging from a concentration of 500000.00 cells/ml to 975.56 cells/ml in wells of a 96 
well plate. The cells were then incubated for 24h at 37 °C with 5 % CO2. Next day, after 
removal of media, 100 µl of 0.5 mg/ml of MTT was added to each well. Next the plate was 
again incubated under same conditions for 2-4 hours, until intracellular purple pigmentation 
was clearly visible through light microscopy. After this the supernatant (MTT) was removed 
and 100 µl of DMSO was added to each well. The plate was left shaking for 30 min at 37 °C. 
The optical density was then read at 570 nm and a graph was plotted. A concentration from 
the linear portion of the graph was chosen for conducting further MTT assays. 
 
5.2.7.2 MTT assay 
 
For the MTT assay, 100 µl of 250000 cells/ml cell suspension was added to each well of a 96 
well plate and incubated for 24h at 37 °C with 5% CO2. Next day the media was removed and 
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100 µl of test concentrations of the amino acids (30 mM to 30 pM) and digoxin (100 µM to 100 
fM) was added to each well. The plates were then incubated at 37 °C with 5% CO2 for 4 h. 
After 4h, supernatant was removed and 100 µl of 0.5 mg/ml (10µl of 5 mg/ml MTT stock added 
to 90µl HBSS) of MTT (made up in HBSS) was added to each well. The plate was then further 
incubated for 2h (until intercellular punctate purple precipitate is visible) under same 
conditions. Next the supernatant containing MTT was removed and 100 µl of DMSO was 
added to each well and the plate was left to shake at 37 °C for 30 min (until the cells have 
lysed and the purple crystals have dissolved). Finally the O.D. was determined by reading the 
plate using a plate reader at 570nm. 
 
5.2.8 Measurement of TEER 
 
Transepithelial electrical resistance (TEER) was measured with an EVOM epithelial 
voltohmmeter (World Precision Instruments). TEER was measured at room temperature each 
time. To ensure this, monolayers were left at room temperature for 15 minutes before 
measuring TEER. TEER was measured whilst growing caco-2 monolayers to follow 
monolayer development and confirm its integrity. TEER was also measured before, during 
and after each permeability experiment. It was ensured that the TEER probe was sterilised in 
70% ethanol between reading different transwells. The pre-experimental TEER was measured 
with monolayers still in the media, whilst the TEER measurements during the permeability 
experiments were performed in HBSS. After the experiments, HBSS was replaced with media 
in each compartment before taking the TEER measurements. Only those monolayers with a 
TEER of above 250 Ωcm2, after correction with blanks, were used for the permeability 
experiments. To calculate TEER net resistance (which is resistance of the blank subtracted 
from the resistance of the monolayer) was multiplied by the cell growth area (4.67 cm2). 
 
5.2.9 Caco-2 permeability assay 
 
After reviving cells, passaging was carried out at least twice before seeding caco-2 cells on 
transwells for permeability experiments. Cells were seeded at a density of 1.3 x 105 cells/cm2 
on polycarbonate-coated transwell membranes. This translates to 1.5 ml of cell suspension of 
a concentration of 4 x 105 cells/ml added to each 6 well transwell. The cells were allowed to 
grow to form a monolayer for ~21 days. Media was changed every 2-3 days to allow healthy 
development of the monolayer. 
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Culture media was changed a day before the transport experiments were to be carried out. 
This prevented the cells from changing to a starved phenotype (18). On the day of the 
experiment, all solutions were pre-warmed. Donor solutions were prepared with appropriate 
concentration of digoxin and amino acid. 
 
The membranes and monolayers were washed with HBSS by transferring the transwells into 
new wells containing HBSS and replacing apical media with HBSS. Following the wash, the 
transwells were incubated with HBSS for 15 minutes before starting the transport experiments. 
Transport experiments were performed in the apical to basolateral (A-B) or B-A direction by 
pipetting the donor solution in the apical or basolateral side respectively. Either way, final 
volume for apical side was kept at 1.5ml and 2.5ml at basolateral side. Donor solutions were 
either digoxin on its own or digoxin with various molar ratios (1:5, 1:10, 1:30, 1:100, 1:300 and 
1:600) of L-arg, L-lys and L-his made up in HBSS. For determining the concentration of the 
receiver compartment, 500 µl samples were withdrawn at each time-point, making sure to 
replace the volume with HBSS. The time-points used is this study were 0, 15, 30, 45, 60, 120 
and 180 min. The transwells were incubated at 37°C with 5% CO2 between each time point to 
allow permeation at a physiological temperature. A final sample was taken from the donor 
compartment to calculate mass balance. 
 




After permeability experiments in A-B and B-A direction, the apparent permeability coefficient 







In this equation, dQ/dt is the rate of permeation of the drug (digoxin) into the receiver 
compartment, whilst A is the surface are of transwell or Caco-2 monolayer and C0 is the initial 
donor compartment concentration. In this case, we took the slope of the linear portion of the 
plot of the concentration in the receiver compartment by time to be dQ/dt. Surface area of the 
transwell was 4.67 cm2, whilst C0 was measured by taking a sample and determining the 
concentration by HPLC. 
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5.2.10.2 Efflux ratio 
 
After determining Papp in both directions, A-B and B-A, it was possible to determine the efflux 
ratio (ER) using the following equation: 
 
𝐸𝑅 =
𝑃𝑎𝑝𝑝 𝐵 − 𝐴
𝑃𝑎𝑝𝑝 𝐴 − 𝐵
 
 
Here, the Papp B-A is the Papp determined as previously described for the basolateral to 





One way ANOVA (multiple comparison) was used to look for overall statistical significance 
within the data and was followed by Tukey’s multiple comparisons test to see exactly where 
the significant difference was. GrapPad Prism was used for statistical analysis and adjusted 






















5.3.1 Digoxin solubility in the presence of amino acid 
 
Solubility of digoxin was investigated in aqueous solutions of both acidic (L-aspartic acid and 
L-glutamic acid) and basic (L-arginine, L-lysine and L-histidine) amino acids. The 
concentration range of the amino acids used was from 62.5 µg/ml to 4500 µg/ml. 
 
 
Figure 5.2: Apparent solubility of digoxin in the presence of L-Arg. Generally the solubility of digoxin 
increased in the presence of L-Arg.  Significant rise in digoxin solubility was observed with 125 (p=0.017), 
250 (p=0.00078), 1000 (p<0.0001), 2500 (p=0.0013), 3500 (p<0.0001) and 4500 µg/ml (p=0.0018) of L-Arg; n=3. 
 
 
Figure 5.3: Apparent solubility of digoxin in the presence of L-His. Generally the solubility of digoxin 
increased in the presence of L-His.  Significant rise in digoxin solubility was observed with 125 (p=0.048), 
250 (p=0.0033), 500 (p=0.031), 1000 (p=0.00039), 1500 (P=0.0041), 2500 (p=0.0011), 3500 (p=0.0062) and 4500 
µg/ml (p=0.00032) of L-His; n=3. 
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Figure 5.4: Apparent solubility of digoxin in the presence of L-Lys.  Significant rise in digoxin solubility 
was observed with 125 (p=0.011), and 3500 µg/ml (p=0.0089) of L-Lys; n=3. 
 
Overall, with the exception of a few outliers, the solubility of digoxin increased with increasing 
concentration of the basic amino acids, especially L-Arg and L-His (Figure 5.2 to Figure 5.4). 
In L-Arg solution of 3500 µg/ml, there was a 1.54 fold increase (Figure 5.2) in digoxin solubility 
compared to control, representing the highest amount of digoxin dissolved with this amino 
acid. Same concentration of L-Lys lead to a 1.17 fold increase (Figure 5.4) in digoxin solubility 
compared to control, representing the highest enhancement in digoxin solubility with the amino 
acid. A 1.40 fold increase (Figure 5.3) in solubility was observed with L-His concentration of 
4500 µg/ml representing the highest amount of drug able to dissolve in the concentration range 
of this amino acid. 
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Figure 5.5: Apparent solubility of digoxin in the presence of L-Asp.  No significant rise in digoxin solubility 
was observed with L-Asp; n=3. 
 
 
Figure 5.6: Apparent solubility of digoxin in the presence of L-Glu.  No significant rise in digoxin solubility 
was observed with L-Glu; n=3. 
 
Unlike basic amino acids, no significant increase in digoxin solubility was observed with the 
acidic amino acids, L-Asp and L-Glu (Figure 5.5 and Figure 5.6). It is also worth noting that 
the chromatogram for digoxin exposed to the acidic amino acids showed two peaks instead of 
the one peak observed whilst obtaining the calibration curve and whilst experimentation with 
basic amino acids. 
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5.3.2 Digoxin permeability through caco-2 monolayer in the presence of basic 
amino acids 
 
5.3.2.1 MTT assay 
 
To investigate whether amino acid are able to increase digoxin permeability, it was essential 
that concentrations that are not cytotoxic to the caco-2 cells were used. To determine the 
optimal concentration of cells needed for carrying out the MTT assay, different concentrations 
of cells were investigated (Figure 5.7). Optical density (O.D.) increased with increasing 
concentrations of cells. From the straight portion of the graph, 250000 cells/ml was chosen to 
proceed with for MTT assays as it gave decent confluence (Figure 5.8) within 24 hours and 




Figure 5.7: Caco-2 cell concentration plotted against O.D. measured at 570 nm to determine the optimal 
concentration of cells for MTT assay; n=16. 
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Figure 5.8: Acceptable (>80%) cell confluence achieved within 24h with 250000 cells/ml for MTT assay. 
 
MTT assays were then conducted for the three basic amino acids, L-arg, L-lys and L-his 
(Figure 5.9) as well as digoxin (Figure 5.10) and percentage cell viability plotted. With all amino 
acids there was an initial decrease in caco-2 cell viability with increasing concentration of the 
amino acid. Further increase had the opposite effect and the cell viability reverted back to 
normal. With L-arg, reduction in cell viability was observed at 3 nM to 300 µM of the amino 
acid (p<0.01). With L-lys however, significant reduction was only seen at a concentration of 3 
nM (p<0.05). Significant reduction with L-histidine was observed between the concentration 
range of 3 nM to 30 µM (p<0.05). Digoxin exhibited a concentration dependent cytotoxicity on 
caco-2 cells where an increase in concentration led to a reduction in cell viability. Significant 
reduction in cell viability with digoxin was observed above 100 nM of digoxin, where the p 
value for 100 nM was <0.05 and for 1, 10 and 100 µM was <0.0001. 
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Figure 5.9: MTT assay was conducted to check for amino acid cytotoxicity. Percentage caco-2 cell viability 
at different concentrations of L-arg, L-lys and L-his; n=8. 
 
 
Figure 5.10: MTT assay was conducted to check for digoxin cytotoxicity. Percentage caco-2 cell viability 
at different concentrations of digoxin; n=8. 
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Figure 5.11: Percentage cytotoxicity of digoxin (Dig) on caco-2 cells. Cytotoxicity increased with increasing 
concentration of digoxin; n=8. 
 
The percentage cytotoxicity of the drug was calculated using the equation below. 
 
% 𝑐𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 = 100 − % 𝑐𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 
 
5.3.2.2 Permeation enhancement of Digoxin with basic amino acids 
 
Before starting the permeability experiments, it was crucial to ensure that the caco-2 
monolayers grown were of good integrity. To check for this, TEER measurements were carried 
out over a 24 day period (Figure 5.12). This also allowed determination of the optimal number 
of days to carry out the permeability experiments post seeding. There was a shallow rise in 
TEER value up to day 13 followed by a steep rise until day 19. The peak TEER was measured 
on day 19 after which TEER value again started falling. Hence optimal days to carry out 
permeability experiments were determined to be around day the days 19-21. 
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Figure 5.12: Transepithelial electrical resistance of caco-2 monolayer grown for 24 days on transwells with 
surface area of 4.67 cm2; n=12. 
 
Due to digoxin solubility enhancement by only the basic amino acids and the presence of an 
additional peak in the chromatogram of digoxin during solubility experiments with acidic amino 
acids, it was decided to proceed with permeability studies using only the basic amino acids. 
Permeability of digoxin on its own (control) and in the presence of digoxin to amino acid molar 
ratios of 1:5, 1:10, 1:30, 1:100, 1:300 and 1:600 were conducted in the apical to basolateral 
(A-B) direction. Significant permeation enhancement, was observed with L-Arg and L-Lys and 
not with L-His. Due to this, permeability experiments in the basolateral to apical (B-A) direction 
were only conducted for digoxin in the presence of L-Arg and L-Lys, specifically at the 
concentrations that gave statistically significant enhancement in digoxin permeability. 
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Figure 5.13: digoxin permeability through caco-2 monolayers on its own and in the presence of L-Arg at 
digoxin to amino acid molar ratios of A) 1:5, B) 1:10, C) 1:30, D) 1:100, E) 1:300 and F) 1:600. Percentage 
dug permeation from apical to basolateral direction (A-B) are presented for all molar ratios whereas for 
basolateral to apical (B-A) direction, only 1:100, 1:300 and 1:600 molar ratios were studied. A-B represented 
by solid line whereas B-A is represented by dashed line; n=3. 
 
In the apical to basolateral (A-B) direction, a time dependent permeation of digoxin through 
Caco-2 monolayers, both in the presence and absence of L-Arg was observed. Also generally, 
the percentage of drug permeating through the caco-2 monolayers increased with increasing 
concentration of L-Arg at each time-point. The maximum digoxin permeation of 50.31% and 
was achieved with a digoxin to L-Arg molar ratio of 1:600 at 180 min. Statistically significant 
enhancement in digoxin permeation was observed with the digoxin to L-Arg molar ratios of 
1:100, 1:300 and 1:600, though only at time points of 120 min and 180 min. For these molar 
ratios, along with the control, permeability experiments in the basolateral to apical (B-A) 
direction were also conducted. Digoxin permeation in the B-A direction also increased with 
time. This allowed the determination of efflux rate in the presence and absence L-Arg. 
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Figure 5.14: Digoxin permeability through caco-2 monolayers on its own and in the presence of L-Lys at 
digoxin to amino acid molar ratios of A) 1:5, B) 1:10, C) 1:30, D) 1:100, E) 1:300 and F) 1:600. Percentage 
dug permeation from apical to basolateral direction (A-B) are presented for all molar ratios whereas for 
basolateral to apical (B-A) direction, only 1:100, 1:300 and 1:600 molar ratios were studied. A-B represented 
by solid line whereas B-A is represented by dashed line; n=3. 
 
Overall with L-Lys a similar pattern to L-Arg was observed in the permeation behaviour of 
digoxin. Like with L-Arg, a time dependent permeation of digoxin through Caco-2 monolayers, 
both in the presence and absence of L-Lys was observed in the A-B direction. However, the 
maximum digoxin permeation of 47.61 % and was achieved with a digoxin to L-Lys molar ratio 
of 1:300, unlike the 1:600 observed with L-Arg, again at 180 min. Again, significant 
enhancement in digoxin permeation was observed with the digoxin to L-Lys molar ratios of 
1:100, 1:300 and 1:600 at time points of 120 min and 180 min. Permeability experiments in 
the B-A direction were conducted for these molar ratios as well as the control, allowing 
calculation of the efflux rate of digoxin in the presence of L-Lys. Digoxin permeation in the B-
A direction also increased with time. 




Figure 5.15: Digoxin permeability through caco-2 monolayers on its own and in the presence of L-His at 
digoxin to amino acid molar ratios of A) 1:5, B) 1:10, C) 1:30, D) 1:100, E) 1:300 and F) 1:600. Percentage 
dug permeation from apical to basolateral direction (A-B) are presented for all molar ratios; n=3. 
 
Permeability experiments in the A-B direction were also done with L-His as a potential 
permeability enhancer. However, unlike L-Arg and L-Lys, L-His showed no statistically 
significant enhancement in digoxin permeability as compared to digoxin on its own. Due to 
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Table 5.1: Table representing apparent permeability coefficient (Papp) and efflux ratio of digoxin (DIG) and 
digoxin combined with L-Arg and L-Lys at digoxin to amino acid molar ratios of 1:100, 1:300 and 1:600. 
Papp values for both the apical to basolateral (A-B) and basolateral to apical (B-A) direction are presented; 
* p<0.05, **p<0.005 and *** p<0.001; n=3. 





DIG 1.39 ± 0.47 2.49 ± 1.07 2.06 
DIG:ARG 1:100 3.50 ± 1.59* 3.18 ± 1.97 1.23 
DIG:ARG 1:300 4.46 ± 0.43*** 4.60 ± 0.50 0.61 
DIG:ARG 1:600 5.52 ± 0.30*** 5.08 ± 1.90 0.63 
DIG:LYS 1:100 3.88 ± 1.14 4.32 ± 2.14 0.85 
DIG:LYS 1:300 5.41 ± 0.76* 3.35 ± 1.16 1.05 
DIG:LYS 1:600 6.43 ± 0.55** 4.04 ± 0.32 0.93 
 
From the permeability data obtained, the permeability coefficient (Papp) of digoxin on its own 
and in combination with various concentrations of L-Arg and L-Lys was calculated in the A-B 
and B-A direction. Digoxin which was combined with L-Arg or L-Lys gave higher Papp values. 
Furthermore, increasing the concentration of the amino acid led to higher Papp, especially for 
the A-B direction.  Significant change in Papp was achieved with 1:100, 1:300 and 1:600 molar 
ratios of digoxin to L-Arg. Whereas, whilst combining with L-Lys, digoxin to L-Lys molar ratios 
of 1:300 and 1:600 were significantly different from control. 
 
From the Papp values, the efflux ratio was calculated, which allowed the assessment of the 
efflux behaviour of digoxin on its own in comparison to its efflux behaviour in the presence of 
basic amino acids L-Arg and L-Lys. Combining digoxin with either L-Arg or L-Lys decreased 
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Table 5.2: Transepithelial electrical resistance across caco-2 monolayers measured before, during (after 
each time point; 0 min, 15 min, 30 min, 45 min, 60 min, 120 min and 180 min) and after (24 h and 96 h) the 
permeability experiment. * Only some of the caco-2 monolayers exposed to 1:600 concentration of amino 
acid recovered to a TEER value above 200 Ωcm2; n=3. 
 
Time point TEER (Ωcm2) S.D. 
Digoxin Before experiment 2009.66 35.05 
 
0 min 1782.38 52.07 
 
15 min 1151.93  37.75 
 
30 min 1066.32 70.26 
 
45 min 1130.14 37.07 
 
60 min 965.13 17.68 
 
120 min 443.65 49.42 
 
180 min 189.91 31.09 
 
24h 1997.20 5.39 
 
96h 1346.52 5.39 
1:10 Before experiment 1438.36 69.11 
 
0 min 1131.70 26.96 
 
15 min 544.83 11.75 
 
30 min 249.07 215.70 
 
45 min 375.16 17.68 
 
60 min 345.58 60.71 
 
120 min 259.96 14.27 
 
180 min 175.90 5.39 
 
24h 2154.43 123.06 
 
96h 1008.72 93.75 
1:30 Before experiment 2758.41 21.06 
 
0 min 2154.43 17.68 
 
15 min 529.27 53.92 
 
30 min 337.80 25.72 
 
45 min 412.52 31.09 
 
60 min 389.17 60.23 
 
120 min 364.26 4.67 
 
180 min 244.40 63.58 
 
24h 3240.98 8.09 
 
96h 801.68 222.03 
1:600 Before experiment 1712.33 23.96 
 
0 min 1179.95 15.01 
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15 min 259.96 7.13 
 
30 min 110.52 16.40 
 
45 min 99.63 25.72 
 
60 min 85.62 5.39 
 
120 min 118.31 11.75 
 
180 min 12.45 7.13 
 
24h 59.15 18.87 
 
96h 372.04* 158.53 
 
In a bid to check the effect of different digoxin and L-Arg/Lys concentrations on monolayer 
integrity during permeability experiments, TEER measurements were carried out for selected 
combinations across the range of concentrations used. The test agents selected for this 
include digoxin on its own as well as digoxin in combination with L-Arg/Lys at digoxin to L-
Arg/Lys molar ratios of 1:10, 1:30 and 1:600. It was found that the TEER values dropped over 
time during the permeability experiments with values being lowest at 180 min. Although higher 
amino acid concentrations led to more abrupt drops in TEER value, digoxin on its own also 
led to substantial drops. Nevertheless, to check whether the monolayer integrity is recoverable 
or not, the monolayers were again incubated with cell culture medium under the general 
conditions detailed under methods. Monolayers exposed to digoxin, 1:10 and 1:30 recovered 
to TEER values of 2000 Ωcm2 or above within 24 hours. However at 96 hours after the 
experiment, only some of the monolayers exposed to 1:600 recovered to a TEER value of 
372.04 Ωcm2. Nevertheless, it was observed that all monolayers exposed to 1:600 recovered 








5.4.1 Digoxin solubility in acidic and basic amino acids 
 
Solubility studies of digoxin in amino acids show that basic amino acids serve as its suitable 
counterions. We were unable to find experimental pKa values for digoxin, however pKa values 
have been predicted to be 7.15 and -3 for its strongest acidic and strongest basic ionisable 
site respectively. If these estimates are correct, in the basic pH of the solutions achieved by 
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all three amino acids, the strongest acidic ionisable site of digoxin is likely to be ionised more 
so than digoxin on its own in water. The percentage ionisation of this site would be in an 
equilibrium dependent on the particular pH of the solution, and is likely to increase with an 
increase in the concentration of the amino acid due to the accompanying increase in pH. 
Although it is possible to calculate the percentage ionisation of the sites, it was not done so 
due to the unavailability of experimental pKa. Nevertheless, in basic amino acid solutions, the 
proportion of anionic digoxin is likely to have increased. This results in the increased digoxin 
solubility observed, since the resulting increase in the proportion of polar drug molecules are 
able to interact with polar water molecules, or in other words become solubilised; polar 
molecules have higher hydrophilicity. 
 
Unlike with basic amino acids, acid amino acids did not enhance digoxin solubility. However 
this can be explained by the degradation of digoxin in the presence of acidic amino acids. 
According to literature, an acidic environment causes hydrolysis of digoxin resulting in its 
degradation (219). Digoxigenin, digoxigenin bisdigitoxoside and digoxigenin monodigitoxoside 
have been identified as degradation products (219, 220). Multiple degradation products 
formed by the hydrolysis of digoxin also explains why an extra peak was seen upon HPLC 
analysis of digoxin in acidic amino acids solutions. 
 
5.4.2 Digoxin permeability 
 
5.4.2.1 Efflux of digoxin and the effect of L-Arg and L-Lys on P-gp 
 
For digoxin on its own, Papp in the B-A direction was around 2 fold greater than the Papp in 
the A-B direction giving an efflux ratio of 2.06. Since digoxin is a substrate of P-gp, making it 
highly prone to efflux through caco-2 cells, an efflux rate greater than two is expected since it 
is suggested that an efflux ratio greater than two indicates the presence of efflux mechanism 
(221). The efflux ratio is in line with literature, since a broad range of digoxin efflux ratios in 
caco-2 cells ranging from 2.57 to 28 have been reported (222-224). Hence, the results 
presented above suggest digoxin used on its own is effluxed out of the cells. Interestingly 
permeability studies of digoxin in the presence of L-Arg and L-Lys in digoxin to amino acid 
molar ratios of 1:100, 1:300 and 1:600 all showed a decrease in efflux ratio due to Papp in B-
A direction being either closer to or less than the Papp values obtained for A-B direction. This 
means that in the presence of these basic amino acids, there is a decrease in efflux of digoxin. 
Since digoxin is a substrate of P-gp, it is likely that amino acid interfere with efflux of digoxin 
through P-gp. 
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Interestingly, majority of P-gp substrates are hydrophobic indicating, its preference for 
pumping out hydrophobic compounds (225, 226). With this in mind, the decrease in efflux of 
digoxin in the presence of basic amino acids might be due to more digoxin being present in 
the hydrophilic form and losing its ability to be recognised as a substrate by P-gp. Although 
many drugs with positive charges are also recognised by P-gp, digoxin is not likely to be 
present in the cationic form in the presence of basic amino acids (226).  
 
Al-Ali AA et al observed an increase in digoxin permeation in the A-B direction using  
permeation enhancers (223). However, considering that the permeation enhancers did not 
decrease permeation in the B-A direction, they suggested that the underlying mechanism is 
unrelated to P-gp inhibition. Since in the results presented here (Figure 5.13, Figure 5.14 and 
Table 5.1) both L-Arg and L-Lys increased the permeation of digoxin in not only the A-B 
direction but also the B-A direction, this is a stronger indication that the underlying mechanism 
does not involve inhibition of P-gp. This is because if P-gp was inhibited by the amino acids, 
a decrease in permeation of digoxin in the B-A direction compared to control would be 
expected. Although this seems like an appropriate interpretation, at this stage P-gp inhibition 
cannot be ruled out.  The reason is that if the increase in permeation enhancing mechanism 
(like one proposed next) is significantly greater than the inhibition of P-gp, the latter may go 
unnoticed; a decrease in digoxin efflux may be concealed by significantly greater permeation 
from the B-A direction.  
 
5.4.2.2 Ion-pair hypothesis 
 
Reduction in ionisation is one of the mechanisms which can be employed to enhance drug 
permeability (227). Along with a decrease in efflux, an increase in digoxin uptake can also 
present as a reduced efflux ratio observed in the presence of L-Arg and L-Lys. This leads to 
the hypothesis of another mechanism which may possibly explain the increase in digoxin 
permeability; ion pair formation between anionic digoxin and cationic L-Arg and L-Lys. 
Although digoxin present in the unionised form can freely diffuse through the caco-2 
monolayer, ionised digoxin wold require other mechanisms (228, 229). This leads to the ion-
pair theory where ion-pair formation occurs between the anionic digoxin molecules and 
cationic amino acid molecules. The resulting digoxin -Arg or digoxin -Lys ion pairs would have 
zero net charge allowing the newly formed lipophilic complexes to passively diffuse through 
the cell membrane (230, 231).  This is aided by the fact that in our experiments, there were 
sufficiently excess moles of amino acid present to form ion pairs, allowing any amount of 
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anionic digoxin to have a cationic pair. Once the pair is absorbed and enters the blood 
circulation, it would become diluted. It is suggested that at this point ion-pair would dissociated 
allowing digoxin to carry out its required function (230). 
 
5.4.2.3 Recovery of caco-2 monolayer TEER value indicates paracellular route 
of permeation 
 
Since there was a decrease in TEER value with each experiment whether in the presence of 
amino acids or in its absence, it warranted an investigation to see if this TEER value was 
recoverable. As presented earlier, the TEER does recover, although more slowly for digoxin 
to amino acid molar ratio of 1:600, past an acceptable level of 250 Ωcm2 (224, 232). 
Nevertheless, this suggests that L-Arg and L-Lys led permeation enhancement may be due to 
a reversible tight junction modulation rather than damage to the cells which is not reversible 
(223, 233). TEER values for the caco-2 cell monolayers are known to decrease with the 
opening of tight junctions (233). Interestingly during MTT assay, it was noticed that the 
intracellular distance increased (Figure 5.16) whether exposed to amino acids or not, again 
hinting towards tight junction modulation. Despite the increase in distance between adjacent 
caco-2 cells, metabolic activity was evident by the presence of purple precipitate within the 
cells. 
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Figure 5.16: Increase in distance between viable caco-2 cells observed during MTT assay in the presence 
and absence of amino acids. 
 
Contrary to the findings presented here, Iyire A et al who also studied basic amino acids as 
permeation enhancers insulin, found that TEER values after the experiments were maintained 
with L-Arg (165). However this can easily be explained by considering that the concentrations 
of the amino acid used by them were greatly lower than those which gave significant 
enhancement in digoxin permeation in this study. Also Iyire A et al used a different cell line 
which may respond differently to amino acids. Nevertheless, Iyire A does report a reduction in 
TEER value for some concentrations of L-Lys used in permeability assays (165). Elshaer A et 
al on the other hand did use the caco-2 cell line and also used amino acids as permeation 
enhancers but for the insoluble drug indomethacin (40). Although they maintained TEER 
values above 300 Ωcm2 throughout the experiments, there was a slight drop in TEER value. 
Furthermore, their transport experiments were only for 90 minutes and they also used 
considerably lower amino acid concentrations. Nonetheless, this highlights that although 
amino acids do serve as permeability enhancers for a broad array of drugs, their concentration 
required for significant permeation enhancement is dependent on the drug being used. 




In conclusion, basic amino acids serve as suitable counterions enabling a concentration 
dependent enhancement of digoxin solubility. Furthermore, high concentrations of basic 
amino acid L-Arg and L-Lys also serve a second function, increasing the permeation of digoxin 
through caco-2 monolayers through mechanisms which may involve increase paracellular 
transport, transcellular transport or inhibition of digoxin efflux by P-gp. Although the integrity 
of caco-2 monolayers was put to question, the recovery of TEER values confirmed non-toxic 
mechanism of permeability enhancement. These amino acids may also hold the potential in 
the delivery of other poorly soluble and permeable drugs; concentration of amino acids 
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6.1 General discussion 
 
Antimicrobial resistance (AMR) is on a rise, whilst majority of the newly discovered drugs are 
unable to reach systemic circulation through oral routes, hindered by their solubility and 
permeability. In a bid to unite researchers and help focus in most crucial aspects of AMR, the 
world health organisation (WHO) set out 5 main objectives in their global action plan. Whilst 
these objectives highlight the need of new antimicrobial agents, they also remind researchers 
to find new ways of overcoming AMR of existing antibiotics. On the other hand tools like the 
biopharmaceutical classification system can be used by formulation scientists, allowing it to 
be used as a criteria where one can modulate the physiochemical properties of a drug with 
the aim for their model drug to move up this solubility and permeability dependent class ladder. 
 
One of the ways to enhance the activity of antibiotics for which bacteria have developed 
resistance is the use of adjuvants (67). Antibiotic adjuvants aim to overcome antibiotics 
resistance by interfering with the resistance mechanisms. Although adjuvants such as β-
lactamase inhibitors are in use and in clinical development, researches are cautious of 
bacteria becoming resistant to these as well, ultimately giving rise to the undesired extensive 
drug resistance (70). Additionally, the use of a second compound along with the antibiotic 
introduces increased risk of potential side effects (167). Likewise, although many techniques 
into solubility and permeability enhancement have been researched into, these often involve 
complex processes and usually enhance one or the other. 
 
Amino acids have been shown by ElShaer A et al, to not only enhance the solubility but also 
the caco-2 monolayer permeability of indomethacin through ion pair formation. They also 
showed that the solubility and permeability of Cip can also be enhanced using these amino 
acids. Whilst enhancing the solubility of insulin, Iyire A et al, showed amino acids to improve 
the permeability of Insulin through buccal cell layers. This prompted exploration of the ion-pair 
concept in tackling AMR in planktonic cells as well as biofilms. Additionally, solubility and 
permeability of two other drugs, TC and digoxin was also investigated. 
 
Solubility of TC and digoxin was explored in the presence of all naturally occurring acidic and 
basic amino acids. Acidic amino acids included aspartic acid and glutamic acid, whilst the 
basic amino acids were arginine, lysine and histidine. A concentration dependent 
enhancement in TC solubility was observed with both acidic and basic amino acids. The 
maximum increase was seen with 4500 µg/ml L-arginine and L-lysine representing a 16.30 
and 25.70 fold increase from control, respectively. Despite this, due to degradation of TC 
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which was likely mediated by oxidation and resulted in colour change from yellow to brown, 
acidic amino acids, which were less effective solubility enhancers were decided to be suitable 
counterions for TC. Nevertheless a substantial, 3.94 and 2.21 fold enhancement in TC 
solubility was observed with 4500 µg/ml L-aspartic acid and glutamic acid respectively. Along 
with this octanol/water partitioning showed that an increase in L-aspartic acid concentration 
resulted in TC becoming more hydrophilic, represented by a decrease in LogP. Acidic amino 
acids on the other hand led to degradation of digoxin. Digoxin solubility enhancement with 
basic amino acids though statistically significant, was substantially less than that seen for TC. 
Solubility of digoxin increased to a maximum of 1.54, 1.40 and 1.17 fold higher than control in 
the presence of 3500 µg/ml L-Arg, 4500 µg/ml L-His and 3500 µg/ml L-Lys respectively. In the 
case of both TC and digoxin, the increase in solubility has been attributed to an increase in 
the presence of their ionised form. The ionised form is in an equilibrium with the unionised 
form with the proportion of both dependent on the pH of the solution. Thus generally, as the 
concentration of the amino acid changes, so does the pH of the solution and hence the 
proportion of the drug in ionised form. Ultimately the ionised forms of the drugs are more easily 
able to interact with the polar water molecules and become solubilised, resulting in the 
increase in TC and digoxin solubility observed. 
 
Permeability studies of digoxin in caco-2 cells were carried out in the A-B direction. For this 
purpose, only basic amino acids were used as potential permeability enhancers due to the 
instability of digoxin in acidic solutions. Substantial increase in digoxin permeability was 
observed with L-Arg and L-Lys, but only at higher digoxin to amino acid ratios (1:100, 1:300 
and 1:600). Thus permeability studies in the B-A directions were only obtained for these 
combinations and Papp for both directions were calculated. It was found that addition of amino 
acids decreases the Papp B-A/Papp A-B ratio. This ratio is known as the efflux ratio and the 
observed pattern is likely due to either an increase in digoxin permeation which is hinted by 
increase in Papp in the A-B direction, a decrease in efflux of digoxin hinted by Papp in the B-
A direction being closer to the values obtained for Papp in the A-B direction, or a combination 
of increase in permeation and a decrease in efflux. 
 
Being the suitable counterions for TC, acidic amino acids were used to study their effect in the 
permeability of TC. For this purpose, accumulation with experiments were conducted which 
give indirect evidence of efflux. These studies were carried out on S. aureus and P. 
aeruginosa. Both pathogens exert high clinical implications and are listed as priority pathogens 
by the WHO (47). To study efflux, intracellular accumulation of ethidium bromide (EtBr) was 
measured which is expected to compete with TC for the efflux pump. Thus, an increase is 
EtBr accumulation represents an increase in accumulation of the drug. Although both L-Asp 
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and L-Glu are able to increase TC accumulation in both bacteria, a species dependent pattern 
in TC accumulation was observed, hinting that the mechanism may be different between 
species. Whilst with S. aureus the increase in TC accumulation was concentration dependent, 
only 30 and 15 mM of the amino acids led to an increase in TC accumulation within P. 
aeruginosa. To see the effect of enhanced drug accumulation on bacteria, growth curves were 
done. Both amino acids on their own adversely affected the growth of S. aureus in a 
concentration dependent manner, whilst their combination with TC resulted in synergy which 
was greatest when 30 mM of the amino acids were used. Whilst L-Asp or L-Glu did not affect 
the growth of P. aeruginosa on their own, their combination with TC showed remarkable 
synergy, especially when TC was combined with 30 mM of the amino acids. The synergy was 
so great that despite 30 mM of the acidic amino acids exerting little to no effect on P. 
aeruginosa growth, their combination with 14.06 µM TC hindered the growth of the bacteria to 
similar levels as 112.50 µM TC on its ow. In other words, only 12.50 % of TC was needed 
when used in conjunction with L-Asp or L-Glu to get similar inhibitory effects as the maximum 
concentration of TC used on its own. Along with the effect on growth, TC and acidic amino 
acid combinations also resulted in synergistic reduction in the production of the toxic pigments, 
pyocyanin and pyoverdine (234, 235). 
 
The effects of acidic amino acids on planktonic bacteria were not restricted to TC but were 
found to enhance Cip accumulation and activity too. Due to the similar patterns of 
accumulation obtained, it can be assumed that the mechanism of enhancing drug 
accumulation by the amino acids is similar irrespective of what drug is used. However, the 
mechanism seems to be dependent on the species of bacteria used, since accumulation 
patterns differ between the two species used. Again when Cip is combined with different 
concentrations of L-Asp or L-Glu, an amino acid concentration dependent accumulation 
pattern is observed in S. aureus, whilst in P. aeruginosa only 30 and 15 mM of the amino acids 
lead to enhanced accumulation of the drug. L-Asp concentration of 15 mM and L-Glu 
concentrations of 15 and 7.5 mM showed noticeable synergy in S. aureus growth when 
combined with 8.49, 4.24 and 2.12 µM Cip. Synergy between the amino acids and Cip on the 
growth of P. aeruginosa was a bit more complicated, where the effectiveness of higher drug 
concentrations was decreased whilst that of lower concentrations was increased. 
Nevertheless, decreasing the dose of drug required is always welcome due to lower risk of 
side effects as well lower costs. Furthermore, as when combined with TC, combining with Cip 
also resulted in synergistic reduction in pigment production by P. aeruginosa. 
 
Biofilm are communities of bacteria which attach themselves to biotic or abiotic surfaces, 
secreting substances which form a matrix surrounding the community and conferring its 
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inhabitants enhanced AMR. One of the ways biofilms confer resistance is by retarding diffusion 
of antibiotics through the matrix. This gave hope to acidic amino acids, known solubility 
enhancers of Cip, in potentially overcoming AMR associated with biofilms and confirmed the 
need to investigate further. Along with this, D-isomers of various amino acids are known to 
possess intrinsic anti-biofilm activity (187). Hence, the anti-biofilm activity of D-Asp and D-Glu 
was studied on S. aureus biofilms. Synergistic effect of combining D-amino acids with Cip was 
also investigated as a potential means to overcome antimicrobial resistance in these biofilms. 
For this purpose biofilm were grown in 24 well plates and their density quantified using the 
crystal violet staining method. Interestingly at equimolar combinations, D-Asp and D-Glu were 
able to significantly disperse (at 20 mM and 40 mM) established biofilms and inhibit (at 10 
mM, 20 mM and 40 mM) new biofilm formation in the absence of an antibiotic. This confirmed 
that acidic amino acids also exhibit intrinsic anti-biofilm activity. Moreover, our study 
successfully confirmed L-amino acids also exhibit anti-biofilm activity; a finding contrary to the 
popular view found in published literature (65, 180, 181). The synergistic effect of acidic amino 
acids with Cip was observed at lower concentration ranges (<40 mM and <90.54 µM, 
respectively). 
 
Confocal imaging revealed S. aureus to possess an interesting structure of the extracellular 
DNA (eDNA) which confers the biofilm structural stability whilst keeping the individual cells 
aggregated through acid-base interactions (202). Furthermore, the amino acids used were 
found to disrupt the honeycomb-like extracellular DNA (eDNA) meshwork whilst also 
preventing its formation. Thus it seems that D-Asp and D-Glu exert their inhibitory and 
dispersal effects through an anti-eDNA mechanism, potentially interfering with the acid-base 
interactions which binds the eDNA with the cells. Ultimately this results in eDNA unable to 
bind to (during inhibition) or eDNA release from (during dispersal) S. aureus cell surface, 
preventing biofilm growth or causing biofilm breakdown respectively. These findings highlight 
that targeting matrix components such as eDNA not only helps fight biofilms on its own, but 
may also be used to potentially enhance the effectiveness of antibiotics which the bacteria is 
potentially resistant to, thus acting as adjuvants. Furthermore, the role of antibiotics in 
increasing antimicrobial resistance is reiterated by the presence of seemingly denser eDNA 
structures when Cip is used on its own compared to control biofilms. This also confirms that 
the mechanisms of acquiring antimicrobial resistance is not limited to cells but also extends to 
the matrix. Thus emphasising the need to use antibiotics in conjunction with ways to disrupt 
the matrix or inhibit its formation. 
 
Many of the adjuvants in use and under research and development, such as β-lactamase 
inhibitors, work in a way where mutation in bacteria can lead to them becoming resistant to 
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the same adjuvant which is meant to exhibit anti-resistance activity. One such example is the 
β-lactamase inhibitor sulbactam (168). Thus though these adjuvants do help overcome 
resistance to antibiotics, the effect seems only temporary, ultimately leading to the need of 
developing drugs which inhibit resistance to the adjuvants, which once were inhibiting 
resistance to an antibiotic (71). This identifies a major gap in research in the field of AMR, for 
ways of overcoming AMR which themselves are not susceptible to resistance. Since the amino 
acids used in the research presented here seem to generally work in a non-specific manner, 
using mechanisms such as modulation of acid-base interactions and ionic interactions such 
as ion-pair formation, it may be that acquiring resistance to such mechanisms may be difficult 
if not impossible for bacteria. 
 
To the authors knowledge, natural acidic amino acids have been shown for the first time to act 
as adjuvants increasing the effectiveness of antibiotics, in both planktonic cells as well as 
biofilms. This introduces a multi-mechanistic approach to overcoming AMR using the said 
substances. Providing useful insights into potential mechanisms employed by amino acids in 
their diverse functionality including those leading to solubility enhancement, permeability 
enhancements in caco-2 cells and bacteria as well as mechanisms employed in anti-biofilm 
activity, this thesis sets the groundwork for exploring individually and in detail the mechanisms.  
 
The thesis highlights that amino acids may be used as potential adjuvants with the role of 
enhancing solubility and permeability of otherwise less soluble and permeable drugs to be 
taken orally. Apart from this, it brings to light the potential application of amino acids as 
substances to overcome AMR. They can be used in diverse applications including wound 
care, medical devices as well as disinfectants. Whilst in disinfectants they may aid in 
decreasing the required concentration of the active ingredients, medical devises can be 
adopted with slow release of amino acids or those coated with amino acids based hydrogels, 
preventing bacterial attachment and biofilm formation on their surfaces. Use of amino acids in 
wound care may prove especially useful since in chronic wounds biofilm formation is a major 
issue. To start off, their application in wound healing, can be investigated in simple scratch 
test based wound models using fibroblasts (236, 237). It is hoped that whilst the anti-biofilm 
activity is likely to prevent infection of the wound model, the acidic pH of the amino acids may 
aid wound healing through increasing fibroblast activity (238). In vivo however, the acidic pH 
is like to have many other benefits including alterations in protease activity, increase in 
macrophage activity as well as angiogenesis (238). 
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6.2 Future work 
 
 Investigating into the mechanisms through which amino acids are able to enhance 
accumulation of drugs within bacteria. This can involve the use of transporter specific 
blockers to elucidate the underlying mechanisms. 
 Investigating anti-biofilm properties of basic amino acids and determining whether 
these have anti-eDNA properties too. 
 Quantifying the amount of e-DNA in the supernatant of treated and untreated biofilms 
and characterising the differences between the two. 
 Determining the underlying mechanism of the anti-eDNA properties of acidic amino 
acids, including investigations into the in vitro interactions between the amino acids, e-
DNA and the proteins, enolase and GAPDH. 
 Exploring the wound healing properties of amino acids using monoculture, co-culture 
or three dimensional cell culture wound healing models. The effect of biofilms (as a 
model for biofilm infected wounds) on wound healing can be explored along with the 
effect of amino acids as potential anti-biofilm wound healing agents. 
 Investigating the gene and protein expression of both planktonic and biofilm bacteria 
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Appendix figure 1: Confocal Image of biofilm dispersed with Cip alone. eDNA is present as seemingly well-
fortified boundaries, enclosing persisting S. aureus cells. 
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Appendix figure 2: Percentage change from control upon biofilm inhibition; n=3. 
 
 
Appendix figure 3: Percentage change from control upon biofilm dispersal; n=3. 
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Appendix figure 4: Effect of D-AA at concentrations of 2.5, 5, 10, 20 and 40mM, and Cip at concentrations 
of 1 MLC, 4 MLC and 8 MLC on the Optical density of planktonic S. aureus growth after 30 minutes of 
exposure. One-way ANOVA showed an overall significant difference within the data and was followed by 
a post-hoc t-test with Bonferroni correction to see which concentration significantly (p<0.005 was taken 
as significant; indicated by * ) killed or effected planktonic growth of S. aureus compared to the control. 
Significant effect on planktonic growth of S. aureus was observed with 20mM and 40mM D-AA; n=6. 
 
 
Appendix figure 5: Effect of NaOH on the anti-biofilm activity of D-AA. Neutralising acidic amino acids 
using NaOH resulted in the anti-biofilm activity of these agents to be halted; n=4. 
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Appendix table 1: Comparison of percent change in biofilm density with percent change in viable cells for 
dispersed biofilms. There is a greater reduction in number of viable cells as compared to the reduction in 
total biomass. This pattern is more prominent in dispersed biofilms than inhibited. 
Dispersing agent Percent reduction 
in biofilm density 
Percent reduction 
in cell viability 
40mM D-AA 30.16 97.59 
40mM L-AA 44.92 98.55 




Appendix table 2: Comparison of percent change in biofilm density with percent change in viable cells for 
inhibited biofilms. There is a greater reduction in number of viable cells as compared to the reduction in 
total biomass. This pattern is more prominent in dispersed biofilms than inhibited. 
Inhibiting agent Percent reduction 
in biofilm density 
Percent reduction 
in cell viability 
40mM D-AA 92.78 99.98 
40mM L-AA 97.01 99.98 
40mM D-AA + 8 
MLC 
93.58 99.99 
 
